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Natural antimicrobials are peptides that are essential components of the innate 
immune system, providing broad-spectrum protection against bacteria, yeasts and 
some viruses.  In addition to their innate immune activity, they exhibit properties 
suggesting they interact with the adaptive immune system. These functions imply 
they may be of particular importance in pregnancy. Intrauterine infection is 
responsible for approximately one third of cases of preterm labour, and normal 
labour is considered an inflammatory process, associated with leukocyte invasion of 
the uterine tissues and increased cytokine production.  Little is known, however, 
about natural antimicrobial expression in pregnant reproductive tract. The aim of this 
thesis was thus to characterize natural antimicrobial production in pregnancy. The 
study focused on two main areas  the lower genital tract, comprised of the vagina 
and cervix; and the innermost fetal membrane, the amnion. 
 
In the lower genital tract, levels of natural antimicrobials were determined in samples 
of cervicovaginal secretions collected from pregnant women, using enzyme linked 
immunosorbance assay (ELISA). In addition Taqman quantitative PCR and ELISAs 
were used to investigate natural antimicrobial production by cell lines derived from 
endocervical, ectocervical and vaginal epithelium. It was found that elafin and 
secretory leucocyte protease inhibitor (SLPI) were found at high concentrations in 
cervicovaginal secretions, but levels were diminished in women with the common 
vaginal infection bacterial vaginosis (p<0.05). Cells derived from the vaginal 
epithelium expressed greater amounts of elafin than cervically derived cells. 
However, elafin and SLPI production could be stimulated in endocervical cells by 
the bacterial product lipopolysaccharide, a response that was not seen in the vaginal 
cell line. 
 
Natural antimicrobial production in the amnion was examined in tissue explants and 
primary cultured amnion cells, using a combination of Taqman PCR and ELISAs. In 
addition, cDNA microarray was carried out to investigate factors controlling 
amniotic antimicrobial production, and the involvement of signalling pathways was 
iii 
studied using specific pathway inhibitors. It was shown that the amnion expressed 
five antimicrobials: human beta defensins (HBD) 1, 2 and 3, SLPI and elafin. 
Expression of HBD2 was significantly upregulated following normal labour 
(p<0.05), with production in primary amnion epithelial cells dramatically increased 
by IL-1ß. The pattern of HBD2 expression in response to IL-1ß was biphasic, which 
suggested involvement of a secondary gene product. Several putative influential 
factors were identified by cDNA micorarray, including the NF-kappaB cofactor NF-
kappaBinhibitorζ. Its relationship to HBD2 was explored. The involvement of both 
NF-kappaB and mitogen activated protein (MAP) kinase p38 signalling appeared 
crucial in the response. 
 
This work has shown that natural antimicrobials are expressed by both the lower 
genital tract, where infections that are associated with preterm labour originate, and 
in the amnion, which is the fetus last line of defence to infection. They may have an 
important role in the prevention of infection associated preterm labour. Further 
characterization of these responses may increase understanding of the physiology, 
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Parturition is characterized by profound changes in uterine and extrauterine 
physiology, culminating in increased myometrial contractility and cervical 
effacement and dilation. The mechanisms controlling the onset of labour are 
incompletely understood. Nevertheless, decidual and fetal membrane activation and 
inflammation of the gestational tissues are key features of the final common pathway 
leading to delivery. Tight regulation of these processes is essential, as an untimely, 
uncontrolled or inadequate response can lead to preterm labour. 
 
Intrauterine infection is a major cause of preterm labour, and appears to be 
particularly associated with early preterm birth. It can also cause activation of the 
fetal inflammatory response, increasing severe neonatal morbidities in these high risk 
infants. Natural antimicrobials are a family of multifunctional proteins produced by 
epithelial and inflammatory cells which have broad-spectrum activity against 
bacteria. They also can modulate the immune response, and their involvement in the 
pathophysiology of a number of infective and inflammatory conditions is recognized.  
Little is known about natural antimicrobials in pregnancy, but they could be 
important components linking infection, inflammation, and labour.  
 
This thesis examines the production of epithelial natural antimicrobials in pregnancy. 
Evidence that natural antimicrobials are expressed in gestational tissues is provided. 
In addition, their involvement in the process of parturition is explored and 
mechanisms regulating their secretion investigated. Further research areas are 





1.2. THE REPRODUCTIVE TRACT IN PREGNANCY 
 
1.2.1. The Uterus 
 
The body of the uterus is predominantly comprised of bundles of smooth muscle 
joined by connective tissue containing many elastic fibres. During pregnancy it 
undergoes remarkable growth. The non-pregnant uterine cavity has a volume of 
around ten millilitres; at term the average volume is five litres. This enlargement is 
mainly secondary to hypertrophy of the muscle fibres, along with an accumulation of 
fibrous tissue and elastic tissue. There are also increases in blood vessels and 
lymphatics. In the first trimester uterine growth is driven by oestrogen, and possibly 
progesterone. After twelve weeks the expanding uterine contents exert the greater 
effect on the increase in uterine size. By term the uterus has changed from a firm, 
thick walled structure, to a thin musculo-elastic sac. 
 
The uterus undergoes spontaneous, mild contractions from the first trimester onwards 
(Braxton-Hicks contractions) which are initially irregular, painless and infrequent. 
Towards the end of gestation these become more frequent and may develop some 
pattern (Challis, Lye et al. 2001) This is associated with an increase in 
responsiveness to uterotonins, mediated by dramatic increases in the number of 
oxytocin-receptors (Ivell, Kimura et al. 2001) and connexins genes (gap junctions) 
allowing increased coupling between myometrial cells (Chow and Lye 1994; 
Lefebvre, Piersanti et al. 1995). A number of other pro-labour or contraction-
associated genes are upregulated, including prostaglandin synthetic enzymes 
(Challis, Sloboda et al. 2002) which promote the establishment of co-ordinated 
contractions leading to parturition. 
 
The non-pregnant uterine cavity is lined by endometrium, which in pregnancy 
becomes decidualized early in the process of implantation, at about day 7-10 post-
conception. The area invaded by the blastocyst is the decidua basalis, wheras the 
decidua capsularis covers the implantation site, and the decidua parietalis is that 
which is away from the implantation site. The functions of decidua are not fully 
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understood, but its crucial position at the maternal-fetal interface suggests it has 
functions in communicating between the mother and fetus. It may have roles in early 
pregnancy development, regulation of the invading trophoblast into the maternal 
tissue and mediation of immune events during pregnancy. It is a metabolically active 
tissue, and can secrete factors which may influence the fetal tissues, as well as being 
responsive to mediators produced by them. 
 
1.2.2. The Cervix 
 
The cervix is a cylindrical structure which is continuous with the body of the uterus. 
It is approximately four centimeters long by one centimeter wide in the non-pregnant 
state, and grows slightly in pregnancy. Its inner surface is called the endocervix, and 
is lined with columnar epithelium containing many branching glands. The ectocervix 
is the portion which protrudes into the vagina, and this is covered by stratified 
squamous epithelium. The two types of epithelia meet at an area called the transition 
zone, around the level of the external os. Underlying the epithelia is connective 
tissue, made up of collagens (mainly type I and III) embedded in proteoglycans. 
There is also a cellular component made up of fibroblasts and smooth muscle cells 
(Norman, Thomson et al, 2004).  
The cervix dilates during labour to a maximum diameter of ten centimetres, to allow 
delivery of the fetus from the uterus. Cervical ripening is the process by which the 
cervix changes from a firm barrier retaining the pregnancy, to a pliable organ which 
yields to the passage of the fetus during parturition. Ripening precedes the onset of 
contractions by some weeks, and is mediated by chemokines and prostaglandins 
(Kelly 2002). These induce neutrophil infiltration of the cervix, which produce the 
collagenases and matrix metalloproteinases that remodel the cervical extracellular 
matrix (Osman, Young et al. 2003). Hydrophobic glycosaminoglycans within the 
connective tissue are replaced by more hydrophilic hyaluronic acid, and the water 
content of the cervix is increased, whilst its collagen content decreases.  
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1.2.3. The Fetal Membranes 
 
The developing human fetus is surrounded by amniotic fluid contained in extra-
embryonic tissues known collectively as the fetal membranes. The inner layer, the 
amnion, contains the amniotic fluid, whilst the outer chorion laeve lies adjacent to 
the maternal decidua. 
 
1.2.3.1. Structure of the Fetal Membranes 
Amnion 
The amnion is first identifiable around day 7-8 after fertilization, before gastrulation.  
It develops as a space that develops in the inner cell mass adjacent to the trophoblast. 
The cells that line this are called amnioblasts, and are the precursors of amnion 
epithelial cells. They are derived from epiblasts, which are the cells which also give 
rise to the three germ cell layers. The amniotic epithelium retains some of the 
multipotency of epiblast cells, right up to term (Miki, Lehmann et al. 2005).  
 
Early in embryogenesis the amnion is composed of an inner layer of amnion 
epithelial cells immediately adjacent to a layer of mesenchymal cells. As the 
amniotic sac expands, the cuboidal epithelial cells replicate at a sufficient rate to 
maintain a continuous layer of cells, connected by desmosomes. This secretes 
collagen types III and IV and the non-collagenous glycoproteins (laminin, nidogen 
and fibronectin) which form a basement membrane for the cells. The majority of the 
tensile strength of the fetal membranes is provided by the zona compacta, 
synthesized by the mesenchymal cells (Casey and MacDonald 1996). This is 
comprised of parallel bundles of interstitial collagens (type I and III) linked to the 
basement membrane by filamentous connections of collagen V and VI (Malak, 
Ockleford et al. 1993). Division of the mesenchymal cells apparently does not keep 
pace with the growing amniotic sac, and they start to become dispersed from around 
10-14 weeks. By the third trimester there are only around one-tenth as many 
mesenchymal cells as epithelial cells, connected by a loose network of connective 
tissue. The spongy or intermediate layer lies between the amnion and chorion and 
contains a non-fibrillar network of collagen (type III) with abundant hydrated 
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proteoglycans and glycoproteins (Malak, Ockleford et al. 1993). There are a few fetal 
macrophages in the amnion, but it is entirely devoid of vasculature, lymphatics, 
smooth muscle and nerve. It is nourished by the amniotic fluid and by simple 




The chorion is approximately 4 times the thickness of the amnion but has far less 
tensile strength. It comprises a basal and a superficial population of cells. The basal 
cells are tightly packed cytotrophoblast cells, adjacent to a basement membrane. The 
superficial cells are mainly fibroblast which are more dispersed, and stabilized by an 
underlying reticular layer. On the outermost surface are remnants of the villous 
stroma adhering to the maternal decidua. In contrast to the amnion, the chorion is 
vascularized. Chorionic mesoderm, particularly at the fetal side, contains vessels 
throughout the second trimester and the maternal side has vessels until term 
(Bernirschke and Kaufmann, 1995).  
 
1.2.3.2. Functions of the Fetal Membranes 
Mechanical Protection 
The amniotic fluid cushions the fetus and helps maintain temperature. It aids 
musculoskeletal development, and is essential for normal pulmonary and 
gastrointestinal development (Underwood, Gilbert et al. 2005). The fetal membranes 
have sufficient strength and elasticity to progressively stretch to approximately 
double their size by term, whilst simultaneously protecting against rapid pressure 
changes caused by fetal movements or external pressure to the maternal abdomen 
(Bryant-Greenwood 1998).   
 
Antimicrobial Properties 
The amniotic cavity resists penetration by potentially harmful microbes, leukocytes 
and neoplastic cells from the maternal compartment. The antimicrobial activity of 
amniotic fluid has long been recognised (Miller, Michel et al. 1976; Tafari, Ross et 
al. 1977; Sachs and Stern 1979; Thomas, Sbarra et al. 1988). Moreover, host defence 
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proteins such as lipopolysaccahride binding protein (LBP) and CD14 which are 
crucial for bacterial recognition and elimination, are essential components of 
amniotic fluid (Roos, Martin et al. 1997; Gardella, Hitti et al. 2001; Espinoza, 
Romero et al. 2002). 
 
In vitro both amnion and chorion have an inhibitory effect on the growth of a diverse 
range of bacteria, and chorioamnion provide a competent barrier to penetration by 
Group B Streptococcus (Kjaergaard, Helmig et al. 1999; Kjaergaard, Hein et al. 
2001). In vivo chorioamniotic membrane has been used as an effective antimicrobial 
dressing for burns and ulcerated skin and cornea, reducing inflammation and 
promoting repair (Ravishanker, Bath et al. 2003; Gomes, Romano et al. 2005). 
Profiling of gene expression patterns in the placenta has shown that the amnion 
expresses high levels of genes such as MUC 1, which codes for a glycoprotein that 
could confer antibacterial and antiadhesive properties to the amnion (Sood, Zehnder 
et al. 2006). 
 
Paracrine interactions and membrane degradation 
The fetal membranes form a bidirectional paracrine link between mother and fetus. 
Fetal  maternal communication occurs via amniotic fluid constituents such as fetal 
urine and lung secretions, whilst in the other direction maternal decidual and blood 
products can pass into the amniotic fluid and enter the fetus via fetal breathing and 
swallowing. In addition, the fetal membranes themselves are metabolically active 
tissues, capable of producing a variety of bioactive compounds. These may act 
locally in the gestational tissues and uterus, but also pass into the amniotic fluid to 
gain access to the fetus, and are involved in a diverse array of physiological 
processes. 
 
It is critical that the membranes are receptive to signals from the fetus, mother and 
fetal-maternal interface, in order to co-ordinate the process of degradation which is 
essential for parturition. A cascade of events occurs involving membrane distortion, 
extracellular matrix deformation and loss of cell-matrix interactions, apoptosis, 
(Menon, Lombardi et al. 2002; Fortunato and Menon 2003) matrix metalloproteinase 
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(MMP)-activation (Bryant-Greenwood and Yamamoto 1995; Riley, Leask et al. 
1999; Menon and Fortunato 2004) and membrane degradation (Lei, Furth et al. 
1996). The timing of this response is crucial, as prelabour preterm rupture of the 
membranes is associated with approximately 30% of cases of preterm delivery 
(Bryant-Greenwood and Millar 2000; Arias and Tomich 1982). 
 
1.2.4. The Vagina 
 
The vagina is a tubular musculo-membranous structure that extends from the uterus 
to the vulva. The upper third arises from the mullerian duct, along with the uterus 
and cervix, whereas the lower third arises from the urogenital sinus. The vagina is 
separated from its relations, anteriorly the bladder and urethra, and posteriorly the 
rectum, by connective tissue called the vesicovaginal septum and rectovaginal 
septum. The upper portion of the vagina is also usually separated from the rectum by 
the pouch of Douglas. The upper end of the vaginal vault is subdivided into the 
anterior, posterior and two lateral fornices by the protruding uterine cervix. The 
vaginal wall is attached to the posterior wall of the cervix at a higher level than the 
anterior wall, thus the posterior fornix is deeper. 
 
The mucosa of the vagina has multiple transverse folds or rugae, and is lined by non-
keratinized stratified squamous epithelium. It is devoid of glands, but is lubricated by 
mucus from the cervix, secretions from the uterus and vestibular glands, and a 
transudate from the rich vascular network of the lamina propria. The mucosa is 
influenced by the menstrual cycle, and under the influence of circulating oestrogens 
in the follicular phase, the epithelial cells synthesize and accumulate glycogen.  
When intact, the mucosal barrier of the vagina forms a physical barrier to infection, 
and cells are continuously desquamated, eliminating attached microbes.  The 
integrity of the mucosal barrier can be affected by bacterial enzymes allowing 
penetration of pathogens (Cauci, Driussi et al. 1998; Olmsted, Meyn et al. 2003). 
 
Lactobacilli are the facultative anaerobic Gram-positive bacteria normally populating 
the vagina, which provide important protection against vaginal infection. They utilise 
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nutrients and produce lactic acid from glucose, which maintains an inhospitable low 
pH in the vagina. At low pH they produce bacteriocin-like substances which are 
bacteriostatic, and biosurfactants that help prevent adherence of pathogens to the 
vaginal epithelium. 
 
1.3. THE INNATE IMMUNE RESPONSE AND INFLAMMATION 
 
The immune system is comprised of two interacting arms- the innate immune system 
and the adaptive immune system (Figure 1.1). The innate immune system is 
phytogenetically ancient and provides the first line of defence against infection. It is 
characteristically rapid and non-specific, preventing penetration of pathogens and 
effecting microbial killing until recruitment of the slower, but more specific adaptive 
immune response (Medzhitov and Janeway 2000). Epithelial cells, granulocytes and 
macrophages are the principal cell types of the innate immune response, whereas the 
adaptive immune response is provided by cells of the lymphoid lineage. 
 
The innate immune response is responsible for stereotypical inflammation seen in 
response to tissue damage, which can occur as a result of physical injury or 
physiological processes such as ovulation and menstruation. Many components of 
the innate immune response are genetically determined resulting in substantial 
variation in the inflammatory response between individuals (Imahara and O'Keefe 
2004). Tissues which interface the external environment, and as such are exposed to 
pathogens, are crucial components of the innate immune system. Epithelial cells 
form a physical barrier to microorganisms, but also actively contribute to microbial 
elimination via production of natural antimicrobials and opsonins. Upon physical 
damage or bacterial penetration, they can produce a variety of inflammatory 
mediators such as chemokines, cytokines and prostaglandins. These augment local 
blood flow and enable the recruitment of leukocytes, which reinforce inflammatory 
mediator production and signal to the adaptive immune system (Dempsey, Vaidya et 
al. 2003). Incoming and resident phagocytes can remove cellular debris, and vascular 
capillary endothelial and fibroblast proliferation result in granulation tissue formation 






Diagramatic representation of the innate and adaptive arms of the immune system.
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phase response are also sometimes a feature. Tight control of inflammation is 
essential, to ensure successful removal/repair of the injurious agent, without 
excessive tissue damage. This involves regulatory factors including glucocorticoids 
and anti-inflammatory cytokines, as well as other unknown mechanisms.  
 
1.3.1. Mediators of Inflammation 
 
The inflammatory response is mediated by a plethora cytokines, chemokines and 
enzymes (Matsukawa, Hogaboam et al. 2000). Many have common functional 
activities, and redundancy is high. Examples of mediators with particular relevance 
to this thesis and/or pregnancy are highlighted below. 
 
1.3.1.1. Cytokines 
Cytokines are soluble proteins or glycoproteins that act as mediators of intra- and 
intercellular communication, and are involved in processes of development, tissue 
repair, haematopoiesis, inflammation and the immune response (Hibbert and 
Johnston 2001). Cytokines function in a complex network where one cytokine can 
influence production of, and response to, many other cytokines. They act at nano to 
pico molar concentrations, interacting with cell surface receptors coupled to 
intracellular signalling systems and second messenger pathways to effect their action 
(Haddad 2002). 
 
Interleukin-1 (IL-1), Tumour Necrosis Factor Alpha (TNFα) and Interleukin-17 (IL-
17) are key cytokines involved in the inflammatory response. 
 
IL-1 
IL-1 is a multifunctional pro-inflammatory cytokine. It exists in two forms- IL-1α 
and IL-1β, which are products of separate genes. These are 17kDa proteins 
consisting of 159 amino acids and 153 amino acids respectively. They exhibit only 
27% protein sequence homology, but are nearly identical in 3 dimensional structure 
and their biological effects are generally indistinguishable 
(www.copewithcytokines.com). Two IL-1 receptors (type 1 [IL-1RI] and 2 [IL-
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1RII]) have been described. IL-1α and IL-1β bind to both receptor types, but only IL-
1RI transduces a signal, whilst IL-1RII acts as a decoy receptor. An endogenous 
antagonist (IL-1RA) of IL-1 has also been identified, which competitively binds IL-
1RI. Receptors are found almost ubiquitously on somatic cells. 
 
IL-1 is secreted by a multitude of cell types, with macrophages, monocyte and 
dendritic cells being major sites of production. Its expression may be invoked by a 
variety of factors including TNFα and endotoxin, whilst inhibitors of secretion 
include prostaglandin E2 (PGE2), glucocorticoids and IL-1RA. It has numerous 
biological effects including chemotaxis of neutrophils and up-regulation of adhesion 
molecules, activation of T helper cells and Natural Killer (NK) cells, stimulation of 
immunoglobulin production, and stimulation of other cytokines. It can act directly or 
indirectly via the induction of PGE2, IL-6, and IL-8 and it also synergises with other 
cytokines such as TNFα (Dinarello 1996). 
 
Studies demonstrating IL-1 expression in the placenta and membranes are detailed in 
Table 1.1. In addition IL-1 is found in myometrium(Winkler, Fischer et al. 1998), 
and cervicovaginal secretions in pregnancy (Mattsby-Baltzer, Platz-Christensen et al. 
1998; Wennerholm, Holm et al. 1998; Doh, Barton et al. 2004; Torbe and Czajka 
2004; Gonzalez Bosquet, Ferrer et al. 2005; Kalinka, Sobala et al. 2005; Culhane, 




IL-1Β Protein RNA 
Villous 
Placenta 
(Baergen, Benirschke et al. 1994)ce (Benyo, Miles 
et al. 1997) ce (Berkowitz, Faris et al. 1990)abcd 
(Flynn, Finke et al. 1982) d (Flynn, Finke et al. 
1985) cd (Gunn, Hardiman et al. 1996) c (Haynes, 
Jackson et al. 1993) ae (Hu, Yang et al. 1992) ace 
(Jokhi, King et al. 1997) ae (Kauma, Matt et al. 
1990) a (Keelan, Marvin et al. 1999) c(Kelly, Carr et 
al. 1995) a(Laham, Brennecke et al. 1996) 
bc(Librach, Feigenbaum et al. 1994) ace (Paulesu, 
King et al. 1991) abce(Simon, Frances et al. 1994) ae 
(Stallmach, Hebisch et al. 1995) ce (Steinborn, 
Gunes et al. 1996) c (Steinborn, von Gall et al. 
1998) c (Taniguchi, Matsuzaki et al. 1991) c 
(Ammala, Nyman et al. 1997) c 
(Bennett, Lagoo-Deenadayalan 
et al. 1996) ce (Bennett, Lagoo-
Deenadayalan et al. 1998) a 
(Bennett, Lagoo-Deenadayalan 
et al. 1999) a 
(Haynes, Jackson et al. 1993) ae 
(Heinig, Wilhelm et al. 1993) c 
(Kauma, Matt et al. 1990) a 
(Stephanou, Myatt et al. 
1995)ce 
Decidua (Baergen, Benirschke et al. 1994) c (Gunn, 
Hardiman et al. 1996) c (Jokhi, King et al. 1997) a 
(Kauma, Matt et al. 1990) a (Lonsdale, Elder et al. 
1996) a (Keelan, Marvin et al. 1999) c (Paradowska, 
Blach-Olszewska et al. 1997) c (Romero, Wu et al. 
1989)c (Simon, Frances et al. 1994) ad (Steinborn, 
Gunes et al. 1996) c (Young, Thomson et al. 2002) 
cd 
(Ammala, Nyman et al. 1997) c 
(Kauma, Matt et al. 1990) a 
(Saito, Nishikawa et al. 1993) ad
Fetal 
Membranes 
(Baergen, Benirschke et al. 1994) cg (Gunn, 
Hardiman et al. 1996) cfg (Kauma, Matt et al. 1990) 
afg (Keelan, Marvin et al. 1999) cfg (Menon, Swan et 
al. 1995) cfg (Paradowska, Blach-Olszewska et al. 
1997)cg (Young, Thomson et al. 2002) cd 
(Kauma, Matt et al. 1990) afg 




TNFΑ PROTEIN RNA 
Villous 
Placenta 
(Benyo, Miles et al. 1997)ce (Berkowitz, Faris et al. 
1990)abcd (Chen, Yang et al. 1991) ace (Haynes, 
Jackson et al. 1993) ae  (Jaattela, Kuusela et al. 
1988)c(Jokhi, King et al. 1997)ae (Kelly, Carr et al. 
1995)a (Laham, Brennecke et al. 1994)bc 
(Paradowska, Blach-Olszewska et al. 1997)c 
(Pijnenborg, McLaughlin et al. 1998)abce 
(Stallmach, Hebisch et al. 1995)ce (Steinborn, 
Gunes et al. 1996)c (Steinborn, von Gall et al. 
1998)c(Vince, Shorter et al. 1992)acde 
(Bennett, Lagoo-Deenadayalan 
et al. 1996) ce (Bennett, Lagoo-
Deenadayalan et al. 1998) a 
(Bennett, Lagoo-Deenadayalan 
et al. 1999) a 
(Chen, Yang et al. 1991) ace 
(Haynes, Jackson et al. 1993) ae 
(Heinig, Wilhelm et al. 1993) c 
(King, Jokhi et al. 1995) ae 
(Vince, Shorter et al. 1992) ac 
(Yang, Yelavarthi et al. 1993) 
ae 
Decidua (Chen, Yang et al. 1991) ac (Deniz, Christmas et al. 
1996) c (Jaattela, Kuusela et al. 1988) c (Jokhi, King 
et al. 1997) a (Laham, Brennecke et al. 1994)c 
(Lonsdale, Elder et al. 1996) a (Paradowska, Blach-
Olszewska et al. 1997) c (Saito, Kasahara et al. 
1993) ad (Steinborn, Gunes et al. 1996) c (Vince, 
Shorter et al. 1992)ac (Young, Thomson et al. 2002) 
cd 
(Chen, Yang et al. 1991) ac 
(Jokhi, King et al. 1997) ad 
(Saito, Kasahara et al. 1993) ad 
(Vince, Shorter et al. 1992) acd 
(Vives, Balasch et al. 1999) ac 
Fetal 
Membranes 
(Chen, Yang et al. 1991)cfg (Fortunato, Menon et 
al. 1994)cg (Paradowska, Blach-Olszewska et al. 
1997)cg (Young, Thomson et al. 2002)cdfg 
(Chen, Yang et al. 1991)cf 
(Fortunato, Menon et al. 
1994)cfg 
 
IL-17 PROTEIN RNA 
Villous 
Placenta 




IL-8 PROTEIN RNA 
Villous 
Placenta 
(Denison, Kelly et al. 1998)c (Elliott, Kelly et al. 
1998) ace (Keelan, Marvin et al. 1999) c (Laham, 
Brennecke et al. 1997) c (Laham, Brennecke et al. 
1999) c (Saito, Kasahara et al. 1994) acde (Shimoya, 
Matsuzaki et al. 1992) abcde (Stallmach, Hebisch et 
al. 1995)c 
(Saito, Kasahara et al. 1994) 
acde (Shimoya, Matsuzaki et al. 
1992) abc 
Decidua (Denison, Kelly et al. 1998) c (Keelan, Marvin et 
al. 1999) c (Saito, Kasahara et al. 1994) acd (Saito, 
Kasahara et al. 1994) ad (Young, Thomson et al. 
2002) cd 
(Dudley, Collmer et al. 1996) c 
(Saito, Kasahara et al. 1994) ac 
(Saito, Kasahara et al. 1994) ad 
Fetal 
Membranes 
(Denison, Kelly et al. 1998) cfg (Dudley, Collmer et 
al. 1996) cf (Fortunato, Menon et al. 1995) cfg (Ito, 
Nakamura et al. 1994) cf (Keelan, Sato et al. 1997) 
cg (Keelan, Marvin et al. 1999) cfg (Laham, 
Brennecke et al. 1997) cg (Laham, Brennecke et al. 
1999) cg (Trautman, Dudley et al. 1992) cg (Young, 
Thomson et al. 2002) cdf 
(Dudley, Collmer et al. 1996) 





Inflammatory mediator expression in placenta and membranes (adapted from 
(Bowen, Chamley et al. 2002)). 
 
 a=first trimester; b=second trimester; c=third trimester; d=localized to immune cells 




TNFα is another prototypic inflammatory cytokine, with multiple pro-inflammatory 
functions. It is a non-glycosylated protein of 17 kDa and has a length of 157 amino 
acids. High-affinity receptors for TNFα are expressed on all somatic cell types with 
the exception of erythrocytes (www.copewithcytokines.com). 
 
TNFα is secreted by macrophages, monocytes, granulocytes, T lymphocytes and NK 
cells following their stimulation by bacterial lipopolysaccharides. Its synthesis is also 
induced by inflammatory stimuli including interferons and IL-2, whereas TGF-β, 
prostaglandin E2 and dexamethasone inhibit its production. TNFα enhances 
phagocytosis and cytotoxicity in neutrophilic granulocytes and also modulates the 
expression of many other proteins, including IL-1 and IL-6 and a number of other 
chemoattractant cytokines. It is a potent chemoattractant for neutrophils and 
increases their adherence to the endothelium. TNFα is also pro-apoptotic and 
cytotoxic to malignant cells (Locksley, Killeen et al. 2001). 
 
Studies demonstrating TNFα expression in the placenta and membranes are outlined 
in Table 1.1. It is also found in cervicovaginal secretions (Mattsby-Baltzer, Platz-
Christensen et al. 1998) in pregnancy. In addition it has been immunolocalized in the 
epithelium of the cervix in labour (Young, Thomson et al. 2002). 
 
IL-17 
IL-17 is a disulfide-linked homodimeric glycoprotein consisting of 155 amino acids 
exerting its actions as a homodimer with a molecular weight around 35 kDa (Yao, 
Painter et al. 1995). IL-17 is a product of activated CD4+ memory T lymphocytes but 
CD8+ memory T lymphocytes can also produce IL-17 after stimulation and it has 
also been detected in eosinophils, neutrophils and human blood monocytes (Kolls 
and Linden 2004). The IL-17 receptor (IL-17R) is a type I transmembrane protein 
and can be detected in epithelial cells, fibroblasts, B and T lymphocytes, 
myelomonocytic cells, marrow stromal cells and vascular endothelial cells (Moseley, 
Haudenschild et al. 2003). IL-17 appears to be involved in the coordination of local 
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tissue inflammation via the induced release of proinflammatory and neutrophil-
mobilizing cytokines.   
In vitro stimulation with IL-17 stimulates production of IL-6, (Yao, Painter et al. 
1995), IL-8, CXCL1 and granulocyte colony-stimulating factor (G-CSF) in human 
bronchial epithelial cells (Jones and Chan 2002), and monocytes release TNFα and 
IL-1β when stimulated with IL-17 (Jovanovic, Di Battista et al. 1998). In mice, IL-17 
is induced in response to Gram-negative bacterial challenge, and mice lacking IL-
17R succumb to bacteraemia and early death after exposure to Klebsiella 
pneumoniae (Ye, Garvey et al. 2001). 
IL-17 has recently been localized in placental trophoblast, and placental 
macrophages (Pongcharoen, Somran et al. 2007) but there are no reports of IL-17 or 
IL-17R expression in the fetal membranes. 
1.3.1.2. Chemokines 
Chemokines are structurally related glycoproteins with chemotactic and/or leukocyte 
activation capabilities.  They are smaller than cytokines- approximately 70 to 130 
amino acids in length and approximately 8 to 10 kDa in molecular weight. They are 
classified into two main subfamilies based on the position of two amino terminal 
cysteine residues, or a four-cysteine motif. CXC chemokines contain a single amino 
acid between the first and second cysteine residues and are generally chemoattractant 
to neutrophils. CC chemokines have adjacent cysteine residues and tend to be 
involved in recruitment of monocytes, lymphocytes, basophils, and eosinophils.  
Two variations have also been identified: lymphotactin, which is specific for 
lymphocytes, and is missing a cysteine at its amnino terminus; and fractalkine which 
has three amino acid residues between the first two cysteines and induces both 
adhesion and migration of leukocytes (www.copewithcytokines.com). 
 
Chemokines act via heptahelical G-coupled receptors. Six CXC receptors (CXCR1-
6) and ten CC receptors (CCR1-10) have been identified. The majority of receptors 
recognise more than one chemokine, and some chemokines bind to more than one 
receptor (Baggiolini 2001). 
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IL-8 
IL-8 (CXCL8) is a potent neutrophil chemokine and an archetypal member of the 
CXCL family. It is a non-glycosylated protein of 72 amino acids, produced by 
processing a precursor of 99 amino acids. IL-8 is secreted by many cell types 
including monocytes, macrophages, fibroblasts, endothelial cells, and epithelial cells, 
most often after stimulation by IL-1 or TNFα. It signals through CXCR1 and 2 
expressed on neutrophils and T lymphocytes (www.copewithcytokines.com). 
IL-8 induces rapid changes in neutrophil shape, activation of endothelial adherence 
factors, and the release of granule contents and formation of oxygen radicals. 
Granule release occurs at relatively high IL-8 concentrations and is enhanced after 
treatment of the cells with inflammatory cytokines. This suggests that it may occur 
once the neutrophil has reached its target, where high levels of chemokines promote 
antimicrobial activity (Baggiolini 2001). 
Studies demonstrating IL-8 expression in the placenta and membranes are shown in 
Table 1.1. It is also found in cervicovaginal secretions (Mattsby-Baltzer, Platz-
Christensen et al. 1998; Wennerholm, Holm et al. 1998; Torbe and Czajka 2004; 
Diaz-Cueto, Cuica-Flores et al. 2005; Gonzalez Bosquet, Ferrer et al. 2005; Kalinka, 
Sobala et al. 2005; Culhane, Nyirjesy et al. 2006) in pregnancy and has been 
immunolocalized in the epithelium and stroma of the cervix in labour (Young, 
Thomson et al. 2002). 
 
1.3.1.3. Prostaglandins 
Prostaglandins are important inflammatory mediators found in virtually all tissues 
and organs. They are synthesized from arachidonic acid, which is released from 
phospholipid membrane stores by the action of phospholipases. Free arachidonic acid 
is then converted to the prostaglandin intermediate prostaglandin H2 (PGH2) via 
another intermediate prostaglandin G2 (PGG2) by the action of prostaglandin-
endoperoxidase synthase (PTGS) 1 or 2 or both (also known as cyclo-oxygenase 
[COX] 1 and 2). PTGS1 is considered to be a constitutively expressed enzyme, 
whereas PTGS2 is inducible by cytokines, growth factors or tumour promoters 
(Olson 2003).  
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PGH2 is rapidly converted to the prostaglandins by the action of specific 
prostaglandin synthases to create thromboxane, prostacyclin, prostaglandin D, 
prostaglandin E or prostaglandin F. Biological actions of prostaglandins are mediated 
by specific receptors, many of which have numerous alternative splice variants. They 
have multiple roles in the inflammatory response including blood flow regulation, 
chemotaxis, and regulation of platelet function and stimulation of pain pathways. 
Prostaglandins have a short half-life, and are broken down to biologically inactive 
metabolites by the action of 15-prostaglandin dehydrogenase (15-PGDH).  
Prostaglandins have vital roles in pregnancy maintenance and the process of 
parturition (Gibb 1998; Challis, Sloboda et al. 2002). Their production in pregnancy 
is tightly regulated in the placenta, fetal membranes, myometrium and cervix 
throughout pregnancy via the expression of enzymes involved in their synthesis and 
breakdown. Tissue expression of prostaglandin receptors is also modulated. 
1.3.1.4. Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) are a large family of zinc dependent 
endopeptidases that have similar structure and functions, but are the product of 
different genes (Massova, Kotra et al. 1998). They are capable of degradation of 
matrix and non-matrix proteins, and are involved in a large variety of physiological 
processes (Nagase and Woessner 1999; Sternlicht and Werb 2001). As well as 
modulating inflammation through regulation of the structure and integrity of the 
extracellular matrix, they exert effects via cleavage of cell surface receptors, 
activation and inactivation of chemokines, and release of pro-apoptotic mediators. 
 
MMPs are widely distributed through most tissues, and production may be either 
constitutive and/or inducible by other mediators. Many are secreted immediately 
after being synthesized; however inflammatory cells also store MMPs as granule 
products for release on activation. Tissue inhibitors of metalloproteinases (TIMPs) 
are the major cellular inhibitors of MMPs, and antagonize their function as well as 
regulating their release and activation (Baker, Edwards et al. 2002). 
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MMPs are crucial in a number of physiological processes in the female reproductive 
tract, including tissue remodelling associated with ovulation and menstruation. In 
pregnancy, regulation of MMPs and TIMPs is vital for successful embryo 
implantation, trophoblast invasion and decidualization, membrane degradation at 
parturition and post-partum uterine involution (Fata, Ho et al. 2000). 
1.3.1.5. Toll-like receptors 
In addition to being driven by cytokines such as IL-1, TNFα and IL-17, inflammation 
can be directly stimulated by microbes. These provoke the innate immune response 
through pattern-recognition receptors such as Toll-like receptors (TLR). TLRs are 
members of the IL-1 receptor superfamily, and they share a cytoplasmic domain with 
IL-1R termed the Toll-like/interleukin receptor (TIR) domain (O'Neill 2000). 
 
Microbial recognition by TLRs occurs via conserved pathogen motifs called 
pathogen associated molecular patterns (PAMPs) (Janeway and Medzhitov 2002). 
PAMPs are specific to micro-organisms and usually essential for the survival or 
immunogenicity of the pathogen. Examples include lipopolysaccharide (LPS) of 
Gram negative bacterial cell walls, lipotechioic acid (LTA) or peptidoglycan of 
Gram-positive bacterial cell walls, zymosan of yeasts, and double stranded (ds) RNA 
of viruses. 
 
Toll-like receptors (TLRs) are a major group of receptors which recognise PAMPs. 
To date 11 TLRs have been identified (TLR 1-11) in the human (Miggin and O'Neill 
2006). TLR4 was the first TLR to be discovered in humans (Medzhitov, Preston-
Hurlburt et al. 1997), and its recognition of LPS is well described (Palsson-
McDermott and O'Neill 2004). The ancillary proteins LPS-binding protein (LBP), 
CD14 and MD-2 are required for optimal TLR4 signalling. LPS is transported in 
serum by LBP which transfers LPS to CD14 at the cell surface. CD14, which may be 
membrane bound or soluble, exhibits high affinity binding for LBP bound LPS, but 
itself lacks an intracellular signalling domain. It is crucial for presentation of LPS to 
the TLR4 signalling complex. MD-2 is a small secreted glycoprotein associated with 
the extracellular region of TLR4, and is essential for LPS binding. 
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Other TLRs recognize different molecular signatures of a pathogen class (Medzhitov 
and Janeway 2000). TLR1 and 6 act in conjunction with TLR2, which recognizes 
peptidoglycan, LPS and zymosan, whereas TLR5 is stimulated by flagellin, a 
constituent of bacterial flagella. TLR3, 7, 8 and 9 are expressed intracellularly on the 
endosome membrane, and recognize intracellular pathogens. TLR3 reacts to viral 
dsRNA, whereas TLR7 and 8 is stimulated by viral single-stranded (ss)RNA and 
TLR9 is essential in CpG DNA recognition (Takeda and Akira 2005). 
 
In pregnancy, TLR 2 and 4 have been identified in placental tissue (Holmlund, 
Cebers et al. 2002; Abrahams, Bole-Aldo et al. 2004; Kumazaki, Nakayama et al. 
2004; Kim, Romero et al. 2005; Rindsjo, Holmlund et al. 2007) and fetal membranes 
(Kim, Romero et al. 2004). There is conflicting evidence regarding lower genital 
tract TLR expression in the human. One study found TLR 1, 2, 3, 5 and 6, but not 
TLR4 in the vagina and ectocervix (Fazeli, Bruce et al. 2005) whereas another has 
identified TLR4 in the vagina (Pivarcsi, Nagy et al. 2005). TLR 1-9 mRNA has also 
been identified in the vagina and uterine tissues of the mouse (Soboll, Schaefer et al. 
2006). TLR 1, 2, 3, 4, 5 and 6 are epithelially expressed in the human endocervix, 
endometrium and fallopian tubes in the non-pregnant female reproductive tract 
(Fazeli, Bruce et al. 2005). TLR2 mRNA and protein expression is higher in the 
fallopian tube and cervix than in the endometrium and ectocervix, whereas TLR4 
expression is greater in the fallopian tube and endometrium (Pioli, Amiel et al. 
2004). Moreover, it has recently been demonstrated that TLR 2, 3, 4 and 9 mRNA 
expression in the endometrium alters during the menstrual cycle (Hirata, Osuga et al. 
2007). 
 
1.3.2. Inflammatory Signalling 
 
Inflammatory gene expression is usually dependent on transcriptional activation, and 
the gene promoters of many inflammatory mediators contain binding sites for the 
nuclear factor kappa-B (NFκB), activated protein-1 (AP-1), CAAT/enhancer-binding 
protein (C/EBP) and/or erythroblast transformation specific domain transcriptional 
regulators (ETS). Mutation or deletion of these elements has been shown to impair 
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the induction of promoters of chemokines, PGTS2, adhesion molecules and matrix 
metalloproteinases essential in the inflammatory response (Kracht and Saklatvala 
2002). Signals from TLR/ILRs, and the distinct TNFα receptors and IL-17 receptors, 
all converge on pathways which are pivotal in regulation of these transcription 
factors  the NFκB and mitogen-activated protein kinase (MAPK) pathways. 
Multiple levels of regulation occur in these pathways, as outlined below. This 
enables a finite number of stimuli to initiate distinct, but related responses, 
depending on the physiological and cellular conditions. 
 





Overview of Inflammatory Signalling (adapted from Kracht and Saklatvala 2002). 
 
1. Receptor activation and recruitment of adaptor proteins 
2. Protein Kinase Cascade 
3. Transcription factor nuclear localization and transcription 
4. mRNA stabilization and post-transcriptional modifications 
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1.3.2.1. Receptor activation and adaptor recruitment 
On ligand activation IL-1R heterodimerizes with an accessory protein (IL-1R-AcP) 
whilst TLRs oligomerize and TNFRs trimerize.  These complexes interact with 
cytosolic adaptor proteins which are essential for further signal transmission. TNFR 
binds to the adaptor TRADD (TNF-receptor-death domain), whilst TIRs bind to an 
adaptor called MYD88 (myeloid differentiation primary response gene 88). These in 
turn, recruit other adaptors  TRAFs (TNF Receptor-associated factors). TRADD 
directly recruits TRAF-2, whereas MYD88 engages TRAF-6, via phosphorylation of 
an IL-1R-associated kinase (IRAK). TRAF-6 also binds directly to liganded IL-17R 
(Kracht and Saklatvala 2002).  
 
Additional adaptors have recently been discovered which add to the complexity of 
the process. MAL (MYD88 Activator Like Protein), TRIF (TIR domain containing 
adaptor inducing interferon-beta) and TRAM (TRIF-related activator molecule) 
interact with defined TLRs, and four IRAKS and several members of the TRAF 
family have now been identified. Regulation of signalling can occur though 
sequestration, phosphorylation and degradation of these adaptor proteins, and 
interaction with negative regulatory adaptors such as IRAK-M or Toll-interacting 
protein (TOLLIP) (Miggin and O'Neill 2006). 
 
1.3.2.2. Activation of protein kinase cascades 
Downstream stimulation of inflammatory signalling pathways occurs via activation 
of IκB kinases (IKKs) in the NFκB pathway, and MAPK-kinases in the MAPK 
pathway. A large number of molecules have been implicated in the activation of 
these proteins, depending on the stimulus and cellular conditions (for reviews see 
(Kyriakis and Avruch 2001; Hayden and Ghosh 2004; Scheidereit 2006), but 
compensatory mechanisms and functional redundancy make elucidation of their roles 
difficult. Several enzymes can regulate kinases of both the NFκB and MAPK 
pathways (eg Mitogen activated/Erk kinase kinase or MEKK1, 2 and 3; MAP3K8; 
and TGFβ activated kinase-1 or TAK-1) and may activate two or more cascades 
simultaneously. Substantial cross-talk between the pathways is recognized.  
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IκB kinases (IKKs) and the NFκB pathway 
Inhibitors of κB (IκBs) are proteins which maintain NFκB dimers in an inactivated 
form in the cellular cytosol. Inflammatory stimuli induce IκB degradation via IKKs. 
IKKα, IKKβ and the scaffold protein IKKγ (also known as NEMO; NFκB essential 
modulator) form a complex, which represents a point of convergence of signals that 
activate NFκB by the so-called canonical pathway (Karin and Delhase 2000). IKKβ 
and NEMO are essential for IκB phosphorylation, which then rapidly undergoes 
polyubiquitinisation and is degraded via the 26s proteosome. This releases NFκB 
transcription factor subunits allowing them to translocate to the nucleus.  
 
A slower non-canonical pathway of NFκB activation, which is dependent on IKKα, 
is also recognized. IKKα is phosphorylated by NFκB inducing kinase (NIK), which 
is activated by a subset of inflammatory stimuli including lymphotoxin β and the 
CD40 ligand, although they can also use the canonical pathway (Bonizzi and Karin 
2004). Other IKK independent mechanisms also exist, which have not yet been fully 
elucidated (Gilmore 2006). 
 
MAPK-kinases and the MAPK pathway 
MAPKs (ERK, JNK and p38) are terminal enzymes in related signalling cascades. 
There are two forms of ERK (ERK1 and 2), three JNKs (JNK 1, 2 and 3) and three 
forms of p38 (p38α, β and γ). Each is activated by dual phosphorylation by a MAPK-
kinase (MKK). MKK1 and 2 activate ERK 1 and 2; MKK4 and 7 synergistically 
activate JNK; and MKK 3 and 6 activate p38. Although the MAPK pathways are 
distinct, there is some overlap in MAPK substrate specificity; for example all three 
MAPKs activate the ETS transcription factors ELK1 and SAP (senescence-
associated protein) 1 and 2 (Kyriakis and Avruch 2001). Negative regulation of 
transcription factors phosphorylated by MAPKs can occur via interactions with 
scaffold and adaptor proteins which retain them in the cytosol (Kracht and Saklatvala 
2002). 
 
Inflammatory and stressful stimuli nearly always activate JNK and p38, but their 
effect on ERK is more variable (Kyriakis and Avruch 2001). ERK can also be 
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stimulated by mitogens and hormones and many of the putative substrates for ERK 
are involved in general cellular processes.  
 
1.3.2.3. Transcription factors 
The NFκB and MAPK pathways can activate members of a variety of transcription 
factor families. There is substantial cross-talk between the pathways.   
 
AP-1 
AP-1 consists of homodimers and/or heterodimers of basic region leucine zipper 
proteins of the c-Jun and c-Fos and the related activating transcription factor (ATF) 
subfamilies (Karin, Liu et al. 1997). Regulation of AP-1 activity occurs via 
phosphorylation of existing subunits, as well as novel gene expression. Dimer 
composition is influenced by the extracellular stimulus and the signalling cascade 
which is activated, and the differential makeup of AP-1 complexes influences their 
DNA binding capacity and capability to mediate gene expression. 
  
NFκB 
NFκB is a family of dimeric proteins which bind to DNA κB elements. These consist 
of 910 base pairs but exhibit a great amount of variability. The group is comprised 
of two subfamilies; the NFκB proteins (in the human NFκB1 and NFκB2; also 
known as p105 and p100) and the Rel proteins (in the human Rel A also known as 
p65; Rel B and C-Rel) (Gilmore 2006). They all share a highly similar domain of 
around 300 amino acids known. This is known as the Rel homology domain (RHD) 
and contains the motif for binding κB elements, as well as a motif for dimerization, 
and a motif for nuclear localization (the nuclear localization signal or NLS) (Baldwin 
1996). 
NFκB1 and 2 (p100 and p105) are precursors which are converted to active DNA 
binding forms, respectively known as p50 and p52, by proteolysis or arrested 
translation (Gilmore 2006). They have long carboxy-terminal domains containing 
multiple copies of ankyrin repeats which inhibit their transcription ability. As such, 
NFκB protein homodimers may act as inhibitors of gene expression in resting cells, 
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and generally only activate transcription when they dimerize with Rel proteins, 
which do possess transactivation domains. 
In vivo all NFκB subunits can form homodimers, except for Rel B, which can only 
form heterodimers. Individual dimers have distinct DNA-binding site specificities, 
and form different protein-protein interactions at target promoters, thus allowing 
regulation of distinct, but overlapping genes, many of which are involved in 
inflammation. 
C/EBP 
C/EBP is a family of six basic region leucine zipper protein transcription factors, 
which contribute to the expression of a number of inflammatory mediators including 
chemokines (Stein and Baldwin 1993) and PGTS2 (Caivano, Gorgoni et al. 2001). 
They bind in different combinations to promoters, replacing or synergizing with 
other factors to maintain gene activation (Poli 1998) and their activity is at least 
partially dependent on phosphorylation by a number of protein kinases. 
 
ETS domain transcription factors 
ETS-domain transcription factors are a large family of proteins that bind to an ETS 
DNA-binding element (Yordy and Muise-Helmericks 2000; Sharrocks 2001). 
Several are important in the regulation of inflammatory genes, including ETS1, 
ELK1 and SAP1. They mediate expression either by direct binding to a promoter, or 
via binding to serum-response elements (SRE) which are found on the promoters of 
some inflammatory genes. The promoters of other transcription factors such as c-Fos 
and Jun B also contain SREs, thus ETS domain transcription factors can indirectly 
induce expression of genes regulated by these molecules. 
 
1.3.2.4. Inflammatory gene repression 
Several mechanisms repress inflammatory gene expression in unstimulated cells. 
Examples are the deacetylation of histones on gene promoters; DNA binding of 
inhibitory units such as OCT (octamer binding protein)1; and the actions of repressor 
proteins for example the NFκB repressor NRF (Kracht and Saklatvala 2002). 
Inflammatory stimuli may enable transcription through removal of these brakes ie by 
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the acetylation of histones and promoter remodelling; the displacement of inhibitory 
units by NFκB or C/EBP; and the conversion of co-factors with repressing functions 
to ones with stimulatory functions. Such processes may have evolved to prevent 
uncontrolled activation of the inflammatory system. 
 
1.3.2.5. mRNA stabilization and post-transcriptional modifications 
Many pro-inflammatory genes are inherently unstable, and may be stabilized by 
components of the MAPK or NFκB pathways (Ross 1995). This provides another 
level of control in the inflammatory response, allowing rapid changes in levels of 
gene expression and protein production to be promptly terminated. Post-
transcriptional modifications can also occur, further regulating protein expression. 
 
1.4. INFLAMMATION, INFECTION AND PRETERM LABOUR 
 
1.4.1. Labour as an inflammatory process 
 
There is a substantial body of evidence suggesting that normal labour is an 
inflammatory process. Levels of IL-1β (Romero, Parvizi et al. 1990; Gunn, 
Hardiman et al. 1996; Laham, Brennecke et al. 1996), TNFα (Romero, Mazor et al. 
1992; Laham, Brennecke et al. 1994) and IL-8 (Laham, Rice et al. 1993; Saito, 
Kasahara et al. 1993) rise in the amniotic fluid in association with normal labour. 
Findings in animal models suggest that this is a cause of the process, rather than a 
consequence of parturition, as intra-amniotic infusion of IL-1β and TNFα can 
stimulate labour (Romero, Mazor et al. 1991; Sadowsky, Adams et al. 2006), and IL-
1β, TNFα and IL-8 can stimulate cervical ripening (Chwalisz, Benson et al. 1994). 
Leukocytes which infiltrate the myometrium, cervix and fetal membranes at or 
around the onset of labour (Young, Thomson et al. 2002; Osman, Young et al. 2003) 
are a source of inflammatory cytokines and chemokines. In addition, the fetal 
membranes, decidua and placenta may contribute to cytokine production (see 
Table1.1).  
Prostaglandins are crucial in the process of parturition. These can stimulate 
myometrial contractions directly (Crankshaw and Dyal 1994) and indirectly via 
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upregulation of oxytocin receptors and synchronization of contractions (Liggins 
1989). They can also stimulate cervical ripening (Kelly 2002) and are implicated in 
fetal membrane rupture via induction of matrix metalloproteinases (McLaren, Taylor 
et al. 2000; Ulug, Goldman et al. 2001). Levels of prostaglandins rise in the maternal 
serum and fetal membranes before or at the time of labour (Olson 2003). This rise 
appears to be mediated, at least in part, by upregulation of PTGS2 in the decidua 
(Hirst, Mijovic et al. 1998; Mijovic, Zakar et al. 1999), fetal membranes (Mijovic, 
Zakar et al. 1997; Slater, Dennes et al. 1999; Sawdy, Slater et al. 2000) and 
myometrium (Sooranna, Grigsby et al. 2006). PTGS2 inhibitors decrease uterine 
contractility in vitro (Sadovsky, Nelson et al. 2000; Sawdy, Pan et al. 2003) and 
delay birth and prolong pregnancy in vivo (Panter, Hannah et al. 1999).   
Changes in NFκB activity are evident within the fetal membranes (Allport, Pieber et 
al. 2001), myometrium (Chapman, Europe-Finner et al. 2004) and cervix 
(Stjernholm-Vladic, Stygar et al. 2004) at the time of labour. Furthermore, NFκB, 
AP-1 and C/EBP regulate expression of PGTS2 (Allport, Pieber et al. 2001; Mohan, 
Sooranna et al. 2007), cytokines (Lappas, Permezel et al. 2002), matrix 
metalloproteinases (Lappas, Permezel et al. 2003) and oxytocin receptors (Terzidou, 
Lee et al. 2006) in the uterine tissues. 
 
1.4.2. The onset of normal labour 
Although it is recognized that labour is associated with an inflammatory response, 
the way this process is normally initiated in the human remains poorly understood. In 
the sheep the onset of uterine activity is mediated by a combination of progesterone 
withdrawal and increased prostaglandin production, caused by increased 
adrenocortical activity in the fetus at the end of gestation. This leads to high levels of 
circulating PGE2 and cortisol which shifts placental steroid synthesis to favour 
oestrogen over progesterone. There is also an increase in placental PTGS2 activity in 
response to fetal corticotrophin releasing hormone (CRH) (Challis, Matthews et al. 
2000). 
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There is no apparent progesterone withdrawal at the end of human pregnancy, and 
circulating levels of progesterone remain high until birth. Nevertheless, many of the 
genes which are upregulated at the time of labour are repressed by progesterone, and 
antiprogesterones can cause cervical ripening and induce the termination of 
pregnancy (Kelly 1994). It has thus been suggested that a functional progesterone 
withdrawal coincides with the onset of human labour (Brown, Leite et al. 2004). This 
may occur via the catabolism of progesterone within the uterus to inactive 
compounds by enzymes such as progesterone 5 alpha-reductase. Mice deficient in 
the type 1 isozyme of this enzyme fail to deliver their young at term despite initiation 
of co-ordinated myometrial contractions. This parturition defect appears to 
correspond to accumulation of progesterone in the cervix and failure of cervical 
ripening (Mahendroo, Porter et al. 1999). Functional progesterone withdrawal could 
also be mediated by alterations in the ratio of progesterone receptor isoforms 
(Thijssen 2005), or changes in cofactor levels which affect receptor transactivation 
(Condon, Jeyasuria et al. 2003). An alternative mechanism may be through the 
activation of NFκB, which has a mutually negative interaction with the progesterone 
receptor (Kalkhoven, Wissink et al. 1996; Pieber, Allport et al. 2001; Condon, Hardy 
et al. 2006) and thus may remove the repressive effect of progesterone from labour-
associated genes. 
In the human, serum levels of CRH early in the second trimester correlate with 
gestation at delivery (McLean, Bisits et al. 1995). CRH expression in the placenta 
and fetal membranes increase towards time of delivery (Riley, Walton et al. 1991) 
and it has also been shown that in vitro prostaglandin synthesis by human fetal 
membranes can be up-regulated by CRH (Alvi, Brown et al. 1999). However no 
direct link between CRH and onset of labour has been proven. 
1.4.3. The onset of preterm  labour 
 
Normal labour occurs between 37 and 42 weeks gestation, whereas preterm labour is 
that occurring before 37 completed weeks. Multiple aetiologies contribute to the 
onset of preterm labour, through a variety of pathological processes. These include 
uterine distension, cervical disease, ischaemia, endocrine disorders, allergic 
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phenomena, abnormal allograft reaction and infection (Romero, Espinoza et al. 
2006).  
 
Although the initiating stimuli vary, they all usually lead to delivery through the 
common pathway of cervical dilatation, myometrial contractions and membrane 
rupture seen in normal labour. It is hypothesized that these insults all, in some way, 
instigate a vigorous inflammatory response, which overwhelms normal inhibitory 
mechanisms and results in irreversible stimulation of the parturition cascade. 
Consistent with this theory, is the observation that levels of inflammatory mediators 
in gestational tissue exposed to preterm labour are higher than those seen in 
association with normal labour (Bowen, Chamley et al. 2002; Keelan, Blumenstein et 
al. 2003).  
 
1.4.4. Infection as a cause of preterm labour 
 
A particularly exaggerated inflammatory response is seen in the fetal membranes and 
amniotic fluid in cases of infection-associated preterm labour (Bowen, Chamley et al. 
2002; Keelan, Blumenstein et al. 2003). Evidence that infection is causative of both 
the inflammation and the labour is provided by animal studies.  These have proven 
that administration of bacteria or bacterial products stimulates labour; that resultant 
increases in inflammatory mediator levels precede the onset of uterine contractions; 
and that adjacent antibiotic therapy can delay or prevent the process (Table 1.2).   
 
In obstetric practice, an association between extrauterine infections such as 
pyelonephritis and pneumonia, and preterm labour has long been recognized. In 
addition, clinical chorioamnionitis, which is characterized by features of maternal 
pyrexia, uterine tenderness and fetal tachycardia is frequently an antecedent of 
preterm delivery. There is now a substantial body of evidence suggesting subclinical 
bacterial infections are also a cause of preterm delivery. This is provided by studies 
involving the microbiological analysis of amniotic fluid samples. Much of the data 
comes from the USA, where amniocentesis is frequently performed on women 
presenting with threatened preterm labour for the diagnosis of infection. This 
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practice is unusual in the UK, so there is a lack of corresponding data from this 
country.   
 












100% Approx 25 h (Celik and Ayar 2002) 
Erythromycin prolongs latency period 
Intrauterine LPS Unclear  82±13 and 63±8 h, 
respectively (controls, 
117±3 h) 
(Bennett, Terrone et al. 2000) 
Uterine catheters implanted on day 16; LPS 
infused on day 17 (term day 22) 
MOUSE     




Not reported (Kaga, Katsuki et al. 1996) 
Preterm delivery rate depended  on mated 
strains 
 LPS  90% Not reported (Lee, Kim et al. 2003) 
20% of mice receiving i.p. saline deliver 
preterm 
 LPS  100% Within 24 h (Gross, Imamura et al. 2000) 
PTGS2 inhibitors decrease preterm birth but 
do not preserve fetal viability 
 IL-1 100% Within 24 h (Romero, Mazor et al. 1991) 
Study done in C3H/HEJ (Tlr4 mutant) mice 
 LPS  70% Not reported (Harper and Skarnes 1973) 
Study done in CD-1 mice; treatment with 
progesterone decreases preterm birth but 
results in no fetal viability 
 LPS  100% 16.8 h (95% CI 15.9
17.6) versus 54.7 h 
(95% CI 43.865.5) 
for saline-injected 
mice 
(Buhimschi, Buhimschi et al. 2003) 
N-acetylcysteine increases latency interval to 











Not reported (Han, Redline et al. 2004) 
Study done in CF-1 mice; F bacterium dental 
pathogen; causes preterm delivery and fetal 
demise 
 LTA  100% at 
75 mg/kg 
Not reported (Kajikawa, Kaga et al. 1998) 
C3H/HEN mated with B6D2F1 mice; higher 
dose of LTA than LPS required to induce 
preterm delivery 
Intrauterine LPS  91% Within 20 h (Elovitz, Wang et al. 2003) 





Not reported (Mussalli, Blanchard et al. 1999) 
107 CFU or less does not induce preterm 
delivery; two maternal deaths with higher 
inoculums 
Intracervical Escher-
ichia coli  
100% Within 36 h (Reznikov, Fantuzzi et al. 1999) 
Il-1β-/-− mice have same rates of preterm 
delivery; TNF antagonist does not prevent 
preterm delivery 
RABBIT     
Intrauterine LPS Induced or 
augmented 
contractions 
Preterm delivery not 
an outcome 
(Katsuki, Kaga et al. 1997) 
LPS infused through intrauterine catheters 
Intracervical Escher-
ichia coli  
100% within 12 days (n=5) (Davies, Shikes et al. 2000) 
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Not reported (Gravett, Haluska et al. 1996) Increased 
MMP-9 levels in amniotic fluid before GBS 













Not reported (Gravett, Witkin et al. 1994)  
No monkeys are febrile or have leukocytosis 
at the time of preterm delivery 
 IL-1 100% (n=5) 1.1+/-0.2 days 
(27.6=/-1.9 in saline 
infused controls) 
(Sadowsky, Adams et al. 2006) 
Elevation in amniotic Il-1β, Il-6, Il-8, 
prostaglandins, MMP9 and leikocytes 







Not analyzed (Sadowsky, Adams et al. 2006) 
Elevation in amnioticIL-1β, IL-6,  Il-8, 
prostaglandins, MMP9 and leukocytes 
 IL-8 0% (n=2) 16.1-23 days (Sadowsky, Adams et al. 2006) 
 IL-6 0% (n=2) 23.7-29.7days (Sadowsky, Adams et al. 2006) 









Within 28 h (Schlafer, Yuh et al. 1994)  
All fetuses become hypoxic; maternal and 




0% (n=4) None delivered 
preterm 
(Grigsby, Hirst et al. 2003)  
Small but significant increase in contractile 




0% None delivered 
preterm 
(Grigsby, Hirst et al. 2003)  





Animal models used to study infection/inflammatory preterm labour (adapted from 
(Elovitz and Mrinalini 2004)).  
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The amniotic cavity is normally sterile. Women with positive amniotic cultures are 
more likely to have preterm delivery, spontaneously rupture their membranes, 
develop clinical chorioamnionitis and/or have an adverse perinatal outcome 
(Romero, Espinoza et al. 2002). Positive culture rates of 12.8% are found in women 
presenting with threatened preterm labour with intact fetal membranes, and in 22% 
of those who actually go on to deliver prematurely (Goncalves, Chaiworapongsa et 
al. 2002). Preterm prelabour rupture of membranes (PPROM) commonly precedes 
preterm delivery, and PPROM occurring in early gestation is that which is most 
likely to be associated with positive amniotic fluid cultures (Watts, Krohn et al. 
1992). 32.4% of all women with PPROM have positive amniotic fluid cultures on 
admission, which rises to 75% at the time of onset of labour, suggesting that 
intrauterine microbial invasion can occur in the interim between membrane rupture 
and the start of contractions (Goncalves, Chaiworapongsa et al. 2002). Studies which 
have identified the presence of bacteria in the amniotic fluid by PCR methods, which 
are more sensitive than culture techniques, have shown even higher incidences of 
intra-amniotic infection (Jalava, Mantymaa et al. 1996; Hitti, Riley et al. 1997; 
Gardella, Riley et al. 2004), with similar rates of adverse outcomes (Yoon, Romero 
et al. 2003).  
 
The most common way for bacteria to access the uterine cavity is by ascension from 
the vagina and cervix. Haematogenous spread of bacteria through the placenta may 
also occur. This is the putative mechanism explaining the recent finding of 
Fusobacterium nucleatum, an oral pathogen, in the amniotic fluid of women with 
preterm labour (Bearfield, Davenport et al. 2002). An association between preterm 
labour and periodontal disease is recognized but a direct link between the two 
conditions has not been proven (Klebanoff and Searle 2006). Rarer methods of 
bacterial spread are from the peritoneal cavity by way of the fallopian tubes, and 
iatrogenic infection from instrumentation of the amniotic cavity.  
 
Once bacteria reach the uterine cavity they can elicit an inflammatory reaction in the 
decidua and, if not contained, the contiguous fetal membranes. Bacteria are 
frequently detected in the chorioamnion in cases of preterm labour. However, 
35 
fluorescent in situ hybridization (FISH) can detect bacteria in the fetal membranes of 
up to 70% of women undergoing prelabour Caesarean section at term, implying that 
colonisation of the chorioamnion is not sufficient for the stimulation of labour or 
penetration of the amniotic cavity (Steel, Malatos et al. 2005). 
 
It is likely that environmental factors and pathogen virulence contribute to the 
establishment of chorioamnionitis. Genetic variation in the inflammatory response 
could also be an important factor and may explain the marked racial differences in 
the incidence of preterm labour which are seen. Single nucleotide polymorphisms in 
the TLR4 gene are more frequent in infants born at preterm gestations (Lorenz, 
Hallman et al. 2002). Polymorphisms in genes coding for IL-1β (Genc, Gerber et al. 
2002) and TNFα (Simhan, Krohn et al. 2003) are seen in increased frequency in 
association with preterm labour in a black population, whilst a polymorphism of the 
IL-6 gene resulting in decreased expression may be protective against preterm labour 
(Simhan, Krohn et al. 2003). Multilocus analysis of several allelles may reveal 
stronger genetic associations with premature birth (Menon, Velez et al. 2006).  
 
Retrospective analysis of amniotic fluid obtained for genetic diagnosis in the second 
trimester of pregnancy has shown that the presence of bacteria (Cassell, Davis et al. 
1983; Gray, Robinson et al. 1992; Horowitz, Mazor et al. 1995) and raised levels of 
IL-6 (Wenstrom, Andrews et al. 1996; Ghidini, Jenkins et al. 1997) and MMP-8 
(Yoon, Oh et al. 2001; Biggio, Ramsey et al. 2005) correlate with preterm delivery 
and pregnancy loss in the third trimester. This implies that infection can occur 
silently in pregnancy, stimulating an inflammatory response which leads to preterm 
loss or delivery only some weeks later. The organisms most commonly found 
associated with preterm labour are low virulence bacteria including Mycoplasma 
hominis, Ureaplasma urealyticum, Gardnerella vaginalis, Peptostreptococci spp and 
Bacteroides (Romero, Sirtori et al. 1989). Long term, low grade inflammatory 
stimulation by such microbes may thus be important in the pathogenesis of preterm 




1.4.5. Bacterial vaginosis and preterm labour 
 
Bacterial vaginosis is a polymicrobial infection of the lower genital tract 
characterized by a deficit of the normal population of lactobacillus, and overgrowth 
of low virulence mixed anaerobic bacteria including Gardnerella vaginalis, 
Mycoplasma hominis, Bacteroides spp, Peptostreptococcus spp, Fusobacterium spp, 
Prevotella spp, Mobiluncus spp (Lamont, 2004). Sufferers may complain of a 
malodorous vaginal discharge, but it rarely causes vulval itch, is not associated with 
a classical inflammatory reaction and in the majority of cases is asymptomatic. 
 
There is substantial evidence showing a relationship between bacterial vaginosis and 
poor perinatal outcome, in particular preterm labour, rupture of membranes and late 
miscarriage (McGregor, French et al. 1990; Kurki, Sivonen et al. 1992; Hay, Lamont 
et al. 1994; Hillier, Nugent et al. 1995) . Women with bacterial vaginosis are also at 
increased risk of a number of other infectious pathologies, such as pelvic 
inflammatory disease, HIV (Human immunodeficiency virus) infection, post-
operative infections and post-partum endometritis (Boyle, Adinkra et al. 2003).  
 
A meta-analysis of case-control and cohort studies showed bacterial vaginosis 
increases the risk of delivery before 37 weeks with an odds ratio of 2.19 (CI 1.54-
3.12) (Leitich, Bodner-Adler et al. 2003). The rates of preterm labour were much 
higher in subgroup analyses where bacterial vaginosis was diagnosed before 20 
weeks and 16 weeks gestation, however other studies have not shown this association 
(Klebanoff, Hillier et al. 2005). Trials investigating the effect of eradication of 
bacterial vaginosis on pregnancy outcome have given contradictory results, and it is 
unclear as to whether this increased risk of preterm labour is a direct result of 
bacterial vaginosis, or if bacterial vaginosis is a surrogate marker of an alternative 
underlying pathology. A systematic review of the treatment of bacterial vaginosis in 
pregnancy has shown little evidence that eradication of bacterial vaginosis results in 
any reduction in the incidence of preterm delivery in a low risk population, although 
some benefit may be seen with treatment before 20 weeks gestation (McDonald, 
Brocklehurst et al. 2007). Treatment of women who are at high risk of preterm 
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labour (who have had a previous preterm delivery) conveys slight protection over 
preterm rupture PPROM and low birth weight, but not preterm delivery (McDonald, 
Brocklehurst et al. 2007). Common treatment regimes for bacterial vaginosis include 
metronidazole and clindamycin given orally or vaginally. Although both are effective 
at eradicating bacterial vaginosis, this review found no benefit of clindamycin or 
intravaginal metronidazole in relation to pregnancy outcome. 
 
Two methods are commonly used for the diagnosis of bacterial vaginosis in research 
studies. Amsels composite criteria provide a clinical diagnosis made by finding 
three of the following four signs:  a homogenous vaginal discharge; an elevated 
vaginal pH (>4.5); clue cells on wet preparation of vaginal secretions; a positive 
whiff test (amine odour) on addition of a 10% solution of potassium hydroxide to a 
sample of vaginal secretions (Amsel, Totten et al. 1983). However, these criteria are 
subjective, poorly reproducible and unpleasant. Analysis of a Gram stain of air dried 
vaginal secretions using Nugents criteria (Nugent, Krohn et al. 1991) provides a 
method of diagnosing bacterial vaginosis which is objective and reproducible, as 
well as being cheap, quick and simple. It has therefore largely replaced Amsels 
criteria as being the gold standard for diagnosis. The technique has the advantage of 
identifying a third group of vaginal flora, intermediate in character, which is 
abnormal, but less florid than that found in bacterial vaginosis (Hillier, Krohn et al. 
1992; Rosenstein, Morgan et al. 1996; Taylor-Robinson, Morgan et al. 2003). 
Diagnosis is made by quantifying the normal and abnormal vaginal flora to obtain a 
score between 1 and 10, with 0-3 being normal (Grade I), 4-6 representing 
intermediate bacterial vaginosis status (Grade II), and 7-10 representing bacterial 
vaginosis (Grade III). In clinical practice techniques for diagnosis of bacterial 
vaginosis are still variable, and heterogeneity in the method used results in 
differences in perceived prevalence of the condition and treatment of it (Keane, Maw 
et al. 2005). 
 
Bacterial vaginosis is generally thought of as a non-inflammatory condition, and the 
number of vaginal polymorphonuclear cells found in bacterial vaginosis is not 
increased with respect to that in healthy women (Cauci 2004; Ramsey, Lyon et al. 
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2005). Nevertheless levels of inflammatory cytokines are increased in vaginal 
secretions when the condition is present. Vaginal IL-1β concentrations are higher in 
women with bacterial vaginosis than in those with normal flora, in the pregnant 
(Imseis, Greig et al. 1997; Mattsby-Baltzer, Platz-Christensen et al. 1998; Cauci, 
Guaschino et al. 2003) and non-pregnant (Spandorfer, Neuer et al. 2001; Hedges, 
Barrientes et al. 2006) states; and return to normal after successful treatment of the 
condition (Basso, Gimenez et al. 2005). IL-1β levels are also higher in women with 
intermediate flora (Hedges, Barrientes et al. 2006). IL-8 concentrations have been 
found to be elevated in vaginal secretions from women with bacterial vaginosis in 
some studies (Wennerholm, Holm et al. 1998; Spandorfer, Neuer et al. 2001; Basso, 
Gimenez et al. 2005), but these findings are not confirmed in other groups work 
(Cauci, Guaschino et al. 2003; Diaz-Cueto, Cuica-Flores et al. 2005). There are also 
mixed reports about levels of IL-1α (Platz-Christensen, Mattsby-Baltzer et al. 1993; 
Imseis, Greig et al. 1997; Wennerholm, Holm et al. 1998). These differences 
probably relate to differences in sample collection and sensitivity of analysis. Levels 
of IL-6 and TNFα (Imseis, Greig et al. 1997; Hedges, Barrientes et al. 2006) do not 
seem to be altered with bacterial vaginosis in vaginal secretions, although levels of 
both IL-1β and TNFα are raised in cervical mucus in the presence of bacterial 
vaginosis (Sturm-Ramirez, Gaye-Diallo et al. 2000). There is no evidence of 
concurrent elevation of serum cytokines in the presence of bacterial vaginosis 
(Hedges, Barrientes et al. 2006). 
 
The prevalence of bacterial vaginosis varies with the population studied, being found 
in 15% of pregnant women in a middle-class area of London (Hay, Lamont et al. 
1994), and 33% of pregnant women in an American inner city area (McGregor, 
French et al. 1995). There is considerable racial disparity, being more common in 
Afro-Caribbean women than Caucasian women (Goldenberg, Klebanoff et al. 1996; 
Royce, Jackson et al. 1999). The condition is associated with a number of factors 
including multiple sexual partners (Morris, Rogers et al. 2001; Smart, Singal et al. 
2004), lesbian sexual activity (Bailey, Farquhar et al. 2004), cigarette smoking 
(Hellberg, Nilsson et al. 2000; Smart, Singal et al. 2004), intrauterine contraceptive 
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device usage (Joesoef, Karundeng et al. 2001) and vaginal douching (Ness, Hillier et 
al. 2002). 
 
Genetic variation among individuals may be responsible for an increased 
susceptibility to both  bacterial vaginosis and preterm delivery, and polymorphisms 
in genes for IL-1β, IL-6, IL-8 and TLR4 have been associated with increased rates of 
bacterial vaginosis in pregnancy (Genc, Vardhana et al. 2004; Goepfert, Varner et al. 
2005). However, one study has found that a TNFα promoter polymorphism 
predisposes to preterm delivery only in the presence of bacterial vaginosis (Macones, 
Parry et al. 2004), suggesting gene-environment interactions are crucial to the 
development of preterm labour. These findings may go some way to explaining the 
conflicting results of bacterial vaginosis treatments on pregnancy outcome.  
 
1.4.6. Clinical aspects of preterm labour and infection 
 
1.4.6.1. Outcomes 
Preterm birth is associated with high rates of perinatal mortality, as well as short and 
long term morbidities which have a substantial burden on healthcare resources. In 
Scotland in 2004, 7.8% of births occurred before 37 weeks, and these accounted for 
64% of neonatal deaths (Scottish Morbidity Report 02 and Scottish Perinatal Infant 
and Maternal Mortality Report; ISD Scotland; http://www.isdscotland.org/) In 
England, Wales and Northern Ireland in 2004, 73% of neonatal deaths were related 
to prematurity (Perinatal Mortality Surveillance, 2004, England, Wales and Northern 
Ireland; Confidential Enquiry into Maternal and Child Health (CEMACH); 
http://www.cemach.org.uk). Approximately one-third of these deliveries are 
iatrogenic, with delivery indicated by conditions such as severe intrauterine growth 
restriction or fulminating pre-eclampsia.  The rest are a result of preterm labour. 
Despite some advances in understanding its aetiology in the last two decades, rates of 
preterm labour have remained static, or even slightly increased. Incidence in the 
developing world is even higher. As yet there is no effective way of preventing 




Infection is responsible for 30-50% of cases of preterm labour. When infection is 
associated with preterm labour, the perinatal outcome is worsened. This is probably 
secondary to activation of the fetal inflammatory response by infectious organisms. 
Fetal bacteraemia has been detected in 33% of babies with infected amniotic fluid, 
compared to 4% of those with negative amniotic fluid culture (Gray, Robinson et al. 
1992). Neonates which have been exposed to intrauterine infection are more likely to 
be affected by severe morbidities including respiratory distress, intraventricular 
haemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia and  
necrotizing enterocolitis, in addition to having higher rates of sepsis (Gomez, 
Romero et al. 1998).  
 
Infection also significantly worsens the perinatal outcome in term parturition 
(Peebles and Wyatt 2002), illustrating that even when infection is not causative of 
the labour process, it can have deleterious effects. The open cervix, and in some case 
ruptured membranes, provide a direct route for microbial ascension from the vagina, 
and acute infection of the uterine contents. 
 
1.4.6.2. Antibiotics for the prevention of preterm labour 
Long standing recognition of an association between infection and preterm labour 
has led to trials of antibiotics for its prevention. One intervention that has been 
successful is the antibiotic treatment of asymptomatic bacteriuria in pregnancy which 
results in a 40% reduction of preterm labour or delivery of a low birth weight infant 
(Smaill 2001). It is unclear whether this decrease is secondary to a reduction in 
subsequent acute urinary tract infection, or whether it represents clearance of 
pathogen colonisation of the genitourinary epithelium.  
 
A recent meta-analysis of antibiotic prophylaxis in the second trimester of pregnancy 
has shown that macrolides (erythromycin, azithromycin, clarithromycin and 
clindamycin) are associated with a moderate decrease in the incidence of preterm 
birth (OR 0.72, confidence interval 0.56-0.93), but metronidazole is associated with a 
slight increase in preterm labour (OR 1.1, confidence interval 0.95-1.29) (Morency 
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and Bujold, 2007). These conflicting results, along with those involving the 
eradication of bacterial vaginosis discussed above, reflect both the complexity of the 
pathogenesis of preterm labour and the heterogeneity of interventional trials. 
 
Indiscriminate antibiotic use can be harmful via the promotion of antibiotic resistant 
strains. They may also have more specific detrimental effects, as illustrated by the 
increased incidence of necrotizing enterocolitis associated with co-amoxiclav use in 
pregnancy (Kenyon, Taylor et al. 2001). Prophylaxis for the prevention of preterm 
labour must therefore be targeted, based on individual risk. The development and 
evaluation of such strategies should be an aim of research in this field. 
 
1.4.6.3. Antibiotics for the treatment of preterm labour 
Intrauterine infection threatens the well-being of the fetus and the mother. By the 
time labour is evident, inflammatory parturition pathways have already been 
activated, thus it seems unlikely that even vigorous treatment of a causative infection 
could arrest the progression of parturition at this stage. Results of a large randomized 
control trial in humans are consistent with this, showing no benefit of antibiotic use 
in the treatment of women presenting with spontaneous preterm labour (Kenyon, 
Taylor et al. 2001). Subsequent meta-analysis of this and other trials, also failed to 
show any neonatal benefits (King and Flenady 2002).  
 
There does seem to be some benefit in the administration of antibiotics in cases of 
preterm rupture of membranes. Erythromycin use decreases the incidence of 
chorioamnionitis, prolongs the latency period to delivery and also lessens neonatal 
morbidities such as neonatal infection, positive blood culture, use of surfactant and 
oxygen therapy and abnormal cranial ultrasound on discharge (Kenyon, Boulvain et 
al. 2004). However, no effect on neonatal mortality is seen. It is possible that 
antibiotics in these cases prevent the sequelae of secondary, acute infections, which 
can evolve once the protective functions of the fetal membranes have been lost. It 




1.5. NATURAL ANTIMICROBIALS 
 
Natural antimicrobials are genetically determined proteins that play a major part in 
both innate and adaptive immunity. They are an ancient form of host defence first 
established in lower phyla such as plants (thionins), insects (eg. cecropins, 
drosomycin and insect defensins) but now appreciated as being vital in the 
mammalian immune response. Over 800 natural antimicrobials have been recognized 
to date (http://bbcm1.univ.trieste.it/~tossi/pag1/htm) A single species will express a 
variety of different proteins, either constitutively or after induction by inflammatory 
stimuli, which can act synergistically to provide broad spectrum antimicrobial 
activity against bacteria, fungi and some viruses (Hancock and Diamond 2000). It is 
increasingly realized that many peptides also have other effects on a wide range of 
host functions (Bowdish, Davidson et al. 2006). 
 
Typically natural antimicrobials are small cationic proteins composed of 12-45 
amino acids containing excess basic lysine, arginine and histidine residues. They are 
divided into four structural classes based on 3-D structure; β-sheets, α-helices, 
extended peptides and loop peptides (Hancock and Diamond 2000). Their microbial 
killing may be effected via a variety of mechanisms including membrane 
depolarization, membrane permeablization, induction of hydrolases, disruption of 
membrane functions and/or damage of critical intracellular proteins (Zasloff 2002). 
Crucial to all these processes are selective interactions with the membranes of micro-
organisms. Mammalian cell membranes are mainly constructed of zwitterionic 
phospholipids, which have no net charge overall, and any phospholipids with anionic 
head groups tend to face inwards. They are also stabilized by a high cholesterol 
content. In contrast, prokaryote membranes have many highly anionic phospholipids 
orientated outwards which interact with positively charged, hydrophobic 
antimicrobials. Natural antimicrobials form aggregates in the lipid bilayer, physically 
disrupting it, and, in some cases, allowing diffusion of peptides to intracellular 
targets (Matsuzaki 1999; Shai 1999; Yang, Weiss et al. 2000). Increasing ionic 
strength generally decreases natural antimicrobial activity, probably via reducing the 
strength of initial interactions. 
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Two major types of human natural antimicrobials are the human beta-defensins 
(HBDs) and two antileukoproteinases- secretory leukocyte protease inhibitor (SLPI) 
and elafin- which have defensin-like properties (Sallenave 2002).  
 
1.5.1. Human beta-defensins (HBDs) 
 
HBDs are members of the larger defensin family, which contain 28  42 amino acids 
which form triple-stranded β sheets on a frame of six disulphide linked cysteines. 
The classification into alpha (α) and beta (β) defensins depends on the position of the 
cysteine bonds, but they have very similar tertiary structures (Zimmermann, Legault 
et al. 1995). The α defensins (Human Neutrophil Peptides 1-4; HNP 1-4) are a 
product of neutrophils, forming 30-50% of the protein content of the azurophilic 
granules (Rice, Ganz et al. 1987). They are also found in the Paneth cells of the small 
intestine (Human Defensins 5 and 6; HD 5 and 6) (Selsted, Miller et al. 1992). A 
third class, the theta (θ) defensins, have been identified (Tang, Yuan et al. 1999), 
which have a circular structure, and enhanced antiviral activities (Lehrer 2004).   
 
HBDs are predominantly epithelial products. The functions of HBD1-4 are the best 
characterized, although genomic data-mining has identified many additional defensin 
genes (Scheetz, Bartlett et al. 2002; Schutte, Mitros et al. 2002; Yamaguchi, Nagase 
et al. 2002). HBD1 was originally identified in an ultrafiltrate of human plasma from 
renal dialysis patients (Bensch, Raida et al. 1995). HBD2 and HBD3 were discovered 
in human skin, and the biological relevance of these factors was indicated by their 
particularly high expression in psoriatic plaques (Harder, Bartels et al. 1997; Harder, 
Bartels et al. 2001). HBD4 was identified by genomic screening techniques (Garcia, 
Krause et al. 2001). 
  
It is now appreciated that HBD1, 2 and 3 are widely expressed, and a substantial 
amount of information regarding their functions has been gained from research of 
their production by skin, gut, respiratory and oral epithelia.  HBD3 is also expressed 
in some non-epithelial tissues including skeletal and cardiac muscle and leukocytes 
(Garcia, Jaumann et al. 2001).  
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Unlike the HNPs, which are stored, HBD concentrations are generally governed by 
synthesis and secretion rates. Production of HBD1 is generally constitutive, whereas 
HBD2 and 3 tend to be upregulated by a variety of inflammatory stimuli including 
bacteria, bacterial products, and cytokines (Zhao, Wang et al. 1996; Harder, Bartels 
et al. 1997; Huttner and Bevins 1999; Mathews, Jia et al. 1999; O'Neil, Porter et al. 
1999; Krisanaprakornkit, Kimball et al. 2000; Harder, Bartels et al. 2001; 
Chadebech, Goidin et al. 2003). The 5 flanking region of the HBD2 gene (DEFB4) 
contains NFκB, C/EBP and AP-1 binding sites (Tsutsumi-Ishii and Nagaoka 2002) 
whilst the region of the HBD3 gene (DEFB103) has C/EBP and AP-1 sites (Jia, 
Schutte et al. 2001). This suggests these elements are important in HBD expression. 
In vivo, HBD2 and HBD3 tend to be found in epithelia in association with infection 
and inflammation, whereas HBD1 is often intrinsically present in healthy tissues 
(Schonwetter, Stolzenberg et al. 1995; Hiratsuka, Nakazato et al. 1998; Liu, Wang et 
al. 1998; Singh, Jia et al. 1998; Milner, Cole et al. 2003; Wehkamp, Fellermann et al. 
2005). However, HBD1 (DEFB1) gene expression may also have an inducible 
component, as it has recently been shown to be stimulated by IFN-γ in vitro (Joly, 
Organ et al. 2005). HBD4 (DEFB104) is also inducible, but has more restricted 
expression, found in testis, stomach, uterus, neutrophils, thyroid and kidney (Garcia, 
Krause et al. 2001). 
 
Clusters of putative HBD genes have been found at 20p13, 20q11.1, and 6p12, but 
most HBDs are found in a cluster at 8p23.1, (Schutte, Mitros et al. 2002). This band 
is a frequent site of chromosomal rearrangements, and the cluster containing DEFB4, 
DEFB103, and DEFB104 is polymorphic in copy number (Hollox, Armour et al. 
2003). Individuals have 212 copies of this repeat per diploid genome. The copy 
number is reflected in mRNA expression levels, and recently Crohns disease has 
been associated with both a decreased copy number of DEFB4 and decreased 
intestinal mRNA expression of HBD2 (Fellermann, Stange et al. 2006). Copy 
number polymorphisms are not associated with severity of lung disease in cystic 
fibrosis (Hollox, Davies et al. 2005). It remains to be seen if the copy number 
correlates with other infectious or inflammatory conditions. 
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HBD1, 2 and 3 have strong activity against Gram-negative bacteria, being 
bactericidal at concentrations of 1-500µg/ml (Harder, Bartels et al. 1997; Schroder 
1999; Harder, Bartels et al. 2001; Chen, Niyonsaba et al. 2005). HBD2 and HBD3 
also have activity against yeasts such as Candida albicans (Harder, Bartels et al. 
1997; Harder, Bartels et al. 2001). There is conflicting data on the effects of 
defensins on Gram-positive organisms. Earlier studies suggested HBD2 had only 
bacteriostatic activity, at concentrations greater than 100µg/ml (Harder, Bartels et al. 
1997). Recent reports have shown HBD1, 2 and HBD3 are all lethal to a range of 
Gram-positive organisms at concentrations as low as 10µg/ml (Chen, Niyonsaba et 
al. 2005) including, in the case of HBD3, multi-drug resistant strains (Harder, Bartels 
et al. 2001). These effects are synergistic with each other and other classes of natural 
antimicrobial such as the cathelicidin LL-37, and lysozyme (Chen, Niyonsaba et al. 
2005). Interestingly, this study found that HBDs have enhanced antimicrobial 
efficiency at low pH (4.6), which had not been shown before (Valore, Park et al. 
1998). 
 
HBDs have a number of functions in addition to their antimicrobial activity, many of 
which involve regulation of the inflammatory and immune responses. HBD2 induces 
histamine release and stimulates prostaglandin D2 production by rat mast cells 
(Niyonsaba, Hirata et al. 2003). HBD2 (Niyonsaba, Iwabuchi et al. 2002) 3 and 4 
(Chen, Niyonsaba et al. 2007) are also chemoattractants for mast cells. The mouse 
orthologue of HBD2, mBD2, is an endogenous ligand for TLR4 on immature 
dendritic cells and induces dendritic cell maturation (Biragyn, Ruffini et al. 2002). In 
humans, HBD2 is chemotactic for dendritic cells and T-cells (Yang, Chertov et al. 
1999) and TNFα treated neutrophils (Niyonsaba, Ogawa et al. 2004) apparently by 
interaction with the CCR6 receptor. Recent studies have shown that HBD2, 3, and 4 
stimulate production of a variety of chemokines and cytokines (IL-8, IL-6, IL-18, IL-
20 IL-10, CCL2, CCL20 and CCL5) from human keratinocytes and also increased 
keratinocyte migration, and proliferation in an EGFR/signal transducer and activator 
of transcription (STAT) dependent way (Niyonsaba, Ushio et al. 2005; Niyonsaba, 
Ushio et al. 2007).  
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1.5.2. The antileukoproteinases- SLPI and elafin 
 
Secretory leukocyte protease inhibitor (SLPI) and elafin are members of the four-
disulphide core family of antiproteinases (Schalkwijk, Wiedow et al. 1999). These 
are produced locally at sites of injury and counteract the effects of excess proteolytic 
enzymes released by inflammatory cells. They also have direct antimicrobial 
activities (Hiemstra, Maassen et al. 1996; Simpson, Maxwell et al. 1999) and can 
regulate the innate and adaptive immune responses (Fitch, Roghanian et al. 2006). 
 
1.5.2.1. Structure and distribution 
SLPI 
SLPI is an 11.7 kDa protein, consisting of 107 amino acids including 16 cysteine 
residues which form eight disulphide bridges (Seemuller, Arnhold et al. 1986). It is 
expressed constitutively by many epithelia, including the mucosa of the respiratory, 
intestinal and genital tracts and oral cavity (Franken, Meijer et al. 1989; Sallenave, 
Silva et al. 1993; Si-Tahar, Merlin et al. 2000; Saitoh, Masuda et al. 2001) as well as 
neutrophils, macrophages and mast cells (Bohm, Aigner et al. 1992; Jin, Nathan et al. 
1997; Sallenave, Si Tahar et al. 1997; Westin, Polling et al. 1999). 
 
The SLPI gene is localized on chromosome 20q12-13. 2 (Kikuchi, Abe et al. 1997) 
and is a non-polymorphic, stable gene but can be modulated at both the 
transcriptional and translational levels (Maruyama, Hay et al. 1994). The promoter 
region has not been extensively studied, but early investigations demonstrated an 
AP-1 and AP-2 consensus site (Abe, Kobayashi et al. 1991). Epithelial expression of 
SLPI expression appears to be tissue specific. It is increased by a variety of 
inflammatory stimuli including LPS, IL-1β, TNFα, EGF, HNPs and human 
neutrophil elastase whilst anti-inflammatory mediators such as TGFβ and IL-10 can 
decrease production (Williams, Brown et al. 2006). 
 
Elafin 
Elafin is a 9.9 kDa protein composed of 95 amino acids and shows 40% sequence 
identity with the SLPI molecule (Sallenave and Silva 1993). Its C-terminal domain 
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contains an antiproteinase site which is similar to that of SLPI. The N-terminal 
contains characteristic sequences which allow it to be crosslinked into polymers or 
bind to extracellular matrix via transglutamination (Nara, Ito et al. 1994). There is 
some evidence that tissue bound elafin is more effective at preventing elastase 
mediated tissue damage in vivo (Tremblay, Vachon et al. 2002).  
 
Elafin was first identified in bronchial mucus (Hochstrasser, Albrecht et al. 1981) 
(Sallenave and Ryle 1991) and has been subsequently found in skin (Wiedow, 
Schroder et al. 1990), intestine (Schmid, Fellermann et al. 2007) and endometrium 
(King, Critchley et al. 2003). It may be constitutively expressed at a low level, but 
expression is greatly induced by IL-1β and TNFα (Sallenave, Shulmann et al. 1994; 
Tanaka, Fujioka et al. 2000). The gene for elafin has 5 regulatory sites for NFκB 
and AP-1(Zhang, Zou et al. 1995), and the response to cytokines appears to involve 
MAPK pathways in the skin (Pfundt, Wingens et al. 2000) and NFκB pathways in 
the lung (Bingle, Tetley et al. 2001). 
 
1.5.2.2. Antiprotease  activity 
SLPI can inhibit a variety of human neutrophil proteases including cathepsin G, 
trypsin, chymotrypsin and chymase, however its greatest activity seems to be against 
neutrophil elastase (Thompson and Ohlsson 1986; Boudier and Bieth 1992). Elafin 
has more restricted antiprotease activity to SLPI, inhibiting porcine pancreatic 
elastase, human neutrophil elastase and proteinase-3 (Schalkwijk, Wiedow et al. 
1999). 
 
1.5.2.3. Antimicrobial activity 
Both SLPI and elafin have direct antimicrobial activity against Gram-negative and 
Gram-positive organisms, but elafin is the more effective agent (Simpson, Maxwell 
et al. 1999).  In SLPI, bactericidal activity is confined to the N-terminal (Hiemstra, 
Maassen et al. 1996), whereas the antibacterial activity of elafin is found in both the 
C- and N-domains, and the full length protein is required for the most efficient 
activity (Simpson, Maxwell et al. 1999). 
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SLPI has in vitro bactericidal activity against Escherichia coli and Staphylococcus 
aureus (Hiemstra, Maassen et al. 1996), Pseudomonas aeruginosa and 
Staphylococcus epidermidis, (Wiedow, Harder et al. 1998) Salmonella typhimurium 
(Si-Tahar, Merlin et al. 2000) and Group A Streptococcus (Fernie-King, Seilly et al. 
2002). In lung fluid the antibacterial properties of SLPI are synergistic with 
lactoferrin and lysozyme, but additive with HBDs and the cathelicidin LL-37 (Singh, 
Tack et al. 2000). SLPI is also antifungal against candida and aspergillus spp 
(Tomee, Hiemstra et al. 1997; Wiedow, Harder et al. 1998), and specific anti-HIV 
activities have been demonstrated in vitro (McNeely, Dealy et al. 1995; McNeely, 
Shugars et al. 1997; Shine, Wang et al. 2002). In vivo, lower concentrations of SLPI 
in vaginal fluid and saliva have been associated with increased vertical and 
breastmilk HIV transmission (Pillay, Coutsoudis et al. 2001; Farquhar, VanCott et al. 
2002). 
 
Elafin has in vitro antimicrobial activity against the Gram-negative respiratory 
pathogen Pseudomonas aeruginosa and Gram-positive Staphyloccus aureus 
(Simpson, Maxwell et al. 1999; McMichael, Maxwell et al. 2005). Cell free 
supernatants of Pseudomonas aeruginosa also stimulate elafin production by 
keratinocytes, suggesting the biological relevance of these findings (Meyer-Hoffert, 
Wichmann et al. 2003). In addition, in vivo antimicrobial effects have been 
demonstrated in mice which express the human elafin secondary to adenoviral gene 
transfer. These show enhanced bacterial elimination and decreased bacterial 
haematogenous spread in response to challenge with Pseudomonas aeruginosa 
(Simpson, Wallace et al. 2001). 
 
The mechanism of antileukoproteinase antimicrobial activity is unclear. They are 
cationic proteins, thus may interact with microbial membranes in a defensin like 
manner.  Like defensins, their bactericidal effects are diminished by high salt 
concentrations (Hiemstra, Maassen et al. 1996).  
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1.5.2.4. Immunomodulatory activity 
SLPI and elafin demonstrate a variety of anti-inflammatory effects in a number of 
tissues which cannot be solely attributed to their antiproteinase or antibacterial 
activities. In an animal model of chemically induced lung fibrosis, administration of 
SLPI decreases tissue damage, and even a truncated form which lacks the anti-
elastase domain, exerts this effect (Mitsuhashi, Asano et al. 1996).  SLPI also 
decreases cortical damage after ischaemic induced stroke in rats (Wang, Li et al. 
2003). Forced expression of elafin reduces inflammation in animal models of 
atherosclerosis (Henriksen, Hitt et al. 2004) and myocardial infarction (Ohta, 
Nakajima et al. 2004). In humans, SLPI and elafin induction appear attenuated in 
Crohns disease, characterized by inflammation affecting the full thickness of 
intestinal wall, when compared to ulcerative colitis, which is an inflammatory 
condition only involving the mucosa (Schmid, Fellermann et al. 2007). 
 
These effects may be mediated in three ways  by inhibition of inflammatory cell 
infiltration, by inhibiting release of inflammatory mediators, and/or by promotion of 
resolution of inflammation (Williams, Brown et al. 2006). SLPI has been shown to 
decrease neutrophil recruitment in a model of arthritis (Sehnert, Cavcic et al. 2004) 
whilst elafin reduces neutrophil infiltration in LPS induced lung injury (Vachon, 
Bourbonnais et al. 2002). SLPI can also inhibit histamine release from mast cells 
(Dietze, Sommerhoff et al. 1990; He, Xie et al. 2004) and suppress eosinophil 
degranulation (Murata, Sharmin et al. 2003). Both SLPI and elafin may promote 
phagocytosis of apoptotic cells. Elafin inhibits neutrophil elastase cleavage of the 
CD14 from macrophages which promotes recognition of apoptotic cells (Henriksen, 
Devitt et al. 2004). SLPI production by macrophages is increased during 
phagocytosis (Odaka, Mizuochi et al. 2003), and SLPI also stimulates production of 
anti-inflammatory cytokines TGFβ and IL-10 (Sano, Shimizu et al. 2000). 
 
Some of the anti-inflammatory effects of the antileukoproteianses may involve 
inhibition of NFκB.  In vitro, overexpression of SLPI suppresses NFκB activation 
(Jin, Nathan et al. 1997; Sano, Shimizu et al. 2003; Henriksen, Hitt et al. 2004). It 
can prevent proteosome dependent IκBβ degradation (Lentsch, Jordan et al. 1999) 
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and also directly bind to NFκB consensus sites on DNA, inhibiting transcription 
(Taggart, Cryan et al. 2005). SLPI also inhibit LPS binding to CD14 and inhibits 
TLR signalling (Ding, Thieblemont et al. 1999). 
 
Studies involving the expression of human elafin in mice have reported that 
antileukoproteinases also have some proinflammatory activities. Forced elafin 
expression upregulates TNFα expression in response to LPS in murine macrophages 
(McMichael, Roghanian et al. 2005), whilst mice expressing elafin show increased 
inflammatory infiltration in response to LPS (Simpson, Cunningham et al. 2001; 
Sallenave, Cunningham et al. 2003). It is appreciated that adenovirus vectors may 
themselves have some effect on the response. In addition, the conflicting results 
between these, and studies using recombinant elafin (Vachon, Bourbonnais et al. 
2002) may be explained by additional effects of transgenic elafin on intracellular 
pathways. Serum TNFα levels in these animals are paradoxically lower, supporting 
the theory that elafin may stimulate local innate immune responses whilst 
downregulating systemic inflammation (Sallenave, Cunningham et al. 2003; 
Williams, Brown et al. 2006).  
 
Recent studies have shown that the antileukoproteinases also interact with the 
adaptive immune response. Elafin increases recruitment of dendritic cells in murine 
lungs exposed to adenovirus-antigen, and promotes a type-1 response evidenced by 
increased production of IFNγ and TNFα. (Roghanian, Williams et al. 2006; 
Williams, Brown et al. 2006). 
 
Wound healing and tissue remodelling are other processes involving the 
antileukoproteinases. SLPI and elafin are produced in response to cutaneous injury 
(van Bergen, Andriessen et al. 1996; Wingens, van Bergen et al. 1998) and SLPI null 
mice show impaired cutaneous wound healing and increased inflammation and 
elastase activity (Ashcroft, Lei et al. 2000; Angelov, Moutsopoulos et al. 2004). SLPI 
can also modulate production of matrix metalloproteinases from monocytes by 
inhibiting enzymes involved in PGE2 synthesis (Zhang, DeWitt et al. 1997).  
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1.5.3. Natural antimicrobials in the reproductive tract 
 
Expression of natural antimicrobial RNA and protein by maternal and fetal tissues in 
pregnancy are summarized in Figures 1.3 and 1.4. 
 
1.5.3.1. α-defensins 
α-defensins are localized in endometrial neutrophils (King, Critchley et al. 2003) and 
expression of HD5 in the endometrium and cervicovaginal lavages is cyclical 
(Quayle, Porter et al. 1998). In the non-pregnant state HD5 has also been detected in 
the vagina, ectocervix, endocervix, endometrium and fallopian tubes (Svinarich, 
Wolf et al. 1997; Quayle, Porter et al. 1998) and HNP 1-3 and HD5 are found in 
cervicovaginal secretions (Valore, Wiley et al. 2006). 
 
In pregnancy HNPs are detectable in the cervicovaginal fluid of approximately 70% 
of pregnant women at 24-29 weeks gestation, and levels positively correlate with 
intermediate bacterial vaginosis status, but not bacterial vaginosis itself (Balu, Savitz 
et al. 2002).  Women with elevated concentrations of cervicovaginal HNPs at 24-29 
weeks also had a greater risk of delivering before 32 weeks (Balu, Savitz et al. 2003). 
However, as HNPs are neutrophil granule products, this elevation may simply reflect 
the neutrophil infiltration that is known to occur in preterm labour, rather than 
actually being involved in the pathogenesis of the condition. mRNA corresponding 
to HNP 1 or 3 had been found in amnion, chorion and placental tissue (Svinarich, 
Gomez et al. 1997), and HD5 mRNA was also found in samples from the chorion 




HBD 1-4 are produced by the endometrium, and their expression varies with the 
menstrual cycle (Fleming, King et al. 2003; King, Critchley et al. 2003; King, 
Fleming et al. 2003). This suggests they may be important in defence at vulnerable 
times such as menstruation and implantation. HBD1 is expressed in vaginal 
epithelium (Valore, Park et al. 1998) and HBD2 is produced by the immortalized 
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human vaginal cell line PK E6/E7 (Pivarcsi, Nagy et al. 2005). In these cells 
expression is significantly upregulated by the microbial products LPS, PG and heat-
killed Candida albicans. In contrast, vaginal expression of the mouse beta-defensins 
1, 2 and 4 are not affected by bacterial products (Soboll, Schaefer et al. 2006). HBD1 
and 2 are present in vaginal secretions in non-pregnant women, and levels are 
decreased in association with bacterial vaginosis (Valore, Park et al. 2002; Valore, 
Wiley et al. 2006).  
 
At the outset of this project there was little published data on the expression of HBDs 
in pregnancy, except for an abstract suggesting HBD1 and 2 mRNA is expressed in 
the placenta and chorion, but not the amnion (Feng, Pan et al. 2003). Since then 
HBD1, 2 and 3 expression in both fetal membranes and placenta has been confirmed 
by immunohistochemistry (King, Paltoo et al. 2007). In addition, this study showed 
HBD2 production by the chorion and placental trophoblast that was responsive to IL-
1β. One other paper has provided further immunohistochemical evidence of HBD3 
expression in the amnion (Buhimschi, Jabr et al. 2004).  
 
1.5.3.3. SLPI and elafin 
SLPI is secreted by the endometrium, and again expression is cyclical (Fleming, 
King et al. 2003; King, Critchley et al. 2003; King, Critchley et al. 2003). Levels are 
also influenced by the levonorgestrel intra-uterine system and the combined oral 
contraceptive pill, suggesting hormonal regulation (Fleming, King et al. 2003). 
Interestingly, progesterone has been shown to influence SLPI, but not elafin 
expression in a cell line expressing the progesterone receptor (King, Morgan et al. 
2003). 
 
In both pregnant and non-pregnant women cervicovaginal concentrations of SLPI are 
decreased in the presence of genital tract infections, including bacterial vaginosis 
(Draper, Landers et al. 2000; Valore, Wiley et al. 2006). SLPI is expressed in the 
vagina in higher levels than in uterine tissues in the mouse, but production is 
unaffected by bacterial products or TLR agonists (Soboll, Schaefer et al. 2006). SLPI 
is also constitutively produced by both vaginal and cervical immortalized human cell 
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lines (VK E6/E7, ECT E6/E7 and END E6/E7), but secretion is not increased by 
treatment with the cytokines TNFα or IFNγ (Fichorova and Anderson 1999).  
 
SLPI is found in the amniotic fluid and levels increase during pregnancy (Zhang, 
Shimoya et al. 2001) and at the onset of labour (Denison, Kelly et al. 1999). 
Decreased levels of SLPI have also been reported in association with prelabour 
rupture of membranes occurring in the absence of infection (Helmig, Romero et al. 
2002). Amnion, chorion and placental secretion of SLPI has been demonstrated 
(Denison, Kelly et al. 1999) and it is also produced by first trimester decidua (King, 
Critchley et al. 2000). Production in the amnion may be stimulated by IL-1β and 
TNFα (Zhang, Shimoya et al. 2001). In addition, SLPI was found in extremely high 
levels in the cervical mucus plug in pregnancy, where it might be important in 
microbial defence and protection against protease mediated fetal membrane damage 
(Helmig, Uldbjerg et al. 1995). PGE2 inhibits its production by the cervix (Denison, 
Calder et al. 1999). 
 
Elafin has been immunolocalized in the vagina (Pfundt, Wingens et al. 2000). It has 
recently also been shown in the placenta and fetal membranes and is secreted by 
trophoblast in response to IL-1β (King, Paltoo et al. 2007). 
 
1.5.3.4. Other antimicrobials 
A number of other natural antimicrobial factors including lysozyme, lactoferrin, LL-
37, Bacteriacidal Permeability Inducing Factor (BPI) and calprotectin have been 
identified in the amniotic fluid and vernix, which may have a role in protection of the 
fetus in pregnancy (Figure 1.4). 
54 
 
Figure 1.3  
 
Fetal and Maternal natural antimicrobial RNA expression in pregnancy.  
* expression identified in non-pregnant reproductive tract. ** expression in immortalized cell line.
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Fetal and Maternal natural antimicrobial proteins in pregnancy.  
*identified in non-pregnant reproductive tract. ** identified in immortalized cell line.
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This thesis concerns aspects of the innate immune response which is a complex 
process involving cytokines, chemokines and natural antimicrobials, briefly outlined 
above. The innate immune response provides our first line of defence against 
infection and is responsible for the inflammation seen in response to injury. 
However, it is increasingly recognised that inflammation is also involved in 
physiological processes, including that of parturition. Normal labour is associated 
with an inflammatory response, but this is exaggerated in case of preterm labour.  
Elucidation of this process is vital, because preterm labour remains the leading cause 
of perinatal morbidity and mortality and rates of this pregnancy complication seem to 
be increasing. 
 
Natural antimicrobials are a relatively under researched component of the innate 
immune response in pregnancy. Nevertheless, they may be important in the 
prevention of infections which are associated with approximately one third of cases 
of preterm labour.  In addition, natural antimicrobials are involved in a variety of 
biological processes relevant to parturition, including chemotaxis, tissue remodelling 
and protease inhibition. Their production in pregnancy is the subject of the studies 
described below. 
 
1.7. HYPOTHESIS AND AIMS 
 
This project was based on the hypothesis that natural antimicrobials are produced by 
epithelia of the reproductive tract in pregnancy. The natural antimicrobials studied 
were the HBDs, SLPI and elafin. They were chosen because they are epithelially 
produced proteins involved in the innate immune system of other organ systems. 
Their production is often affected by bacterial microflora, bacterial wall products 
such as LPS and LTA, and inflammatory cytokines such as IL-1β and IL-17. It was 
hypothesized that these factors may also influence natural antimicrobial production 
in the reproductive tract in pregnancy.  
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Two areas were focused on  the lower genital tract (cervix and vagina) and the 
amnion. The lower genital tract was chosen as this area is host to a diverse 
microflora and frequently exposed to pathogens, so would seem to have an effective 
innate immune system. The amnion is the innermost fetal membrane. Although it is 
the last to be affected by ascending infection, it is the inflammatory response of this 
tissue which is crucial in the onset of labour. Natural antimicrobials may be a 
component of this. 
  
The principal aims of the studies in the lower genital tract were 
 
o To establish if HBDs, SLPI and elafin are present in cervicovaginal 
secretions in pregnancy. 
o To investigate whether levels of HBDs, SLPI and elafin in 
cervicovaginal secretions vary in association with bacterial vaginosis, 
a condition where there is abnormal vaginal flora. 
o To examine HBD, SLPI and elafin expression in vaginal, ectocervical 
and endocervical epithelial cell lines, and the effect of LPS, LTA and 
IL-1β on production.  
 
The principal aims of the studies in the amnion were 
 
o To determine whether HBDs, SLPI and elafin are expressed by the 
amnion. 
o To examine the effect of labour on the expression of HBDs, SLPI and 
elafin in the amnion.  
o To investigate the effect of the inflammatory cytokines on the 
production of HBDs, SLPI and elafin in the amnion, and explore 








2. General Methods 
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All materials, reagents and cell lines used are detailed in Appendix 1. 
Recipes for reagents are provided in Appendix 2. 
 
2.1. SAMPLE COLLECTION 
 
2.1.1. Ethical approval and consent 
 
Approval from the Lothian Local Research Ethics Committee (REC: Reference 
number 04/S1101/24) was granted for all experimental work described in this thesis. 
Written information was provided and informed consent was obtained from 
participants who donated biological samples (Appendix 3). 
 
2.1.2. Amnion, choriodecidua and placenta 
 
Amnion was collected from a total of 40 women undergoing prelabour elective 
Caesarean section at 38-39 weeks and seven women who had a spontaneous vertex 
delivery (SVD) at 38-40 weeks. Indications for Caesarean section were breech 
presentation, previous Caesarean section or maternal request. In three prelabour 
cases choriodecidua and placenta were also collected. This study was designed to 
examine natural antimicrobial production in normal low risk pregnancies. All women 
were therefore healthy with no medical conditions and a normal BMI. They had 
uncomplicated singleton pregnancies, with no signs of infection (pyrexia, history of 
prolonged rupture of membranes, uterine tenderness or irritability). Women were 
excluded if they were under 16 years old, or had positive serology for HIV or 
Hepatitis B. In addition, samples were discarded if meconium stained liquor was 
found or there was a placental abnormality on gross inspection.  
 
Amnion for explant culture and primary cell culture was stripped in its entirety from 
underlying tissue, up to the origin of the umbilical cord, rinsed and transported back 
to the laboratory in sterile phosphate buffered saline (PBS).  
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Fetal membranes for RNA extraction were collected within 5 minutes of delivery. 
Amnion was stripped from the underlying choriodecidua and each tissue washed 
thoroughly in PBS. Samples were taken from sites at least 5 cm from the site of 
membrane rupture or placental edge, and areas with adherent blood were avoided. 
Preliminary experiments showed that two 12mm discs of chorion and three 12mm 
discs of amnion provided optimal concentrations of RNA after extraction. Discs were 
cut from the membrane using a sterile cork borer and submerged in 2ml RNAlater. 
Samples were taken in triplicate, stored at -80°C and processed in batches within 21 
days. Full thickness placental samples, approximately 0.5cm2, were taken in 
duplicate from central cotyledons, and placed in 5ml of RNAlater, before storage as 
above. 
 
Samples of whole fetal membranes were collected for histological assessment and 
immunohistochemistry. Strips of full thickness membrane, approximately 0.5cm 
wide, extending from the site of membrane rupture to the placental edge were cut and 
fixed in 10% neutral buffered formalin overnight at 4°C. They were then rinsed in 




RNA from endometrium was used as a positive control for natural antimicrobials, 
kindly supplied by Professor Hilary Critchley (LREC/1702/94/6/17). As individual 
natural antimicrobials are differentially expressed throughout the menstrual cycle, 
endometrium was used from the period of maximal expression for each natural 
antimicrobial (Menstrual for elafin and HBD2; Proliferative for HBD4; Mid-
secretory for HBD1, HBD3 and SLPI (King, Critchley et al. 2003)).  
 
Samples were collected from women undergoing gynaecological procedures for 
benign conditions. All had regular menstrual cycles (28-35 days) and had not 
received any hormonal treatments for 3 months prior to biopsy collection. Menstrual 
cycle stage was determined from the date of the patient's last menstrual period 
(LMP), circulating serum oestradiol and progesterone concentrations and histological 
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dating. Endometrial biopsies were immersed in Tri-reagent for RNA extraction. A 
portion was also fixed in 10% neutral buffered formalin overnight at 4 °C, stored in 
ethanol and then wax embedded for subsequent histological examination, which was 
normal in all cases. 
 
2.1.4. Cervicovaginal secretions 
 
Cervicovaginal secretions were obtained from women (n=113), with uncomplicated 
singleton pregnancies attending community antenatal clinics in the second trimester 
of pregnancy (12-20 weeks gestation). The collection method is detailed in chapter 3. 
 
2.2. IN VITRO CULTURE 
 
All cells and tissues were maintained at 37°C in 5%CO2 and 95% air in humidified 
conditions. 
 
2.2.1. Cell culture 
 
2.2.1.1. Primary Amnion Epithelial Cells 
Amnion epithelial cells were cultured using a method provided by Professor P 
Bennetts group at Imperial College, London (Bennett, Rose et al. 1987). Amnion 
was washed in sterile PBS, cut into strips, approximately 5 cm long and steeped in 
0.5mM EDTA (Ethylenediaminetetraacetic acid) at room temperature for 15 minutes. 
Cells were dissociated by incubation in 100ml of Dispase solution (2.5mg/ml) at 
37°C for 45 minutes. The strips of tissue were removed to 60 ml of Rosewell Park 
Memorial Institute Medium (RPMI 1640) culture medium, and cells detached by 
vigorously shaking for 90 seconds. This process was repeated in a further 40ml of 
RPMI, the solutions combined and centrifuged for 5 minutes at 8,000g. Cells were 
resuspended at a concentration of 1.5-2.0 x 106 per ml in RPMI 1640 medium 
supplemented with 10% fetal calf serum, penicillin (50µg/ml) streptomycin 
(50µg/ml) gentamycin (20µg/ml) and L-glutamine (2mM). Viability was assessed by 
trypan blue exclusion. 2.5ml of cell suspension per well was plated in 6 well plates. 
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After 24 hours of culture, cells were washed twice and fresh medium added. Cells 
usually achieved confluence within a further 24 hours, whereupon medium was 
changed to serum-depleted (2% FCS) for 20 hours before treatments were added. 2% 
FCS was used because preliminary experiments showed decreased cell viability after 
48 hours of culture in the absence of serum. Treatments are detailed in Chapters 4 
and 5. Unless otherwise stated, treatments were applied in quadruplicate, with one set 
of replicates used for RNA extraction, and one set used for protein analysis.  
 
Epithelial origin of primary cultured cells was confirmed by immunocytochemistry, 
with over 95% of cells positive for the epithelial cell marker pancytokeratin (section 
2.5.2). 
 
2.2.1.2. WISH Cells, FL Cells and He-La Cells 
FL, WISH and He-La cells were plated at a density of 0.5x106cells/ml (2.5 ml per 
well) in 6 well plates. They were otherwise cultured in a manner identical to primary 
amnion cells. 
 
2.2.1.3. VK2 E6/E7, ECT E6/E7 and END E6/E7 cells 
VK2 E6/E7, ECT E6/E7 and END E6/E7 cells were cultured in keratinocyte serum 
free media, supplemented with 0.1ng/ml human recombinant epidermal growth 
factor (EGF), 0.05 mg/ml bovine pituitary extract (BPE) and 44.1mg/L calcium 
chloride (to give a final concentration of 0.4mM). They were plated at a density of 
0.5x106cells/ml (2.5 ml per well) in 6 well plates. 
 
2.2.2. Amnion explant culture 
 
Amnion for explant culture was washed in PBS, and adherent blood clot carefully 
removed. 12mm discs were cut using a cork borer and placed in 12 well plates in 1.5 
mls of RPMI 1640 medium supplemented with 10% fetal calf serum, penicillin 
(50µg/ml) streptomycin (50µg/ml) gentamycin (20µg/ml) and L-glutamine (2mM). 
The following day tissue was gently washed and serum-depleted (2% FCS) medium 
added before a further 20 hours of culture. Treatments were added as detailed in 
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Chapter 4. Following treatment, amnion was removed to RNA storage solution 
(RNAlater), and stored at -80°C for subsequent RNA extraction. Three discs of tissue 
were used for each RNA extraction; therefore each treatment was applied to six wells 
to provide duplicate samples. Media from each set of three discs was combined and 
stored at -20°C for ELISA.  
 
2.3. RNA EXTRACTION AND REVERSE TRANSCRIPTION 
 
Real-time PCR allows quantification of transcription levels of specific genes, relative 
to the amount in a control sample. This technique was used to examine natural 
antimicrobial mRNA cultured cells and tissue explants. 
 
2.3.1. RNA extraction 
 
RNA was extracted using the RNeasy mini system which uses centrifuge columns 
containing silica-gel membranes to selectively bind RNA. Salt and ethanol 
containing buffers are then applied, to wash away contaminants, and the RNA eluted 
with water. 
 
Separate protocols were used for extraction from cells and tissue. Cultured cells were 
denatured in RLT buffer which contains guanidine isothiocyanate (GITC) to inhibit 
RNase activity, and homogenized by repetitive (>6 times) passage through an 18-
gauge needle and syringe. Amnion tissue is tough and elastic, and was more difficult 
to lyse efficiently. Preliminary experiments found that homogenization in tri-reagent, 
an extraction agent containing phenol and GITC, using the TissueLyser (Qiagen), 
gave optimal RNA yields. A DNA digestion was also required, to remove genomic 
DNA contamination. The protocols are detailed below. 
 
2.3.1.1.  RNA extraction from cultured cells 
Cells were denatured with 350µl per well of RLT buffer and passed through an 18-
gauge needle 6 times. Equal volumes of 70% ethanol were then added to each sample 
and mixed by inversion. This mixture was applied to RNeasy mini spin columns, and 
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centrifuged for 15 seconds at 8,000g at room temperature, whereupon the lysate was 
discarded. 700µl of RW1 buffer was added to each tube, and centrifuged for another 
15 seconds. The mini-spin columns were then transferred to fresh collection tubes, 
and washed twice with 500µl of RPE buffer. They underwent a 2 minute and a 1 
minute centrifugation, to ensure all traces of ethanol were removed, which could 
interfere with downstream reactions. RNA was eluted using 50µl of RNase free 
water. RNA was stored at -80°C. 
 
2.3.1.2. RNA extraction from explants and tissue 
Samples (which had been frozen in RNA storage buffer- RNAlater) were thawed, 
and removed to a secure-lock eppendorf with 1 ml of tri-reagent and a 5 mm stainless 
steel bead. Samples were agitated by the TissueLyser for four 3 minute cycles at 30 
Hz.  
 
RNA was precipitated by the addition of 200µl of chloroform, mixed thoroughly and 
transferred to Eppendorf phase lock tubes. Centrifugation at 18,000g for 15 minutes 
at 4°C separated the homogenate into an aqueous and an organic phase, with RNA 
being retained in the aqueous phase. This was removed to a clean tube, and an equal 
volume of ethanol added and mixed by inversion. The mixture was then applied to an 
RNeasy mini-column, and centrifuged for 15 seconds at 8,000g at room temperature. 
The lysate was discarded, 350µl of RW1 buffer added, and the column spun again. 
DNase I was diluted in buffer, and applied directly to the silica membrane, and 
incubated at room temperature for 15 minutes. The column was washed with a 
further 350µl of RW1 buffer. The mini-spin columns were then transferred to fresh 
collection tubes, and washed twice with 500µl of RPE buffer. They underwent a 2 
minute and a 1 minute centrifugation, to ensure all traces of ethanol were removed. 
RNA was eluted using 50µl of RNase free water. RNA was stored at -80°C. 
 
65 
2.3.2. RNA integrity and measurement 
 
2.3.2.1. Agilent Bioanalysis 
RNA quality was checked by the Agilent 2100 Bioanalyser system in combination 
with RNA6000nano chips. This uses microcapillary electrophoresis to determine the 
concentration and integrity of RNA, and shows the percentage of ribosomal 
impurities present. Agilent software allows calculation of the RNA integrity number 
(RIN), a standardized means of expressing RNA integrity (Schroeder, Mueller et al. 
2006). 
 
 RNA obtained from tissue was found to vary in quality and quantity, thus all tissue-
derived RNA was assessed using the Agilent Bioanalyzer. Only samples with intact 
18S and 28S peaks were reverse transcribed.  
 
RNA obtained from cultured cells was of a consistently high standard, with RIN of 
>8 in the initial 60 samples analyzed (Figure 2.1). Subsequent samples were 
therefore presumed to be intact, and were only quantified and assessed for purity by 
spectrophotometry. 
 
2.3.2.2.  Spectrophotometry 
RNA optical density was measured at 260 and 280nm, to allow calculation of the 
concentration and purity of the sample, using the Genequant RNA/DNA calculator or 
the Nanodrop ND-1000 spectrophotometer.  A 260:280 value of around 1.8 indicates 
a pure RNA sample. Ratios of 1.7 to 2.1 were taken to be acceptable. RNA was 
stored at 80°C for further use. 
 
2.3.3. Reverse Transcription 
 
200ng template RNA was reverse transcribed using random primers with MgCl2 
(5.5mM), dNTPs (1mM), random hexamers (2.5µM), RNAase inhibitor (0.4IU/µl), 
and multiscribe reverse transcriptase (1.25IU/µl), in a total volume of 10µl.  Mineral 
oil was added to prevent evaporation, and samples were incubated for 60 minutes at 
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25oC, 45 minutes at 48oC and then at 95oC for 5 minutes. Resultant complementary 






Scanned results of RNA from amnion explant analyzed by the Agilent Bioanalyser. 
The graph represents the fluorescence of the 18S and 28S fragments, from which the 
concentration is calculated. The 28S:18S ratio indicates the purity of the sample, 
with values approximating 2 being pure. The electropherogram is a graphical 
representation of the integrity of the sample, whereas the RIN number is a 
standardized means of expressing RNA integrity, from 0-10. 
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2.4. TAQMAN QUANTITATIVE POLYMERASE CHAIN REACTION 
 
Taqman quantitative PCR quantifies transcription of a specific gene by detecting the 
release of a fluorescent reporter dye.  Forward and reverse primers recognize the 
target DNA sequence, whilst a probe recognizes a sequence between the annealing 
sequences of the two primers.  This probe is labeled with two fluorescent dyes: a 5 
reporter dye (see below) and a 3 quencher dye (TAMRA; 6- 
carboxytetramethylrhodamine).  When the intact probe is annealed to the target DNA 
the quencher dye is in close proximity to the reporter dye, and suppresses its 
fluorescence. When the target sequence is amplified during a PCR reaction the probe 
is cleaved by the endonuclease activity of Taq polymerase, resulting in the separation 
of the two dyes so that the quencher dye can no longer suppress the reporter 
fluorescence (Figure 2.2).  Fluorescence is thus increased allowing measurement of 
PCR product. Detection of non-specific amplification is avoided because 
fluorescence is detected only if the probes target sequence is amplified. 
 
 The amount of ribosomal 18S in samples is constant, relative to the amount of 
cDNA present. Concurrent measurement of ribosomal 18S and a specific amplicon is 
possible through labelling with reporter dyes emitting different wavelengths (18S 
uses VIC; chemical name not released: all other amplicons use FAM; 6-
carboxyfluorescein). Quantification of the specific amplicon can be thus related to 
the abundance of ribosomal 18S. Subsequent analysis relates this amount to the 




Taqman quantitative PCR Reaction. 
A. Polymerization: Primers and probe polymerize to template cDNA.  
Fluorescence is low as the quencher dye (Q) suppresses the fluorescence of 
the reporter dye (R).   
B. Displacement and cleavage:  As the primer extends along the template, the 
probe is displaced and then cleaved by the actions of Taq polymerase. This 
separates the reporter dye from the suppressive effects of the quencher.   
C. Polymerization is completed: The fluorescence increases and this allows 
measurement of the amount of PCR product generated. 




A reaction mix was made from Stratgene PCR mastermix, 18S control primers and 
probes (50nM), and forward and reverse primers (300nM) and hybridization probe 
(200nM probe) specific to the gene of interest. Samples were run in at least 
duplicate, in Taqman Fast optical PCR plates (Applied Biosystems), with each 
replicate comprising of 2µl of cDNA and 18µl reaction mix. Three negative controls 
were included on each PCR plate. An RT-negative sample generated at the time of 
reverse transcription (RNA template with no reverse transcriptase enzyme) was used 
to exclude genomic DNA contamination. An RT-H2O sample generated at the time 
of reverse transcription (water in place of RNA template) was used to ensure 
specificity of reversed transcription. A TaqMan-reaction negative control where 
cDNA was replaced with water was also included. Wells were sealed with optical 




The amount of target mRNA was normalized to the amount of 18S RNA and this 
value was related to that of an internal control, using the formula 2-∆∆CT.  CT is the 
cycle number at which the PCR signal crosses a threshold.  ∆CT is the difference 
between the CT values for the specific amplicon and 18S. ∆∆CT refers to the 
difference between the ∆CT value of the sample and the internal control. Thus 2-∆∆CT 
gives a value showing the fold difference in the amount of amplicon compared to 
control. 
 
2.4.3. Primer and probes  
 
Primers and probes were designed using the PRIMER express program (Perkin-
Elmer Biosystems, MA, USA). In an effort to avoid amplification of any 
contaminating genomic DNA, probes were designed to span an intron junction 
between two exons. If this was not possible then primers were taken from separate 
exons. The sequences for the primers and probes used are shown in Table 2.1. 
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BLAST (Basic Local Alignment Tool) searches (www.ncbi.nlm.nih.gov) were 
performed to determine the presence of sequences in the scientific databases that are 
similar to those amplified by each set of primers. The results from these include an 
expect value (E) which indicates the number of sequences which similarly match the 
sequence of interest,  that could be expected to be found by chance when searching 
the databases. An E value of 1 would suggest that 1 sequence with similar matching 
could be found by chance. The results of these searches showed that, in all cases, the 
primer and probe sets used were unlikely to amplify an inappropriate template. E 
values for each primer probe set are shown in Table 2.1. 
 
Primers and probes were validated using serially diluted RNA. Analysis of PCR data 
by the ∆∆CT method is dependant on 18S and the gene of interest replicating with 
similar efficiencies. This was determined by plotting the CT value against the 
logarithm of the total amount of RNA in ng. The slopes of the lines should 
approximate -3.3 and have a correlation co-efficient of >0.95. Representative data is 
shown in Figure 2.3. Within assay variation of the PCR measurement of specific 
amplicon in cDNA was calculated from 6 replicates (relative standard deviation), and 
accepted if <10%. 
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Sequences of primer probe sets used for Taqman quantitative PCR, with BLAST 
expect value (E). The lower the E value, the lower the chance that another sequence 
matches the sequence of interest. 
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y = -3.4105x + 29.65
R 2 = 0.9762
y = -3.1438x + 17.742
















y = -3.5329x + 31.704
R 2 = 0.9838
y = -3.5896x + 17.407
















Validation of BMP2 (A) and CD69 (B) primer probe sets. 
The CT (cycle threshold) value is plotted against the logarithm of the total amount of 
RNA in ng. If the gene of interest and 18s primer and probes set amplify with equal 
efficiency the slopes of the lines should approximate -3.3 and have a correlation co-
efficient of >0.95. Intra-assay variation was 4.9% and 4.11% respectively. Other 





2.5. ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
ELISAs can quantify the amount of a given protein in a solution, through comparison 
with a standard curve created from samples containing known concentrations. The 
assays performed in this project were all two-site ELISAs. 
 
A two-site or sandwich ELISA uses plates coated with an antibody raised against one 
epitope of the substance to be measured. The solution of interest, or the standard, is 
then added, and the substance binds to the antibody.  Next a detection antibody is 
added, which is raised against a second epitope and labelled with biotin. Streptavidin 
peroxidase is then added. Streptavidin complexes strongly with the biotin and the 
peroxidase can be detected by addition of substrate (Tetramethyl benzidine, urea 
hydrogen peroxide, sodium acetate; Appendix 2). The reaction is stopped with 
sulphuric acid solution and absorbance measured by spectrophotometry OD450 
(Figure 2.4). 
 
Standard curves were constructed and sample measurements calculated by the Assay 
Zap program (Assay Aqp, BioSoft, Cambridge UK). Assays were validated by 
performing serial dilutions of a sample and confirming that when the absorbance was 
plotted a linear response was obtained which was parallel to the standard curve. 
Representative data is shown in Figure 2.5. Assay precisions were calculated using 
the formula standard deviation/mean x 100 to give the relative standard deviation 
(rsd). The intra-assay coefficient of variation (rsd) was determined from at least 6 
replicates of a quality control sample. The inter-assay coefficient of variation (rsd) 
was determined from the quality control values of at least 6 different plates. 
However, this was not calculated for all ELISAs because in some experiments all 




























Plates are coated with an antibody raised against substance to be measured. When the 
solution of interest, or the standard, is added the substance binds to the antibody.  A 
biotin labelled detection antibody is then applied which binds to substance X using a 
different epitope. Streptavidin peroxidase complexes with the biotin and the addition 
of substrate produces a differential colour shift, measurable by spectrophotometry. 
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Validation of SLPI ELISA. 
Absorbance at OD 450nm of SLPI standards in pg/ml (A) or the dilution factor of 






2.5.1. HBD2 ELISA 
 
An assay development kit containing capture antibody, biotinylated detection 
antibody, and recombinant HBD2 was used. 96-well plates were coated with goat 
polyclonal antiHBD2 (100µl/well, 25µg/ml) diluted in PBS, and incubated at room 
temperature overnight. Non-specific binding was blocked by the addition of 200µl 
per well of dry coat and a further incubation for 2 hours at room temperature. Plates 
were washed four times with wash buffer. Standards of recombinant human HBD2 
were serially diluted in ELISA buffer with tween, from 1000pg/ml to 1.95pg/ml. 
100µl of standard or sample were applied in duplicate, and incubated at 4°C 
overnight. The following day plates were washed four times, before application of 
biotin labelled detection antibody diluted in ELISA buffer with tween (100µl/well, 
5µg/ml). Plates were incubated for 2 hours on an orbital plate shaker, before being 
washed another four times. 100µl per well of streptavidin peroxidase at 0.02IU was 
added, and incubated for 15 minutes, again on an orbital plate shaker. Plates were 
thoroughly washed six times, and 200µl per well of substrate added. Colour was 
allowed to develop for approximately 5 minutes, at which point 50µl per well of 2N 
sulphuric acid was added to stop the reaction. Plates were read at an optical density 
of 450nm within 30 minutes of quenching. The intra-assay precision was 8% rsd, the 
inter-assay precision was 10% rsd and the detection limit of the assay was 8pg/ml. 
 
2.5.2. HBD3 ELISA 
 
HBD3 assay was performed in a similar way to the HBD2 assay, using reagents from 
an assay development kit. Capture antibody was applied at a concentration of 
3µg/ml, standards ranged from 4000 to 7.8pg, and detection antibody was used at a 
concentration of 0.25µg/ml. The intra-assay precision was 4.9 % rsd and the 
detection limit of the assay was 62 pg/ml. 
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2.5.3. IL-8 ELISA 
 
IL-8 ELISA was performed in a similar way to the HBD2 assay, using matched pairs 
of capture antibody and biotinylated detection antibody, and recombinant human IL-
8. Capture antibody was applied at a concentration of 2µg/ml, standards ranged from 
1000 to 7.8pg/ml and detection antibody was used at a concentration of 62.5ng/ml. 
The intra-assay precision was 9.4% rsd, the inter-assay precision was 7.7% rsd and 
the detection limit of the assay was 7.8pg/ml. 
 
2.5.4. IL-1β ELISA 
 
IL-1β ELISA was performed in a similar way to the HBD2 assay, using matched 
pairs of capture antibody and biotinylated detection antibody, and recombinant 
human IL-1β.  Capture antibody was applied at a concentration of 2µg/ml, standards 
ranged from 10,000 to 78pg/ml and detection antibody was used at a concentration of 
62.5ng/ml. The intra-assay precision was 3% rsd, the inter-assay precision was 
23.2% rsd and the detection limit of the assay was 78pg/ml. 
 
2.5.5. IL-1RA ELISA 
 
IL-1RA ELISA was performed in a similar way to the HBD2 assay, using matched 
pairs of capture antibody and biotinylated detection antibody, and recombinant 
human IL-1RA.  Capture antibody was applied at a concentration of 5µg/ml, 
standards ranged from 10,000 to 78pg/ml, and detection antibody was used at a 
concentration of 83ng/ml. The intra-assay precision was 5.2% rsd, the inter-assay 
precision was 9.8% rsd and the detection limit of the assay was 78pg/ml. 
 
2.5.6. TNFα ELISA 
 
TNFα ELISA was performed in a similar way to the HBD2 assay, using matched 
pairs of capture antibody and biotinylated detection antibody, and recombinant 
human TNFα.  Capture antibody was applied at a concentration of 2µg/ml, standards 
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ranged from 2000 to 31.2pg/ml, and detection antibody was used at a concentration 
of 100ng/ml. The intra-assay precision was 3.8% rsd, the inter-assay precision was 
5.0% rsd and the detection limit of the assay was 31.2pg/ml. 
 
2.5.7. SLPI ELISA 
 
A  SLPI assay kit was used, containing plates precoated with capture antibody, and 
all required reagents and buffers. Samples and standards (100µl, range 5000 to 
20pg/ml) were diluted in dilutant provided, applied and incubated at 37°C for 1 hour. 
Plates were washed with wash buffer, and detection antibody (100µl) added.  Plates 
were incubated for 2 hours on an orbital plate shaker at room temperature, and then 
washed again. Streptavidin peroxidase was applied to each well (100µl, 0.02IU) and 
incubated for 15 minutes. 100µl of the provided substrate was then added after a 
further wash, and the reaction was quenched with stop solution (100µl). The intra-
assay precision was 7.8% rsd; the inter-assay precision was 6.5% rsd and the 
detection limit of the assay was 20pg/ml. 
 
2.5.8. ELAFIN ELISA 
 
A kit was also used for the elafin assay, containing plates precoated with capture 
antibody, and all required reagents and buffers. Samples and standards (100µl, range 
10,000 to 156pg/ml) were applied and incubated at room temperature for 2 hours. 
Plates were washed with wash buffer, and detection antibody (100µl) added.  Plates 
were incubated for 2 hours on an orbital plate shaker at room temperature, and then 
washed again. Streptavidin peroxidase was applied to each well (100µl, 0.02IU) and 
incubated for 15 minutes. 100µl of the provided substrate was then added after a 
further wash, and the reaction was quenched with stop solution (100µl). The intra-
assay precision was 10.8% rsd, the inter-assay precision was 3.1% rsd and the 
detection limit of the assay was 160pg/ml. 
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2.5.9. Total Protein Assay 
 
To avoid bias secondary to variation in cell numbers, the amount of total cellular 
protein was determined whenever media from primary cells was analysed by ELISA 
and used as a denominator in analysis of results. After media was harvested and 
stored at -20°, cultured cells were washed twice with cold PBS. 300µl of protein lysis 
buffer, supplemented with protease inhibitor, was added to each well, and incubated 
on ice for 10 minutes. Cells were detached using a cell scraper, and incubated for 
another 10 minutes. Lysate was repetitively drawn through a pipette tip ten times, 
and then centrifuged at 8000g for 15 minutes at 4°C. Supernatant was stored at -20°C 
until further use. 
 
The amount of protein in cultured cells and cervicovaginal secretion samples was 
measured using a Biorad commercial assay. This contains an acidic dye that binds to 
protein and exhibits a differential colour shift detectable by spectrophotometry. 
Comparison with a standard curve provides a measurement of protein concentration.  
 
Standard curves were generated using bovine serum albumin (BSA) diluted in 
distilled water to concentrations from 2.29µg/ml to 294µg/ml. 25µl of standard or 
appropriately diluted sample were added to each well of a 96 well plate in at least 
duplicate. 5ml of reagent A was added to 100µl of reagent S and 25µl of the mixture 
was added to each well. 100µl of reagent B was then added to each well and colour 
development monitored. Plates were read in an OD spectrophotometer in absorbance 
mode, wavelength 690nm after 10 minutes.    
 
2.6. IMMUNOHISTOCHEMISTRY AND IMMUNOCYTOCHEMISTRY 
 
2.6.1. Haematoxylin and Eosin (H and E) 
 
H and E staining was used to check morphology of tissue samples. 5µ tissue sections 
were dewaxed in xylene for 5 minutes, rehydrated in descending grades of ethanol, 
and washed in H2O. They were stained in haematoxylin for 2 minutes, then rinsed in 
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1% acid alcohol (1-5 seconds) and Scotts tap water (30-60seconds) with washes in 
H2O in between. Slides were then counterstained with Eosin (5-10 seconds), rinsed, 
and rehydrated in ascending grades of alcohol. They were mounted from xylene with 




The amnion is comprised of a continuous monolayer of epithelial cells, with a more 
sparsely distributed fibroblast layer underneath. An antibody for pancytokeratin was 
used to identify the epithelial layer in tissue sections and confirm the epithelial origin 
of cultured primary amnion cells. Cultured cells were fixed in neutral buffered 
formalin (NBF) for 30 minutes at 23°C, then stored in ethanol 70 % at 4°C. Cells and 
tissue sections (5µ) were rehydrated in descending grades of ethanol. Cells were 
permeabilised in 0.05% Triton for 10 minutes, whereas tissue sections underwent 
antigen retrieval by pressure cooking in sodium citrate for 5 minutes. After washing 
in PBS, samples were incubated with methanol H2O2 to inhibit endogenous 
peroxidase activity which can cause non-specific staining. Blocking serum was 
added for 30 minutes to block non-specific binding. Mouse antibody to 
pancytokeratin (1:100 in blocking serum) was then added and samples were 
incubated in a humidified chamber overnight at 4 °C. A no antibody control was 
included in each run. The next day the cells/slides were washed twice in PBS with 
Tween (PBST), and a secondary antibody (rabbit anti-mouse, 1:500 in blocking 
serum) added for 60 minutes.  A further 2 washes with PBS were performed, and 
then Avidin-Biotin Complex (ABC) applied for 30 minutes. After a further 2 washes 
with PBST, 3, 3 diaminobenzidine (DAB) was added to produce a brown stain. 
Harriss haematoxylin was applied as a counterstain for 2 minutes. Cells were stored 
in distilled water, and tissue sections were rehydrated in ascending grades of alcohol 
and mounted from xylene with pertex mounting medium. 
 
2.7. STATISTICAL ANALYSIS 
Analysis was carried out with the software package Graphpad Prism. Statistical tests 








3. Natural Antimicrobial 






The lower genital tract is constantly exposed to pathogenic bacteria, yet infections 
occur comparatively rarely. It is well recognised that the epithelia form a physical 
barrier to infection, and the resident lactobacilli create an inhospitable environment 
for pathogens. However, there is a growing body of evidence suggesting the vaginal 
and cervical epithelia also actively contribute to microbial elimination via their 
innate immune response. This chapter investigates the innate immune response of the 
cervix and vagina, and its relationship to the commonest infection of the lower 
genital tract  bacterial vaginosis.  
 
Bacterial vaginosis is characterized by a deficit of the lactobacilli that normally 
populate the vagina, and overgrowth of mixed anaerobic bacteria. It does not cause a 
classical inflammatory reaction and in the majority of cases it is asymptomatic. 
Nonetheless, it is associated with increased incidence of a number of infective 
pathologies, in particular preterm labour, preterm rupture of membranes and late 
miscarriage (Guaschino, De Seta et al. 2006). 
 
The hypothesis that bacterial vaginosis is associated with deranged levels of natural 
antimicrobials and cytokines is examined in this section. Cervicovaginal secretions 
were collected from pregnant women with normal flora, intermediate flora, and 
bacterial vaginosis, and differences in antimicrobial and cytokine concentrations 
were measured. In addition, vaginal, endocervical and ectocervical epithelial cell 
lines were used to study in vitro production of natural antimicrobials, and to compare 





All materials, reagents and cell lines used are detailed in Appendix 1. 
 
3.2.1. Specimen Collection 
 
Cervicovaginal secretions were obtained from women with uncomplicated singleton 
pregnancies attending community antenatal clinics. Women were excluded if they 
had placenta praevia, vaginal bleeding, known current urinary tract or sexually 
transmitted infection or reported antibiotic use within the previous two weeks. 
 
Samples were self-collected by applicator tampon insertion for 15 minutes and 
removed to 10ml of PBS. This method of collection is relatively non-invasive and 
has been shown to be acceptable to women, safe and effective (Wilkinson, Ndovela 
et al. 1997). Duplicate slides were immediately made from samples using a method 
adapted from Sturm et al (2002), shown to have excellent agreement for diagnosis of 
bacterial vaginosis when compared with vaginal smear (Sturm, Moodley et al. 2002). 
PBS was drawn up and re-expressed through the tampon three times using a sterile 
20 ml. A drop of the eluted fluid was then allowed to air dry on a microscope slide, 
for subsequent Gram stain. The tampon was replaced in the remaining PBS, and 
transported to the laboratory where they were stored at 4°C and processed within 24 
hours of collection.  
 
Preliminary experiments were carried out on 43 samples obtained from women at 
any gestation to validate the method.  Levels of SLPI were found to be significantly 
greater in samples from women who reported having sexual intercourse in the 
previous 24 hours than in those who denied having intercourse. It was assumed that 
this was secondary to high levels of SLPI in seminal fluid, and in subsequent 
experiments women were excluded if they gave a history of sex in the 48 hours prior 
to sampling. A history of recent bathing had no significant effect on natural 
antimicrobial levels. Results from a simple questionnaire given to the women 
indicated that the test was acceptable. 
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Subsequent experiments were carried out on samples obtained only from women 
under 20 weeks gestation. 115 samples were collected in total. Two samples were 
excluded, as slides for vaginal flora assessment were inadequate or lost. 
 
3.2.1.1.  Extraction of secretions 
10mls of acetic acid 0.25% was added to the tube containing the tampon and 
remaining PBS, and the solution was expressed and redrawn through the tampon six 
times to ensure release of basic proteins and peptides. Preliminary experiments 
compared the weight of a tampon prewetted with 1ml of fluid (to mimic vaginal fluid 
volume) before and after elution with acetic acid. This showed over 99% of the 
sample was excreted from the tampon using this method (n=10). The eluted fluid was 
centrifuged at 380 G for 15 minutes to remove debris, divided into 5ml aliquots, 
lyophilized and stored at -80°C.  
 
3.2.1.2. Gram stain 
Slides of cervicovaginal secretions were flooded with crystal violet oxalate for 2 
minutes and iodine for 3 minutes, then washed with acetone and counterstained with 
neutral red for 3 minutes. They were air dried, and mounted with pertex mounting 
medium. 
 
3.2.2. Diagnosis of Bacterial Vaginosis 
 
Diagnosis of bacterial vaginosis was made using Nugents criteria (Nugent, Krohn et 
al. 1991). Four x1000 oil immersion fields per slide were viewed and the average 
number of Lactobacilli, Gardnerella vaginalis spp/Bacteroides spp, and Gram 
variable rods per field determined. A total score of 0-10 was calculated using 
Nugents scoring system (Table 3.1). A score of 0-3 was considered normal, whereas 






Nugents scoring system (0-10) for Gram-stained vaginal smears a.  
aMorphotypes are scored as the average number seen per oil immersion field. Total 
score = Lactobacilli + Gardnerella vaginalis and Bacteroides spp + curved rods. 
b0= No morphotypes present; 1 < 1 morphotype present; 2 = 1-4 morphotypes 
present; 3= 4-30 morphotypes present; 4= >30 morphotypes present. 
 
        
A        B 
Figure 3.1 
Gram stained smears of cervicovaginal secretions. 
Figure A shows normal bacterial flora, where lactobacilli predominate. Figure B 
shows bacterial vaginosis, characterized by a paucity of lactobacilli and overgrowth 








0 4+ 0 0 
1 3+ 1+ 1+ or 2+ 
2 2+ 2+ 3+ or 4+ 
3 1+ 3+  
4 0+ 4+  
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3.2.3. Total Protein Assay 
 
The amount of protein in cervicovaginal secretion samples was measured as detailed 




Levels of HBD2, HBD3, ELAFIN, SLPI, IL-8, IL-1β and IL-1RA were measured in 
cervicovaginal secretion samples by ELISA, as described in Section 2.5.1-8. 
 
3.2.5. VK2 E6/E7, END E6/E7 and ECT E6/E7 cell culture 
 
VK2 E6/E7, END E6/E7 and ECT E6/E7 cells were cultured as described in section 
2.2.1.3. Cells were treated with lipopolysaccharide (LPS; 1µg/ml), lipoteichoic acid 
(LTA; 500ng/ml), recombinant human IL-1β (10ng/ml) or progesterone (1µM) or 
equivalent volumes of vehicle (serum free media for bacterial wall products and 
cytokines; ethanol for progesterone) for 0 or 24 hours. Treatments were performed in 
quadruplicate. RNA was extracted from one set of duplicates for analysis of natural 
antimicrobial and cytokine expression by Taqman quantitative PCR (method and 
primer and probes detailed in Section 2.3-4). A pooled sample from END E6/E7 cells 
was used as a positive control. Media was harvested from the other set of duplicates, 
stored at -20°C and analyzed by ELISA (Section 2.5).  
 
3.2.6. Statistical analysis 
Categorical data was analyzed using chi-square test, with confidence intervals 
determined by the modified Wald method. Continuous data was analyzed using the 
Kolmogorov-Smirnov test for normality. Parametric data was analyzed using paired 
t-test (2 groups) or one-way ANOVA (3 or more groups) with Tukeys test to assign 
individual differences. Non-parametric data was analyzed using the Kruskal-Wallis 
test. Graphs of parametric data represent mean +/- SEM. Graphs of non-parametric 
data represent median +/- interquartile range (box) and range (whiskers). P<0.05 was 




3.3.1. Sample characteristics 
 
58.1% (65/112) of women sampled had normal flora, 17.8% (20/112) had 
intermediate flora and 24.1% (27/112) had bacterial vaginosis. There were no 
significant differences between the groups in terms of age, gestation at sampling, or 
ethnic origin. The group with bacterial vaginosis contained more smokers than the 
other groups (Table 3.2). 
Table 3.2 
Characteristics of women from whom cervicovaginal secretion samples were 
obtained. aData expressed as mean (+/- SEM) and analyzed by one-way ANOVA. 
bData expressed as percentage (95% confidence interval) and analyzed by chi-square 
test. 
 
3.3.2. Follow-up data 
 
This study was not powered for correlation of outcome with either bacterial 
vaginosis status or natural antimicrobial levels. However, delivery details were 
collected where possible, to enable use in any future larger trials. 
 
 Normal Flora Intermediate flora Bacterial Vaginosis P value
































Data was available for 100 of the women involved in the study. Data was missing 
from five women who had moved care to a different maternity unit after booking. It 
was not possible to establish reasons for the other cases of loss to follow up, but fetal 
loss before 24 weeks is a possible reason why this information was not available on 
the obstetric data management system.  
 
Two women had stillbirths, one at 28 weeks and one at 35 weeks. There were nine 
further deliveries before 37 weeks (preterm delivery rate of 9.2%). Seven of these 
occurred before 34 weeks. Of the women who delivered preterm, 6 had a diagnosis 
of bacterial vaginosis (66.7%), 1 had intermediate flora, and 2 had normal flora. 
 
3.3.3. Bacterial vaginosis status and protein levels in cervicovaginal secretions 
 
The total protein concentration was lower in cervicovaginal secretion samples from 
women with bacterial vaginosis (median 28.7 mg/ml; interquartile range 23.1-39.1 ) 
than from those with normal (median 41.9 mg/ml; interquartile range 34.9-50.8) or 





























Mean (mg/ml) +/- SEM concentration of total protein in cervicovaginal secretions 
obtained from women in the second trimester of pregnancy with normal vaginal 
flora, intermediate vaginal flora, or bacterial vaginosis. ***P<0.001 determined by 






3.3.4. Bacterial vaginosis status and levels of natural antimicrobial in 
cervicovaginal secretions 
 
Cervicovaginal secretions were analysed for the natural antimicrobials HBD2, 
HBD3, SLPI and elafin using ELISA. 
 
Elafin was found in all 112 samples of cervicovaginal secretions, at much higher 
concentrations than the defensins (range 987.3-10000ng/ml). The median 
concentration of elafin in samples obtained from women with bacterial vaginosis 
(1343 ng/ml; interquartile range 1150-1547) was significantly lower than those of 
samples obtained from women with normal (1608 ng/ml; interquartile range 1319-
2319) (P<0.01) or intermediate flora (1543 ng/ml; interquartile range 1341-2080) 
(P<0.05; Figure 3.3). 
 
SLPI was also detectable in all 112 samples of cervicovaginal secretions (range 24.5 
 12451 ng/ml). The median concentration of SLPI in samples obtained from women 
with bacterial vaginosis (1344 ng/ml; interquartile range 588-2051) was significantly 
lower than that of samples obtained from women with normal flora  (2240; 
interquartile range 997-4108) (P<0.05; Figure 3.4). 
 
HBD2 was found in 110 out of 112 samples (range 0-2306 pg/ml). There was no 
difference in median HBD2 concentrations in samples from women with normal 
flora (median 663 pg/ml; interquartile range 340-2084), intermediate flora (median 
1205 pg/ml; interquartile range 430-2270), or bacterial vaginosis (median 632 pg/ml; 
interquartile range 192-2677). (P=0.61; Kruskal-Wallis test). 
 
HBD3 was the least abundant natural antimicrobial; being detectable in only 31 out 
of 112 (27.6%) samples of cervicovaginal secretions (range 0-1998 pg/ml). There 
was no significant difference in the proportion of HBD3 negative samples in women 
with normal flora (73.8%), intermediate flora (65%) and bacterial vaginosis (74.1%). 




























Median concentrations of Elafin (ng/ml) +/- interquartile range (box) and range 
(whiskers) in cervicovaginal secretions obtained from women in the second trimester 
of pregnancy with normal vaginal flora (n=66), intermediate vaginal flora (n=20), or 




























Median concentrations of SLPI (ng/ml) +/- interquartile range (box) and range 
(whiskers) in cervicovaginal secretions obtained from women in the second trimester 
of pregnancy with normal vaginal flora (n=66), intermediate vaginal flora (n=20), or 
bacterial vaginosis (n=27). *P<0.05 determined by Kruskal-Wallis test. 
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3.3.5. Bacterial vaginosis status and levels of cytokines in cervicovaginal 
secretions 
 
Cervicovaginal secretions were analysed for IL-1β, IL1RA, IL-8, and 
CCL5/RANTES using ELISA. IL-1β and IL-8 are proinflammatory cytokines which 
can stimulate production of natural antimicrobials. Along with IL1RA, they have 
been examined in other studies of bacterial vaginosis (Imseis, Greig et al. 1997; 
Mattsby-Baltzer, Platz-Christensen et al. 1998; Wennerholm, Holm et al. 1998; 
Spandorfer, Neuer et al. 2001; Cauci, Guaschino et al. 2003;  Basso, Gimenez et al. 
2005; Diaz-Cueto, Cuica-Flores et al. 2005;  Hedges, Barrientes et al. 2006). 
Comparison of these results could thus be used as validation of the sample collection 
technique. CCL5/RANTES is another chemokine which has been reported to be 
secreted by cervical cells (Fichorova and Anderson 1999) but has not been examined 
in cervicovaginal secretions to date.  
 
IL-1β was detectable in 96 out of 113 samples (range 0  9580 pg/ml). The median 
concentration of IL-1β in samples obtained from women with bacterial vaginosis 
(640.3 pg/ml; interquartile range 258.3-1120)  was significantly higher than that of 
samples obtained from women with normal flora (195.3 pg/ml; interquartile range 
93.6-465.4) (P<0.01; Figure 3.5). 
 
IL-1βs antagonist IL1RA was detectable in all 113 samples of cervicovaginal 
secretions, at much higher concentrations than IL-1β (range 15.6  7566 ng/ml). The 
median concentrations of IL1RA in samples obtained from women with bacterial 
vaginosis (730.4 ng/ml; interquartile range 447.5-1304) and intermediate flora (658.9 
ng/ml; interquartile range 398.5-851.9) were both significantly higher than those of 
samples obtained from women with normal flora (257.8 ng/ml; interquartile range 
27.3-425.8) (P<0.01 and P<0.05; Figure 3.6). 
 
IL-8 was detectable in 109 out of 113 samples of cervicovaginal secretions (range 0-
17362 pg/ml). There were no significant differences in the median concentrations of 
IL-8 in samples obtained from women with normal flora (1748 pg/ml; interquartile 
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range 839.2-3924) intermediate flora (2176 pg/ml; interquartile range 754-4346) or 
bacterial vaginosis (3318 pg/ml; interquartile range 261.4-6655) (P=0.49; Kruskal-
Wallis test). 
 
CCL5/RANTES were not detectable in any of 18 cervicovaginal secretion samples 



























Median concentrations of IL-1β (pg/ml) +/- interquartile range (box) and range 
(whiskers) in cervicovaginal secretions obtained from women in the second trimester 
of pregnancy with normal vaginal flora (n=66), intermediate vaginal flora (n=20), or 
























Median concentrations of IL-1RA (ng/ml) +/- interquartile range (box) and range 
(whiskers) in cervicovaginal secretions obtained from women in the second trimester 
of pregnancy with normal vaginal flora (n=66), intermediate vaginal flora (n=20), or 




3.3.6. Natural antimicrobial production by vaginal, ectocervical and 
endocervical cell lines 
 
Expression of natural antimicrobial mRNA was compared in vaginal keratinocyte 
VK2 E6/E7 (VK2), ectocervical ECT E6/E7 (ECT) and endocervical END E6/E7 
(END) cell lines using Taqman PCR. 
 
VK2 cells expressed significantly more elafin mRNA than ECT or END cells 
(P<0.001), whereas no differences in expression of SLPI, HBD1 or HBD3 mRNA 
were detected between the cell lines (Figure 3.7). HBD2 was detected at very low 
levels in VK2 cells, but was found in only one sample out of three from each other 
cell line. HBD4 was not expressed in any of the cells (data not shown). 
 
The secretion of elafin, SLPI, HBD2 and HBD3 was assessed in each cell type by 
performing ELISA on cell media. At the time of experimentation, no reliable assay 
for HBD1 was available. Cells were grown to confluence, and then washed twice to 
remove any adherent natural antimicrobials. Fresh media was added and immediately 
removed for assay (timepoint 0 hours). This was done in order to ensure results 
represented natural antimicrobial secretion by an intact monolayer of cells as 
opposed to those secreted whilst the cells were growing to confluence, or any 
inherent in the media. Fresh media was added and cells cultured for 24 hours, at 
which point media was again harvested for assay (timepont 24 hours). 
 
There was detectable secretion of elafin by VK2 and END cells at 24 hours 
(P<0.001), but there was no detectable production by ECT cells (Figure 3.8 A). SLPI 
was secreted by all three cell lines (P<0.001; Figure 3.8 B). HBD2 was secreted at 
much lower levels, with significant production at 24 hours by VK2 cells only 




























































































































Mean +/- SEM expression of natural antimicrobial mRNA in VK (n=3), ECT (n=3) 
and END (n=3) cells, relative to positive control by Taqman qPCR. A=Elafin, 




































































Mean +/- SEM amount of elafin (A), SLPI (B) and HBD2 (C) (pg/ml) secreted by 
VK2 (n=3), ECT (n=3), and END (n=3) cells obtained at 0 and 24 hours, as 
measured by ELISA. UD= undetectable. **P<0.01 ***P<0.001 (Paired t-test).  
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The effect of LPS, LTA or IL-1ß stimulation (duration 24 hours) on production of 
elafin, SLPI and HBD2 was investigated in each cell type.  
 
3.3.6.1. Elafin 
Production of elafin mRNA (Taqman qPCR) and protein (ELISA) by VK2 cells was 
unaffected by any of the treatments (Figure 3.9 A and B). LTA decreased expression 
of elafin mRNA; and LPS and IL-1ß increased expression of elafin mRNA in ECT 
cells approximately 2-fold (P<0.05; Figure 3.9 C). However ECT cells did not 
secrete detectable amounts of elafin protein, even after stimulation (Figure 3.9 D). In 
END cells LPS significantly upregulated expression of elafin at both mRNA and 
protein level (P<0.05 and P<0.001; Figure 3.9 E and F). 
 
3.3.6.2. SLPI 
No treatment affected expression of SLPI mRNA in any cell lines (Figure 3.10 A, C 
and E). Nonetheless, LPS and IL-1ß increased secretion of SLPI protein by END 
cells (P<0.05; Figure 3.10 F) 
 
3.3.6.3. HBD2 
Expression of HBD2 mRNA in unstimulated cells was too low to give meaningful 
results using Taqman PCR. There was a trend for increased production of HBD2 by 
VK2 cells upon stimulation with IL-1ß, but this did not reach statistical significance 







































































































































































































































Mean +/- SEM expression of elafin mRNA relative to untreated control determined 
by Taqman PCR (Figures A, C and E) and elafin protein in pg/ml determined by 
ELISA (Figures B, D and F) in VK (n=3), ECT (n=3) and END (n=3) cells, 
following 24 hours stimulation with LPS (1µg/ml), LTA (500ng/ml) or IL-1ß 
(10ng/ml). UD= undetectable. *P<0.05 and ***P<0.001 (One-way repeated 






































































































































































































































Mean +/- SEM expression of SLPI mRNA relative to untreated control determined 
by Taqman PCR (Figures A, C and E) and SLPI protein in pg/ml determined by 
ELISA (Figures B, D and F) in VK (n=3), ECT (n=3) and END (n=3) cells, 
following 24 hours stimulation with LPS (1µg/ml), LTA (500ng/ml) or IL-1ß 
(10ng/ml).  *P<0.05 (One-way repeated measures ANOVA with Tukeys post-test). 
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3.3.7. Cytokine production by vaginal, ectocervical and endocervical cell lines 
 
Expression of IL-1ß, IL1RA and IL-8 mRNA was compared in VK2, ECT and END 
cell lines using Taqman PCR.  
 
VK2 cells expressed more IL-1ß mRNA than ECT (P<0.05) or END (P<0.01) cells, 
but levels of IL1RA mRNA were similar in all three cell lines (Figure 3.11 A and B). 
Expression of IL-8 mRNA was lower in VK2 cells than in ECT cells (P<0.05; Figure 
3.11 C). 
 
Stimulation of the three cell lines with LPS, LTA or IL-1ß for 24 hours did not 
significantly effect expression of IL-1ß, IL1RA or IL-8 mRNA (data not shown). 
 
3.3.8. The effect of progesterone on natural antimicrobial and cytokine 
production by vaginal and cervical cell lines 
 
Treatment of VK2, ECT and END cells with progesterone 1µM for 24 hours did not 
significantly affect mRNA expression of SLPI, elafin, HBD1, HBD3, IL-1ß, IL1RA 
or IL-8, as determined by Taqman qPCR (data not shown). 
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Mean +/- SEM expression of cytokine mRNA in VK (n=3), ECT (n=3) and END 
(n=3) cells, relative to positive control determined by Taqman qPCR. A= IL-1ß, 





Natural antimicrobials in cervicovaginal secretions 
This chapter showed that natural antimicrobial proteins are a component of 
cervicovaginal secretions. SLPI and elafin were consistently present, and found at 
much higher concentrations than HBD2 or HBD3. Both antileukoproteinases were 
found in sufficient amounts to contribute to the microbiocidal capacity of 
cervicovaginal fluid. SLPI has been previously reported in cervical secretions 
(Kramps, Franken et al. 1984). It is also found at extremely high levels in the 
cervical mucus plug in pregnancy, and levels of SLPI are 10-12 fold higher in 
cervicovaginal secretions in pregnancy than in the non-pregnant state (Helmig, 
Uldbjerg et al. 1995). Elafin has been immunolocalized in the vaginal epithelium 
(Pfundt, Wingens et al. 2000) but this is the first report of its presence in 
cervicovaginal secretions. 
 
In this study levels of both SLPI and elafin were found to be lower in women with 
bacterial vaginosis, but there was no evidence of changes in defensin levels. The 
finding that levels of SLPI are decreased in association with bacterial vaginosis 
corroborates those of Draper et al. They found that cervicovaginal concentrations of 
SLPI are decreased in the presence of genital tract infections, including bacterial 
vaginosis, in both pregnant and non-pregnant women (Draper, Landers et al. 2000). 
Another study in non-pregnant women found decreased SLPI in cases of bacterial 
vaginosis diagnosed by Amsels criteria (Valore, Wiley et al. 2006). However, this 
study also found diminished levels of HBDs associated with bacterial vaginosis, 
which differs from the findings in this chapter. Samples were collected by vaginal 
washout with water and defensins measured by immunoblot assay, and these 
conflicting results may be a result of different research methodology. Alternatively, 
they could reflect variations in cervicovaginal innate immunity in the pregnant and 
non-pregnant states, which is an area for upcoming investigation.  
 
The deficiency in SLPI and elafin in bacterial vaginosis may result from the change 
in bacterial flora. In the mouth, commensal bacteria induce the expression of HBD2 
(Krisanaprakornkit, Kimball et al. 2000), and a similar mechanism may exist in the 
106 
lower genital tract. Thus the decrease in numbers of lactobacilli, the normal 
commensal of the vagina, seen in bacterial vaginosis may reduce the stimulus for 
natural antimicrobial production. The resultant innate immunosuppression could 
predispose to the establishment of other infections, including HIV and those that can 
cause preterm labour. Lactobacilli have been shown to stimulate HBD2 protein in 
vaginal cells cultured with dendritic cells (Valore, Wiley et al. 2006). The 
phenomenon has not been described with either SLPI or elafin, but the diverse nature 
of vaginal flora in both healthy women and those with bacterial vaginosis 
complicates its study.  
 
Alternatively, the deficiency in SLPI and/or elafin may precede bacterial vaginosis, 
rather than being a consequence of the infection. Both SLPI and elafin have activities 
against Gram-positive and Gram-negative bacteria (Hiemstra, Maassen et al. 1996; 
Simpson, Maxwell et al. 1999). If they form an integral part of cervicovaginal 
defences, a deficit may predispose to the overgrowth of pathogenic bacteria. Genetic 
polymorphisms could underlie such a deficiency, by causing a generalized decrease 
in innate defences. In this case, bacterial vaginosis could represent a global 
vulnerability to infections, including those that cause preterm labour, rather than 
directly linking the conditions. This could also explain the observation that 
periodontal infection is associated with higher rates of preterm delivery. Valore et al 
(Valore, Wiley et al. 2006), found a return to normal cervicovaginal levels of SLPI 
after treatment of bacterial vaginosis. This makes a deficiency in constitutive 
production less likely, although does not exclude the possibility of an attenuated 
response to infectious agents or cytokines. 
 
HBD3 has not been described in the lower genital tract before. It was absent in the 
majority of samples of cervicovaginal secretions examined, or found only at low 
levels. HBD2 was also found at relatively low concentrations. This is in agreement 
with findings in vaginal secretions in non-pregnant women (Valore, Park et al. 2002). 
In optimal laboratory conditions beta-defensins are active at low micro molar 
concentrations (Ganz 2003), but activity deteriorates with increasing salt 
concentrations and plasma proteins. It seems unlikely that the beta-defensins would 
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have much antimicrobial capability in cervicovaginal secretions at the concentrations 
found. However, they are highly basic proteins, which tend to be intimately 
associated with epithelial surfaces. They thus may be present locally at high enough 
concentrations to effect microbial neutralization, but this remains difficult to prove. 
 
Bacterial vaginosis is associated with a high pH, secondary to the deficiency in 
lactobacilli which may influence natural antimicrobial attachment to tissues, but may 
also have other consequences. A recent study has shown that HBDs have more 
effective antibacterial activity in acidic environments (Chen, Niyonsaba et al. 2005). 
This implies that bacterial vaginosis may be associated with decreases in natural 
antimicrobial function, further promoting bacterial overgrowth and/or secondary 
infections. 
 
Cytokines in cervicovaginal secretions 
Cytokine levels in cervicovaginal secretions were also examined with relation to 
bacterial vaginosis. Bacterial vaginosis is generally thought of as a non-inflammatory 
condition. Nevertheless, levels of the inflammatory cytokine IL-1ß are increased in 
cervical and vaginal secretions when the condition is present (Imseis, Greig et al. 
1997; Mattsby-Baltzer, Platz-Christensen et al. 1998; Spandorfer, Neuer et al. 2001; 
Cauci, Guaschino et al. 2003; Basso, Gimenez et al. 2005; Hedges, Barrientes et al. 
2006; Valore, Wiley et al. 2006). The results of this study also show this. There was 
however, no evidence of an associated rise in IL-8, which is the major chemotactic 
factor for neutrophils. It has been speculated that in bacterial vaginosis there is 
microbial inhibition of IL-8 production in response to IL-1ß, although the 
mechanism for this is not clear (Cauci, Guaschino et al. 2003). The diminished 
response may explain why the number of vaginal polymorphonuclear cells found in 
bacterial vaginosis is not increased with respect to that in healthy women (Cauci 
2004; Ramsey, Lyon et al. 2005). CCL5/RANTES is another neutrophil chemotactin, 
which is reported as being produced by cervical cells (Fichorova and Anderson 
1999). This was undetectable in all samples of cervicovaginal secretions examined. 
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There is conflicting data regarding the response of IL-1ßs antagonist IL1RA in 
bacterial vaginosis. Genc et al found increased IL1RA levels in bacterial vaginosis 
(Genc, Vardhana et al. 2004), whereas Valore et al didnt detect a significant 
difference (Valore, Wiley et al. 2006). In this study IL1RA was raised in women 
with both bacterial vaginosis, and in women with intermediate flora. It has been 
suggested that a disproportionate rise in IL-1ß in comparison to IL1RA is associated 
with vaginal leucocytosis (Donders, Bosmans et al. 2000), and preterm delivery 
(Genc, Vardhana et al. 2004). In this study the IL1RA: IL-1ß ratio was not different 
in any group (data not shown).  
 
Sample collection and diagnosis of bacterial vaginosis 
Determining the prevalence of bacterial vaginosis was not an aim of this study. The 
sample group was too small for accurate evaluation of the prevalence of such a 
common condition, which should be carried out in a much larger cohort. Similarly, 
correlation of pregnancy outcome with bacterial vaginosis status or natural 
antimicrobial levels is not valid in such a small sample group, and this data was 
provided for completeness. 
 
With this proviso, the incidence of bacterial vaginosis found was surprisingly high at 
24.1%. This is lower than 33% found in an inner city group in the USA (McGregor, 
French et al. 1995) but higher than the 15% found in a middle class area in London 
(Hay, Morgan et al. 1994). Consideration has to be given to possible reasons for this. 
Incidence of bacterial vaginosis is higher in early pregnancy than in later pregnancy 
or general gynaecology populations, when most large studies in the UK have been 
performed. Nevertheless, a recent Danish study in 3540 predominantly Caucasian 
women under 20 weeks gestation found a prevalence of bacterial vaginosis of only 
17% (Svare, Schmidt et al. 2006). Here bacterial vaginosis was diagnosed using the 
less well-established Schmidt method that uses unstained vaginal smears. Only one 
study has been performed comparing the Schmidt and the Nugent diagnostic methods 
(Schmidt and Hansen 2001). This suggested that Nugents criteria might give a 
higher rate of false positives than the Schmidt method of diagnosis, which could 
explain the differences in prevalence seen. However, Nugents method was chosen in 
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our study as it has been validated and is extensively used for clinical diagnosis and in 
research (Nugent, Krohn et al. 1991; Hillier, Krohn et al. 1992; Tam, Yungbluth et 
al. 1998). It is recognized that a large-scale comparison of diagnostic methods is 
desirable, and standardized methods should be used in subsequent research to ensure 
the greatest applicability of the work. 
 
Samples of cervicovaginal secretions were collected from pregnant women below 20 
weeks gestation. Sample collection was carried out at this time as there is some 
evidence that bacterial vaginosis occuring early in pregnancy is more likely to be 
associated with poor pregnancy outcome (Leitich, Bodner-Adler et al. 2003). 
Cervicovaginal secretions were self-collected by tampon insertion which avoided the 
need for speculum examination. This is less time and resource consuming in busy 
community antenatal clinics and may be more acceptable to women and their 
attendant midwives. The method has been validated for the diagnosis of bacterial 
vaginosis (Sturm, Moodley et al. 2002) and a similar method has been successfully 
used in a previous study of components of vaginal fluid (Valore, Park et al. 2002). 
Unfortunately it was not possible to diagnose other genital tract infections in this 
study. Although it is likely that the rates of such infections are low in the population 
studied, these could be a confounding factor on results.  
 
A problem with the method of sample collection used is that the amount of 
cervicovaginal secretions obtained may vary and the decreased amount of SLPI and 
elafin seen in women with bacterial vaginosis may merely represent smaller sample 
volumes obtained from these women. In order to minimize variation, identical 
tampons were used throughout the study, and inserted for a standard time (15 
minutes). Initially tampons were weighed pre and post specimen collection to 
estimate sample volume so levels could be expressed per mililitre, but this was found 
to be neither accurate nor practical. Instead the amount of total protein in each 
sample was ascertained, and it was anticipated that this could be used to standardize 
results by expressing the amount of the substance of interest as a proportion of the 
amount of total protein. However, it was found that the amount of total protein 
obtained from women with bacterial vaginosis was lower than that obtained from 
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women with normal flora. This agrees with results from a study in non-pregnant 
women where the authors suggest that in bacterial vaginosis the overgrown bacteria 
metabolize cervicovaginal proteins (Valore, Wiley et al. 2006) and if true invalidates 
total protein as a measure of sample volume. Nonetheless when total protein was 
used as a denominator for natural antimicrobial and cytokine levels, similar patterns 
were seen (data not shown). The trend for lower natural antimicrobial levels in 
women with bacterial vaginosis was less pronounced, and although SLPI was still 
significantly decreased the decrease in elafin was not significant. The increase in 
cytokines was more apparent.  
 
A possible influence on sample volume is pH. More basic protein may be available at 
the low pHs found in vaginas with healthy flora, than at the higher pHs found in 
bacterial vaginosis. In our sampling method tampons physically dislodged samples 
from the walls of the vagina, so it is less likely that pH would have a major influence. 
In addition, the similar cytokine patterns seen in this study and those of others add 
credence to the method of specimen collection. Nonetheless, the effect of pH is 
worth further investigation, and sampling with acidified medium should be 
considered in future research. 
 
In this study, the vast majority of participants were Caucasian, reflecting the 
population in Edinburgh. The groups of women with bacterial vaginosis, 
intermediate flora and normal flora were comparable in age and gestation, however 
there were more smokers in the group with bacterial vaginosis. This is not surprising 
as smoking is an independent risk factor for bacterial vaginosis, exhibiting a dose 
response effect, although the reasons for this are not clear (Hellberg, Nilsson et al. 
2000). The amines cotinine and nicotine are concentrated in the cervical mucus of 
smokers, (McCann, Irwin et al. 1992), but the biological relationship of these to the 
development of bacterial vaginosis has not been studied. It is possible that they may 
alter the pH of the lower genital tract, predisposing to change in bacterial flora. The 
association between smoking and natural antimicrobial levels has also not been 
investigated. The numbers in this study are too small to give valid analysis in this 
respect. It is interesting to note however, that levels of HBD2 seemed to be higher in 
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smokers than non-smokers (data not shown), and this would make an interesting area 
for further study.  
 
In vitro natural antimicrobial production 
Cervicovaginal fluid is a mixture of secretions from the vagina, and the ectocervical 
and endocervical glands. In vitro experiments were performed in order to further 
investigate the production of natural antimicrobials and cytokines by the individual 
epithelia. Although primary cell cultures would be desirable for this, tissues for the 
development of cultures from the vagina and cervix are not readily obtainable. 
Instead human papillomavirus E6/E6E7 immortalized vaginal, ectocervical and 
endocervical epithelial cell lines were used. These have been shown to maintain a 
phenotype similar to primary cell cultures of the tissues of origin (Fichorova, 
Rheinwald et al. 1997). In addition these cell lines have been derived from the same 
patient, using the same immortalization protocol (Fichorova, Rheinwald et al. 1997) 
and they were cultured under identical conditions. This minimizes variation 
secondary to genetics and methodology, allowing a more valid comparison of the 
antimicrobial and cytokine production of the different cell types. 
 
Vaginal and endocervical cell lines exhibited different profiles of elafin, SLPI and 
cytokine production. The vagina is host to a diverse microflora, and tolerant to a 
variety of bacteria and foreign antigens. In contrast the endocervix is the normally 
sterile channel to the upper genital tract, where microbial penetration can be 
extremely detrimental. It thus seems logical that the two areas would have different 
innate immune responses  a theory supported by results of the cell line experiments.  
Under basal conditions the vaginal cell line expressed more elafin than the ecto or 
endocervical cell lines. In animal models elafin has been shown to inhibit 
inflammatory infiltration in arterial and lung wall (Zaidi, You et al. 2000; Vachon, 
Bourbonnais et al. 2002), and can also inhibit NFκB and AP-1 activation (Henriksen, 
Hitt et al. 2004; Butler, Robertson et al. 2006). Thus elafin may have an anti-
inflammatory role in the lower genital tract. The vaginal cell line also exhibited 
lower expression of the neutrophil attractant IL-8 mRNA, although there was higher 
expression of IL-1ß. Lack of vaginal neutrophil infiltration in bacterial vaginosis is 
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well recognised, despite the presence of pathogenic organisms (Cauci 2004; Ramsey, 
Lyon et al. 2005) and low local expression of IL-8 could contribute to this. 
 
There was no change in expression of any natural antimicrobial or cytokine in the 
vaginal cell line upon LPS, LTA or IL-1ß stimulation, suggesting some innate 
immune tolerance in this tissue. The mechanism of this is unclear. There is 
conflicting evidence regarding vaginal expression of TLR4 (Fazeli, Bruce et al. 
2005; Pivarcsi, Nagy et al. 2005), however TLR4 mRNA was detected in VK2 cells. 
In addition CD14 mRNA was expressed. In the intestine, which also hosts a diverse 
microflora, a variety of mechanisms have been recognized which promote microbial 
tolerance (Cario and Podolsky 2005). These include alterations in cellular 
localization of TLRs and the interactions of negative adaptor proteins or co-factors 
such as TOLLIP. Investigation of similar mechanisms in the genital tract is 
warranted. 
 
 LPS did affect the endocervical cell line. Both elafin mRNA and protein was 
upregulated in response to LPS in endocervical cells. In addition SLPI protein was 
increased, although there was no increase in SLPI mRNA expression evident, 
suggesting that this may be a result of release of stored SLPI rather than de novo 
synthesis. 
 
The upregulation of elafin and SLPI at the endocervix in response to inflammatory 
stimuli could serve several purposes. They are directly antimicrobial, and may help 
to eliminate pathogens from the normally sterile area (Simpson, Maxwell et al. 1999; 
Sallenave 2002). SLPI and elafin also exhibit some pro-inflammatory activities, and 
LPS induced inflammatory cellular infiltration is increased in murine lung expressing 
the human elafin gene (Simpson, Cunningham et al. 2001; Sallenave, Cunningham et 
al. 2003). This suggests they may enhance the protective innate immune response at 
the site of microbial invasion. In comparison to the vaginal epithelium, the 
endocervix is lined by a single layer of columnar epithelium thus is more susceptible 
to disruption.  The potent protease inhibitor activity of SLPI and elafin could 
decrease tissue damage from human neutrophil elastase and other proteases released 
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at the sight of inflammation (Sallenave, Si Tahar et al. 1997; Simpson, Wallace et al. 
2001). In monocytes SLPI inhibits LPS induced MMP production and PGE2 via 
inhibition of PGHS-2 (Zhang, DeWitt et al. 1997); both molecules are crucial in the 
remodelling of the cervix in labour, and uncontrolled release could lead to preterm 
delivery. Finally, the endocervix is the primary site of plasma and T cell localization 
in the lower genital tract (Anderson, Davidson et al. 1996). In overwhelming 
infection SLPI and elafin produced here may be involved in the recruitment and 
modulation of the adaptive immune response (Roghanian, Williams et al. 2006). The 
production of SLPI and elafin in the genital tract requires further investigation, which 
must include consideration of the interactions between the epithelial cells, other 
inflammatory cells and stromal cells. They possess many functions that could be 
relevant in reproductive biological processes, and in the long term may even have 
therapeutic potential as modulators of infection and inflammation. 
 
The ectocervical and endocervical cell lines had similar patterns of unstimulated 
natural antimicrobial and cytokine secretion. However, there was little evidence of a 
response to LPS in the ectocervical cells, making it more similar to the vaginal cell 
line than the endocervical cell line in this respect. This phenotype reflects its 
position, as the external portion of the cervix, which is also under constant exposure 
to bacteria and antigens.  
 
HBD expression was low in all the cell lines, with HBD3 protein production 
undetectable in all three cell lines, and only low level secretion of HBD2 by the 
vaginal cell line. This corresponds with our findings in cervicovaginal secretions. 
The low mRNA expression of HBD2 made it impossible to accurately assess the 
effect of stimuli on the cells using Taqman PCR. Nevertheless, examination of 
protein secretion did not indicate any significant effect of LPS, LTA or IL-1ß on 
HBD2 production. This finding is supported by those of a previous report which 
showed vaginal expression of the mouse beta-defensins 1, 2 and 4 are not affected by 
bacterial products (Soboll, Schaefer et al. 2006). However, another study, which used 
a different immortalized vaginal cell line, showed HBD2 was secreted and 
expression was significantly upregulated by the microbial products LPS, PG and 
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heat-killed Candida albicans (Pivarcsi, Nagy et al. 2005). These divergent findings 
may reflect differences in the cell types used. 
 
There is some evidence that progesterone can influence the production of SLPI and 
other natural antimicrobials. They are expressed cyclically in the endometrium 
(King, Critchley et al. 2000; King, Fleming et al. 2003) and can be modulated by 
hormonal contraception (Fleming, King et al. 2003). Progesterone also upregulates 
expression of SLPI mRNA in a breast epithelial cell line, and increases secretion of 
SLPI by cervical explants (Denison, Calder et al. 1999). Expression of natural 
antimicrobial mRNA by vaginal, ectocervical, and endocervical cell lines was, 
however, unchanged by 24 hours of progesterone treatment. Cytokine expression 
was similarly unaffected, despite progesterone receptor mRNA expression in all the 
cell lines being confirmed by Taqman PCR. This may indicate that progesterone is 
not a major influence on the innate immune responses of the lower genital tract.   
 
Additional in vivo assessment of the effect of progesterone was planned, through the 
analysis of cervicovaginal secretion samples collected from women who were 
enrolled on the STOPPIT trial (https://www.charttrials.abdn.ac.uk/stoppit/). This is 
a multicentre double blind randomised placebo controlled study of daily vaginal 
progesterone gel (90mg) from 24 -34 weeks gestation, for the prevention of preterm 
birth in twins. Samples were collected from participants in Edinburgh once whilst on 
the trial, and once after the intervention had been stopped. Due to overall slow 
recruitment to the trial, it has now been extended, and unblinding will not occur until 
2008. This means analysis of the results could not be included as part of this thesis. 
 
Summary 
In summary, this chapter provides further evidence that the lower genital tract has an 
active innate immune system, capable of producing natural antimicrobials, 
chemokines and cytokines. The study of cell lines has suggested divergent responses 
of vaginal and cervical epithelia, reflecting their differing functions.  Elafin has, for 
the first time, been identified as a component of cervicovaginal secretions. Levels of 
both elafin and SLPI were diminished in bacterial vaginosis, signifying potential 
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involvement in either the pathogenesis of the infection, or its sequelae which include 
preterm labour and increased HIV transmission. Their role was speculated on, and 
further study of these functions could broaden understanding of inflammatory 









4. Natural antimicrobial 




The fetal membranes require competent defences to protect against pathogens that 
can jeopardise the pregnancy. Natural antimicrobials are essential components of the 
innate immune system (Ganz 2003) with broad-spectrum activities against bacteria, 
yeasts and some viruses (Bals 2000). They provide a complementary chemical 
barrier to the physical barrier properties of epithelial surfaces. Their production by 
the innermost fetal membrane, the amnion, was investigated in this chapter. 
 
The bacterial product lipopolysaccharide (LPS) has been shown to stimulate HBD3 
mRNA in so-called amnion derived FL cells (Buhimschi, Jabr et al. 2004). However, 
this cell line has now been shown to be derived from cervical He-La cell 
contaminants (Nelson-Rees and Flandermeyer 1976) (www.atcc.org), thus the 
validity of this finding is unclear. The other commercially available amnion cell 
line, WISH, is similarly contaminated (Kniss, Xie et al. 2002) (www.atcc.org). In 
this chapter natural antimicrobial expression in primary cultured amnion cells and 
He-La cells was compared to expression in the FL and WISH cell lines, to clarify 
whether these are a suitable model for studying the innate immune response in the 
amnion. 
 
Natural antimicrobial production was also examined in amnion tissue in labour and 
non-labour settings. Labour is an inflammatory process, mediated by leukocyte 
invasion of the fetal membranes, and increased cytokine concentrations (Kelly 1996; 
Bowen, Chamley et al. 2002; Keelan, Blumenstein et al. 2003; Yellon, Mackler et al. 
2003). In many tissues natural antimicrobial expression is stimulated by bacterial 
products and inflammatory cytokines such as LPS, IL-1β and TNF-α (Singh, Jia et al. 
1998; Mathews, Jia et al. 1999; O'Neil, Porter et al. 1999; Garcia, Krause et al. 2001; 
Harder, Bartels et al. 2001; King, Fleming et al. 2002; Tsutsumi-Ishii and Nagaoka 
2003), and the role of these mediators on natural antimicrobial production in the 
amnion was explored. In addition, the effects of IL-17, and dexamethasone were 
assessed. IL-17 is a T-cell cytokine which is a potent inducer of the natural 
antimicrobial HBD2 in tracheobronchial epithelium (Kao, Chen et al. 2004). 
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Dexamethasone has been shown to influence HBD2 expression in intestinal 
epithelial cell lines (Witthoft, Pilz et al. 2005). 
 
The aim of this research was to determine natural antimicrobial expression in the 
amnion and establish the effect of inflammatory cytokines on their production. 
Natural antimicrobials may be an important component of the inflammatory response 
associated with parturition. It was anticipated that results of these investigations 




All materials, reagents and cell lines are detailed in Appendix 1. 
 
4.2.1 Specimen Collection 
 
Samples were collected as described in Section 2.1.2. The samples used in the 




Patient samples used in experiments in Chapter 4 
Tissue Experimental Use No 
Prelabour amnion (Elective LSCS) Primary amnion epithelial cell culture 30 
Prelabour amnion (Elective LSCS) Amnion explant culture 4 
Prelabour amnion (Elective LSCS) RNA extraction and Taqman PCR 8 
Prelabour choriodecidua (Elective 
LSCS) 
RNA extraction and Taqman PCR 3 
Prelabour placenta (Elective LSCS) RNA extraction and Taqman PCR 3 
Postlabour amnion (SVD) RNA extraction and Taqman PCR 7 
Endometrium(menstrual phase) RNA extraction and Taqman PCR 1 
Endometrium(proliferative phase) RNA extraction and Taqman PCR 1 
Endometrium(midsecretory phase) RNA extraction and Taqman PCR 1 
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4.2.2 In Vitro culture 
 
4.2.2.1 Primary amnion epithelial cell culture 
Primary amnion epithelial cells were cultured as detailed in Section 2.2.1.1.  
Cells were treated with recombinant human IL-1β 0.01-100ng/ml; TNFα 10ng/ml; 
IL-17 10ng/ml; LPS 1µg/ml; dexamethasone 1µM and/or IL-1β 10ng/ml; or 
equivalent volumes of vehicle (serum free media for cytokines; ethanol for 
dexamethasone). Doses were indicated by previous published reports TNFα, IL-1β 
and LPS (Krisanaprakornkit, Kimball et al. 2000); IL-17 (Kao, Chen et al. 2004) and 
dexamethasone (Witthoft, Pilz et al. 2005)]. In addition IL-1β dose response 
experiments were carried out (see results). Treatments were applied for 0, 1, 2, 3, 6, 
12, 16, 24, or 48 hours as detailed in results. 
 
Experiments were performed in quadruplicate. RNA was extracted from one set of 
duplicates for analysis of natural antimicrobial expression by Taqman quantitative 
PCR (Section 2.3-4). Media was harvested from the other set of duplicates, stored at 
-20°C and analyzed by HBD2 ELISA (Section 2.5.1). The remaining cells were 
lysed for total cellular protein quantification (Section 2.5.9). 
 
4.2.2.2  FL/WISH/He-La cell culture 
FL/WISH and He-La cells were cultured as detailed in Section 2.2.1.2. 
 
4.2.2.3 Amnion Explant culture 
12mm amnion explants were cultured as detailed in Section 2.2.2. Explants were 
treated with recombinant human IL-1β 10ng/ml or an equivalent volume of serum 
free media, for 24 hours. Media was harvested, stored at -20°C and analyzed by 
HBD2 ELISA (Section 2.5.1). Explants underwent RNA extraction for analysis of 
natural antimicrobial RNA expression by Taqman quantitative PCR (Section 2.3-4). 
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4.2.3 Tissue RNA extraction 
 
RNA was extracted from fresh amnion, choriodecidua and placental samples as 
detailed in Section 2.3.1.2, and analysed for natural antimicrobial expression by 
Taqman quantitative PCR (Section 2.3). 
 
4.2.4 Statistical Analysis 
 
Taqman quantitative PCR data was analyzed using the ∆∆CT method as described in 
Section 2.4.2. In experiments designed to assess the effects of treatments, where 
treated samples were related to untreated controls, normalizing the untreated data to a 
value of 1 invalidates subsequent statistical analysis.  Statistical analysis was 
therefore performed on the ∆CT values of samples (where ∆CT is the difference 
between the cycle threshold values of the amplicon of interest and 18s). In 
experiments where all samples were related to the same positive control, this was not 
necessary, and analysis was performed on the final relative values. 
 
The distribution of data was determined using the Kolmogorov-Smirnov test for 
normality. Parametric data was analyzed using the paired t-test (2 groups) or one-
way ANOVA and Tukeys test to assign individual differences (3 or more groups). 
Repeated measure ANOVA was used when appropriate. Graphs of parametric data 
represent mean +/- standard error of the mean (SEM). Non-parametric data was 
analyzed using the Friedman test. Graphs of non-parametric data represent median 




4.3.1 Natural antimicrobial expression in primary cultured amnion epithelial 
cells is different from that in FL, WISH and He-La cell lines. 
 
Primary cultured amnion cells expressed HBD1, HBD2, HBD3, SLPI and elafin 
mRNA, but not HBD4 (Figure 4.1 A-F). 
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Natural antimicrobial mRNA expression was significantly different from that in FL 
and WISH cell lines. HBD2 mRNA was expressed in primary amnion cells but 
undetectable in FL and WISH cells (Figure 4.1 B) and HBD1 and HBD3 were 
expressed at higher levels in primary amnion cells than in FL and WISH cells 
(Figure 4.1 A and C; P<0.05). Conversely, SLPI and elafin mRNA were significantly 
lower in primary amnion cells than in either FL or WISH cells (Figure 4.1 E and F; 
P<0.05). Defensin mRNA expression in FL and WISH cells was similar to that seen 
in the He-La cervical cell line that contaminates them, but  SLPI and elafin mRNA 
expression was lower in FL cells than in He-La cells (Figure 4.1 E and F; P<0.05). 
 
4.3.2 Expression of natural antimicrobial mRNA in amnion, choriodecidua 
and placenta. 
 
Amnion tissue expressed mRNA for HBD1, HBD2 (2/3 samples), HBD3, SLPI and 
elafin, but not HBD4 (Table 4.1). HBD1, HBD3, SLPI and elafin were also 
expressed in the choriodecidua and placenta, whereas HBD2 was undetectable in 
these tissues. There were no significant differences in levels of expression of the 
other natural antimicrobials between the three tissue types, although there was a 
trend for increased expression of HBD3 in the amnion.  

































Mean (+/-SEM) expression of natural antimicrobial mRNA in amnion, choriodecidua 
and placenta obtained at term prelabour Caesarean section at term (n=3), relative to 



















































































































































































































































































Mean +/- SEM expression of natural antimicrobial mRNA in primary cultured 
amnion cells obtained at prelabour Caesarean section at term (n=5), FL cells (n=3), 
WISH cells (n=3) and He-La cells (n=3) relative to amount in positive control 
(endometrial mRNA), as determined by Taqman qPCR. A=HBD1, B=HBD2, 
C=HBD3, D=HBD4, E=SLPI, F=ELAFIN. UD= undetectable. *P<0.05 primary 
amnion cells, compared to FL cells, WISH cells and He-La cells. a=P<0.05 FL cells 
compared to He-La cells (One-way ANOVA with Tukeys post-test). 
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4.3.3 HBD2 mRNA expression was increased in amnion tissue that had been 
exposed to labour 
 
HBD2 mRNA expression was significantly higher after normal labour (spontaneous 
vertex delivery) than after prelabour elective Caesarean section (Figure 4.2 B; 
P<0.05). Expression of HBD1, HBD3, SLPI and elafin was not significantly 
different in labour or non-labour settings (Figure 4.2 A, C, D, E). 
 
4.3.4 IL-1β increased HBD2 expression in amnion tissue explants 
 
Treatment with IL-1β 10ng/ml for 24 hours upregulated expression of HBD2 mRNA 
(Figure 4.3 A; P<0.05), and protein (Figure 4.3 B; P<0.05) in amnion explants but 
had no significant effect on the production of HBD1, HBD3, SLPI or elafin (data not 
shown). 
 
4.3.5 IL-1β increased HBD1 and HBD2 expression in primary cultured 
amnion cells 
 
Treatment with IL-1β 10ng/ml upregulated expression of HBD1 and HBD2 mRNA 
in primary cultured amnion cells at 6 and 12 hours (Figure 4.4 A; P<0.05 and B; 
P<0.001), but had no significant effect on the production of HBD3, SLPI or elafin 
(Figure 4.4.A, C, D and E). 
 
4.3.6 IL-1β had a dose response effect on HBD2 mRNA expression in primary 
cultured amnion epithelial cells 
 
IL-1β had a dose responsive effect on HBD2 mRNA, which peaked at 1ng/ml and 



























































































































































































































Natural antimicrobial mRNA expression in amnion tissue obtained at prelabour 
Caesarean section (n=8) or following normal labour (n=7), relative to positive 
control (primary amnion mRNA) as determined by Taqman qPCR. A=HBD1, 








































































A Mean +/- SEM expression of HBD2 mRNA in amnion explants obtained at 
prelabour Caesarean section at term (n=4) and treated with IL-1β 10ng/ml  for 0 and 
24 hours, relative to the amount in time matched unstimulated control, as determined 
by Taqman qPCR. *P<0.05 (One-way repeated measures ANOVA with Tukeys 
post-test). B Median +/- interquartile range amount of HBD2 (pg/ml) secreted by 
amnion explants obtained at prelabour Caesarean section at term (n=5) +/- IL-1β 
10ng/ml treatment at 0 and 24 hours, as measured by ELISA. *P<0.05 (Friedman 
test). 
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Mean +/- SEM expression of natural antimicrobial mRNA in primary cultured 
amnion epithelial cells obtained at prelabour Caesarean section at term (n=5) and 
treated with IL-1β 10ng/ml for 6 and 12 hours, relative to amount in time matched 
unstimulated control, as determined by Taqman qPCR. A=HBD1, B=HBD2, 
C=HBD3, D=SLPI, E=ELAFIN. *P<0.05 ***P<0.001 (Oneway repeated measures 
































































Mean +/- SEM expression of HBD2 mRNA in primary cultured amnion cells (n=3) 
after 6 hours of treatment with IL-1β 0.01ng/ml, 0.1ng/ml, 10ng/ml or 100ng/ml, 
relative to amount in untreated control, as determined by Taqman qPCR. * P<0.05 
(One-way repeated measures ANOVA with Tukeys post-test). 
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4.3.7 IL-1β had a time dependent effect on HBD2 expression in primary 
cultured amnion epithelial cells 
 
The early response of HBD2 to IL-1β treatment was investigated at 1, 2, 3 and 6 
hours in four samples. This showed that HBD2 mRNA expression became 
significantly upregulated after 3 hours of treatment (Fig 4.6 A; P<0.05).  
 
The pattern of HBD2 mRNA expression in response to more sustained treatment 
with IL-1β was examined in five biological samples at 3, 6, 12, 16, 24 and 48 hours. 
Treatment significantly upregulated HBD2 mRNA production compared to 
unstimulated control at all time points examined (Fig 4.6 B; P<0.05). There was no 
significant change in HBD2 mRNA expression in unstimulated controls over the 48 
hour period (Fig 4.6 C).  
 
In all five samples HBD2 mRNA was produced in a biphasic pattern (Fig 4.6 D) with 
two peaks in expression. A typical response from one sample is shown, as the 
periodicity of the response varied between samples, thus the pattern was not as 
evident when data were averaged.  
 
HBD2 protein production was significantly increased by treatment with IL-1β 
10ng/ml at 24 and 48 hours (Figure 4.7; P<0.001). 
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Figure 4.6 A and B 
Mean +/- SEM expression of HBD2 mRNA in primary cultured amnion epithelial 
cells obtained at prelabour Caesarean section at term (A: n=4; B: n=5) and treated 
with IL-1β 10ng/ml for 1, 2, 3 and 6 hours (A) or 3, 6, 12, 16, 24 and 48 hours (B), 
relative to amount in time matched unstimulated control, as determined by Taqman 















































































































Figure 4.6 C and D 
C: Mean +/- SEM expression of HBD2 mRNA over 48 hours, in untreated primary 
cultured amnion epithelial cells obtained at prelabour Caesarean section at term 
(n=5), relative to the amount in the 3 hour sample, as determined by Taqman qPCR.  
D: Mean expression of HBD2 mRNA in a typical sample of primary cultured amnion 
epithelial cells obtained at prelabour Caesarean section at term (n=1), +/- IL-1β 
10ng/ml at 3, 6, 12, 16, 24 and 48 hours relative to amount in time matched 


















































Mean +/- SEM amount of HBD2 (pg/ng total cellular protein) secreted by primary 
cultured amnion cells obtained at prelabour Caesarean section at term (n=5) +/- 
treatment with IL-1β 10ng/ml at 3, 6, 12, 16, 24 and 48 hours, as measured by 
ELISA. ***P<0.001 (One-way repeated measures ANOVA with Tukeys post-test). 
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4.3.8 The effects of TNFα and LPS on HBD2 expression in primary cultured 
amnion cells were different from those of IL-1β 
 
4.3.8.1  TNFα 
Treatment with TNFα 10ng/ml upregulated expression of HBD2 mRNA in primary 
cultured amnion cells at 6 and 12 hours (Figure 4.8 A; P<0.001), but had no 
significant effect on the production of HBD1, HBD3, SLPI or elafin (data not 
shown). 
 
When the temporal response of HBD2 to TNFα stimulation was compared to that of 
IL-1β, the patterns of expression were markedly different. HBD2 expression was 
significantly lower at each time point in response to TNFα (Figure 4.8 B; P<0.05).  
 
4.3.8.2 LPS 
Treatment with LPS 1µg/ml for 6 and 24 hours had no significant effect on 
expression of HBD1, HBD2, HBD3, SLPI or elafin mRNA (Data not shown). 
 
4.3.9 The effect of IL-17 on HBD2 expression in primary cultured amnion 
epithelial cells was similar to that of IL-1β 
 
Treatment with IL-17 10ng/ml upregulated expression of HBD2 mRNA in primary 
cultured amnion cells at 6 and 12 hours (Figure 4.9 A; P<0.001), but had no 
significant effect on the production of HBD1, HBD3, SLPI or elafin (data not 
shown). 
 
The pattern of HBD2 expression in response to IL-17 was very similar to that of IL-
1β, and there was no significant difference in mRNA expression in response to either 
cytokine (Figure 4.9 B and C). 
 
In contrast, IL-17 and IL-1β invoked distinct patterns of mRNA expression of 
another innate immune effector, IL-8 (Figure 4.9 D). 
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Expression of HBD2 mRNA in primary cultured amnion epithelial cells obtained at 
prelabour Caesarean section at term, relative to amount in time matched unstimulated 
control, as determined by Taqman qPCR. A. Mean +/- SEM after treatment with 
TNFα10ng/ml for 6 and 12 hours (n=3) B. Mean +/- SEM after treatment with TNFα 
10ng/ml for 3, 6, 12, 16, 24 and 48 hours (n=2). *P<0.05 **P<0.01***P<0.001 (One 
way repeated measures ANOVA with Tukeys post-test) 
134 





















































































Figure 4.9 A and B 
Expression of HBD2 mRNA in primary cultured amnion epithelial cells obtained at 
prelabour Caesarean section at term, relative to amount in time matched unstimulated 
control, as determined by Taqman qPCR. A. Mean +/- SEM after treatment with IL-
17 10ng/ml for 6 and 12 hours (n=3) B. Mean +/- SEM after treatment with IL-17 
10ng/ml for 3, 6, 12, 16, 24 and 48 hours (n=4). *P<0.05 ***P<0.001 (Oneway 




































































































Figure 4.9 C and D 
C. Typical pattern of expression of HBD2 mRNA in primary cultured amnion 
epithelial cells obtained at prelabour Caesarean section at term, relative to amount in 
time matched unstimulated control, as determined by Taqman qPCR after treatment 
with IL-17 10ng/ml or IL-1β 10ng/ml for 3, 6, 12, 16, 24 and 48 hours (n=1). 
D. Mean +/- SEM IL-8 mRNA expression in primary cultured amnion epithelial cells 
obtained at prelabour Caesarean section at term, relative to amount in time matched 
unstimulated control, as determined by Taqman qPCR after treatment with IL-17 
10ng/ml or IL-1β 10 ng/ml for 3, 6, 12, 16, 24 and 48 hours (n=3). *P<0.05 (One
way repeated measures ANOVA with Tukeys post-test). 
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4.3.10 Dexamethasone abrogates the effect of IL-1β on HBD2 and IL-8 
expression in primary cultured amnion epithelial cells 
 
Treatment with dexamethasone 1µM alone had no effect on HBD2 mRNA 
expression in primary cultured amnion epithelial cells. However, when cells were 
treated with dexamethasone in addition to IL-1β, HBD2 mRNA expression was 
significantly less than in cells treated with IL-1β alone at 6 and 24 hours (Figure 4.10 
A). The effect of IL-1β on IL-8 mRNA expression was also diminished at 6 hours 
when dexamethasone was added (Figure 4.10 B). 
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Expression of HBD2 (A) and IL-8 (B) mRNA in primary cultured amnion epithelial 
cells obtained at prelabour Caesarean section at term, relative to amount in time 
matched unstimulated control, as determined by Taqman qPCR. Mean +/- SEM after 
treatment with Dexamethasone 1 µM and/or IL-1β 10ng/ml for 0, 6, and 24 hours 






Natural antimicrobials are host defence proteins with antibiotic, chemotactic and 
inflammatory activities. In this chapter their expression in the amnion was examined. 
Two factors suggested the amnion was an important site to study. Firstly, as it is the 
innermost fetal membrane, the amnion is critically positioned to protect the fetus 
from ascending infection.  Secondly, the inflammatory response of the amnion is 
crucial in parturition, as cytokine release from inflammatory cells stimulates 
amniotic production of prostaglandins. These ripen the cervix and augment 
myometrial contractions. Amniotic natural antimicrobials could be an important 
component of the inflammatory response associated with labour. 
 
This study found that the amnion produces five natural antimicrobials. Amnion tissue 
expresses mRNA for HBD1-3, SLPI and elafin, but not HBD4. It is likely that this is 
produced by the amnion epithelial cell layer, as primary amnion epithelial cells also 
expressed mRNA for HBD1-3, SLPI and elafin. Other recent reports have also 
shown HBD1-3, elafin and SLPI immunopositivity in the amniotic epithelial layer 
(Zhang, Shimoya et al. 2001; Buhimschi, Jabr et al. 2004; King, Paltoo et al. 2006), 
and SLPI and elafin mRNA expression in amnion tissue (Zhang, Shimoya et al. 
2001; Tromp, Kuivaniemi et al. 2004). It is possible, however, that contaminating 
cells contributed to production. Some fibroblast contamination is inevitable, but 
cultures used were >95% positive for the epithelial cell marker pancytokeratin, 
preliminary experiments showed cultures were consistently >95% negative for the 
mesothelial cell marker vimentin. The stromal layer of the amnion does contain very 
few tissue macrophages, which are mainly of fetal origin (Bulmer and Johnson 
1984), however it seems unlikely that these cells would persist in cell culture in 
consistently high numbers to significantly effect results.  
 
Natural antimicrobials produced by the amnion may be secreted into the amniotic 
fluid, or diffuse through the fetal membranes. Alternatively, as they are highly basic 
proteins, they may remain associated with the membrane, forming an antimicrobial 
barrier on the surface of the tissue. Acid washing of endometrial explants has been 
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shown to increase detachment of natural antimicrobials, for measurement by ELISA 
(King, Critchley et al. 2000). This technique was tried in preliminary experiments 
and showed no obvious effect. It may, however, be worth further investigation, 
especially if used in conjunction with new imaging techniques such as confocal 
microscopy of amnion explants (Ackerman, Hughes et al. 2005) and the improved 
antibodies now available for natural antimicrobial study. 
 
 
Natural antimicrobial expression in commercial cell lines 
Only one study has examined defensin production in the amnion before (Buhimschi, 
Jabr et al. 2004). This concluded that the bacterial wall product LPS, could stimulate 
expression of HBD3. However it was performed on the so-called, amnion derived FL 
cell line. Although this was originally created from immortalized primary amnion 
epithelial cells, it became contaminated with, and eventually replaced by, He-La cells 
(Nelson-Rees and Flandermeyer 1976; Ogura, Yoshinouchi et al. 1993) 
(www.atcc.org). The other commercial amnion cell line, WISH cells, is similarly 
affected (Kniss, Xie et al. 2002),  nevertheless both these cell lines are frequently 
used in pregnancy research (Dutheil, Malhomme et al. 1997; Spaziani, Tsibris et al. 
1997; Hansen, Drew et al. 1999; Allport, Slater et al. 2000; Keelan, Helliwell et al. 
2001; Ackerman, Rovin et al. 2004; Buhimschi, Jabr et al. 2004) and have been cited 
as having some comparable responses to primary cultured amnion cells (Ackerman, 
Zhang et al. 2005). When the expression of natural antimicrobials in primary amnion 
cells was compared to that in FL and WISH cells marked differences were seen. 
There was significantly greater expression of HBD1, 2 and 3 and lesser expression of 
SLPI and elafin in primary amnion epithelial cultures than in either cell line. This 
shows that FL and WISH cells are not valid for the in vitro study of amniotic natural 
antimicrobials. The observation that LPS had no effect on defensin production in 
primary amnion cells, in contrast to Buhimischis findings in FL cells (Buhimschi, 
Jabr et al. 2004), corroborates this. Natural antimicrobial expression in WISH cells 
did resemble that of He-La cells, although FL cells expressed slightly less SLPI and 
elafin than He-La cells. This implies there may be phenotypic differences in these 
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two cell types, despite their similar genetic fingerprint (Nelson-Rees and 
Flandermeyer 1976).  
 
Natural antimicrobial expression in the fetal membranes 
Natural antimicrobial expression was compared in amnion, choriodecidua and 
placenta. HBD1, HBD3, SLPI and elafin were expressed in all tissue types. HBD2 
mRNA was only detectable in the amnion (2/3 samples) and HBD3 expression also 
tended to be greater in the amnion than in choriodecidua and placenta. Although 
these results didnt attain significance in the small numbers of samples examined, 
they did indicate that the amnion provides an important contribution to natural 
antimicrobial production. The observation that HBD2 mRNA was undetectable in the 
choriodecidua and placenta contrasts with the findings of King et al, who identified 
HBD2 in both the chorion trophoblast and syncitiotrophoblast layer of the placenta 
using immunohistochemistry (King, Paltoo et al. 2006). HBD2 is classically thought 
of as an inducible natural antimicrobial and expression is usually negligible in the 
absence of inflammatory stimuli. Indeed, when King et al examined cultured 
placental trophoblast and syncitiotrophoblast, they found HBD2 mRNA was induced 
by IL-1β. Lack of such stimulation in the prelabour state may explain why it was 
undetectable in the samples examined in this study.  
 
Expression of HBD2 mRNA was significantly higher in amnion obtained after 
normal labour, a process mediated by leukocyte invasion of the uterine tissues and 
increased production of cytokines (Keelan, Blumenstein et al. 2003). Increased 
HBD2 may be desirable during parturition, as the open cervix provides an easy route 
for the ascension of infective organisms. HBD2 is also chemotactic for neutrophils 
(Niyonsaba, Ogawa et al. 2004) and immature dendritic cells and T cells (Yang, 
Chertov et al. 1999), and thus could participate in the recruitment of inflammatory 
cells seen in labour. Labour had no effect on production of other natural 
antimicrobials, suggesting their expression in the amnion at term is either 
constitutive, or already maximally stimulated before the onset of labour.  
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IL-1β stimulation of natural antimicrobials 
IL-1β is an inflammatory cytokine which stimulates natural antimicrobial production 
in a variety of tissues (Singh, Jia et al. 1998; Mathews, Jia et al. 1999; O'Neil, Porter 
et al. 1999; Garcia, Krause et al. 2001; Harder, Bartels et al. 2001; King, Fleming et 
al. 2002). Levels of IL-1β are increased in the fetal membranes and amniotic fluid at 
parturition (Keelan, Blumenstein et al. 2003), and IL-1β can stimulate labour in 
animal models (Sadowsky, Adams et al. 2006). These factors suggested that IL-1β 
could be involved in upregulation of HBD2 in the amnion seen after normal labour. 
Its effect on natural antimicrobial production in amnion explants was thus examined. 
IL-1β resulted in a significant increase in HBD2 expression, at both mRNA and 
protein level, but did not affect other natural antimicrobials. This was consistent with 
the findings from tissues exposed to labour, suggesting IL-1β may be responsible for 
the effect.  
 
Amnion consists of a layer of epithelial cells with an underlying layer of sparsely 
distributed fibroblasts, either of which could be responsible for the production of 
natural antimicrobials observed in tissue explants. However, primary amnion 
epithelial cells cultured in isolation responded to treatment with IL-1β in a similar 
way to full thickness explants. This indicates that HBD2 from the amnion is an 
epithelial product, and probably little modulation by fibroblasts occurs.  
 
IL-1β also resulted in an increase in expression of HBD1 mRNA which was 
statistically significant. Until recently, it was widely accepted that HBD1 was 
constitutively produced by epithelia  whereas HBD2 was highly inducible by various 
cytokines, microbes and bacterial products (Krisanaprakornkit, Weinberg et al. 1998; 
Harder, Meyer-Hoffert et al. 2000; Hao, Zhao et al. 2001; Nitschke, Wiehl et al. 
2002; McDermott, Redfern et al. 2003). Recent studies, however, have demonstrated 
HBD1-4 may all be produced in a constitutive or inducible manner, depending on the 
site of production and stimulus applied (Yang, Biragyn et al. 2004; Joly, Organ et al. 
2005; Vankeerberghen, Nuytten et al. 2005). Nevertheless, HBD1 expression was 
not increased after normal labour, and the increase in HBD1 mRNA observed in 
response to IL-1β in the amnion was only marginal; thus it may not be clinically 
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relevant. A lack of suitable antibodies meant that it was not possible to verify an 
increase of HBD1 protein.  
 
IL-1β did not influence primary amnion epithelial mRNA expression of SLPI. This 
differs from findings by Zhang et al, who demonstrated an increase in SLPI protein 
production by primary amnion cells after stimulation with IL-1β (Zhang, Shimoya et 
al. 2001).The effect was only seen after 48 hours, however, which is not typical of an 
innate immune response, which is characteristically rapid. It may represent a 
secondary response, not seen at the time points examined in this study.  
 
Elafin mRNA expression is increased in samples of whole fetal membranes in cases 
of chorioamnionitis (Tromp, Kuivaniemi et al. 2004), and IL-1β treatment stimulates 
elafin production in chorion trophoblast cells (King, Paltoo et al. 2006).  In contrast, 
IL-1β had no effect on elafin expression in the amnion. This could suggest that 
chorion provides the greater contribution to elafin production in infected fetal 
membranes.  
 
HBD2 expression in the amnion was further investigated in primary amnion 
epithelial cells, to characterize production. IL-1β increased HBD2 mRNA expression 
in a dose responsive way, which peaked at 1ng/ml and then plateaued. Subsequent 
timecourse experiments used a dose of 10ng/ml, to allow for any possible 
metabolism of the molecule. When examined over 48 hours, IL-1β upregulated both 
HBD2 mRNA and protein. The pattern of HBD2 mRNA production in response to 
IL-1β was intriguing, and has not been described before. In all 5 samples examined, 
HBD2 mRNA showed a biphasic response, though the periodicity of the response 
varied. The first peak in production occurred within a few hours, which is typical of a 
rapid innate immune response. The second peak was slower, and may represent 




The effect of other inflammatory mediators 
The effects of other stimulants on the amnion were examined, to see if they also 
produced a biphasic pattern of HBD2 mRNA expression. LPS is a Gram-negative 
bacterial wall product which activates the innate immune response via Toll-like 
receptor 4 (TLR4) (see Section 1.2.6.5). This receptor shares the same cytoplasmic 
domain as the IL1R (Toll/Interleukin Restriction or TIR domain) and can activate 
identical pathways (Aderem and Ulevitch 2000). However LPS had no effect on 
HBD2 expression in the amnion, even though expression of TLR4, and its necessary 
co-factor CD14, was confirmed by Taqman PCR (data not shown). This contrasts 
with findings in epidermal keratinocytes (Harder, Bartels et al. 1997), oral mucosa 
(Mathews, Jia et al. 1999) and endometrium (King, Fleming et al. 2002), where both 
IL-1β and LPS influence HBD2 production, suggesting that different mucosa have 
developed distinct regulatory mechanisms of natural antimicrobial production. 
 
Several factors can reduce susceptibility to LPS, which could operate in the amnion. 
These include expression of negative regulators of the NFκB pathway such as 
TOLLIP (toll interacting protein) and IRAK-M (IL-1 receptor associated kinase), and 
expression of a non-signalling form of MYD88 (for review see (Cario and Podolsky 
2005). Availability of the receptor may be another factor modulating the LPS 
response as the amnion exhibits trafficking of TLR4 from the apical surface to the 
basal surface of cells in the presence of infection (Adams, Lucas et al. 2006). It is of 
interest that intestinal epithelium also demonstrates shuttling of TLR4 in the presence 
of infection (Cario, Brown et al. 2002), and IL-1β, but not LPS, can stimulate HBD2 
production in colonic epithelial cell lines (O'Neil, Porter et al. 1999), resembling the 
response in the amnion.  
 
Even if LPS does not directly stimulate HBD2 production from amnion epithelial 
cells, it may indirectly influence production by provoking IL-1β release from other 
cells such as neutrophils and macrophages. In this situation it could act to limit the 
spread of infection, and may also augment neutrophil chemotaxis (Figure 4.11). The 
expression of natural antimicrobials in cases of preterm labour and/or infection is an 
area for subsequent investigation. 
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TNFα and IL-17 are two other key cytokines of the innate immune response. 
Although IL-1β, TNFα and IL-17 signal through distinct receptors, they utilize the 
same signalling pathways  NFκB and MAPK, thus their effect on HBD2 production 
was examined.  
 
HBD2 was stimulated by TNFα treatment in a markedly different pattern to IL-1β. 
On the other hand IL-17 and IL-1β had very similar effects on HBD2, although 
different effects on another innate immune effector, IL-8. Taken together these 
findings suggest that inflammatory signalling in the amnion is regulated at more than 
one level, with influences occurring downstream to the ligand /receptor interaction.  
This is a characteristic of the innate immune system, which is dependent on only a 
few pathways, but can generate a variety of effects due to multiple regulatory 
mechanisms, at both transcriptional and post-transcriptional levels (Kracht and 
Saklatvala 2002). Putative factors in the control of the HBD2 response in the amnion 
are investigated in the next chapter. 
 
TNFα is upregulated in amniotic fluid and fetal membranes in association with 
labour (Romero, Manogue et al. 1989; Laham, Brennecke et al. 1994; Stallmach, 
Hebisch et al. 1995; Arntzen, Kjollesdal et al. 1998; Weiyuan and Li 1998; 
Shobokshi and Shaarawy 2002), but less is known about IL-17 expression in 
pregnancy. It is produced mainly by activated CD4+ T-cells, as well as neutrophils 
and eosinophils (Kawaguchi, Adachi et al. 2004). It has not been conclusively 
identified in murine trophoblast (Chaouat, Zourbas et al. 2002; Ostojic, Dubanchet et 
al. 2003), but has recently been identified in human trophoblast from term placentas, 
early miscarriage and molar pregnancy, as well as Hofbauer cells (Pongcharoen, 
Somran et al. 2007). There are no published reports if IL-17, or its receptor, in the 
fetal membranes. This study showed that amnion cells could respond to IL-17 in 
vitro. Further investigations should be performed to establish whether it has a role in 
vivo. In particular, its involvement in the process of parturition should be assessed, as 
IL-17 can induce PTGS2 (COX2) expression in keratinocytes (Kanda, Koike et al. 





Stimulation of HBD2 in amnion epithelial cells 
1. LPS, in conjunction with LBP and CD14, activates amnion epithelial cells; 2. 
Chemokines are released attracting neutrophils and macrophages; 3. IL-1β is released 
from inflammatory cells, which promotes further chemotaxis; 4. IL-1β stimulates 
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production of HBD2, which forms a protective barrier on the amnion surface, and 
augments chemotaxis of inflammatory cells 
Dexamethasone upregulates HBD2 in intestinal cell lines (Witthoft, Pilz et al. 2005), 
and has some pro-inflammatory functions in the amnion, such as the upregulation of 
prostaglandin E2 and PTGH-2 in amnion fibroblasts (Whittle, Gibb et al. 2000; Sun, 
Ma et al. 2003). It had no effect on HBD2 expression in the amnion when applied in 
isolation. Nevertheless, it did diminish the effect of IL-1β on both HBD2 and IL-8 
production, perhaps via its ability to inhibit both NFκB and AP-1 DNA binding 
(Lukiw, Pelaez et al. 1998). The involvement of these signalling pathways are further 
explored in the next chapter.  
 
Although glucocorticoids are commonly used in clinical obstetrics to promote fetal 
lung maturation in threatened preterm labour, caution is advised in administration in 
cases of chorioamnionitis due to a theoretical risk they may worsen infection (RCOG 
Green top guideline No 7, RCOG press 2004). The findings of this study support this 
recommendation, as modification of amniotic HBD2 production by glucocorticoids 




In summary, the experiments in this chapter demonstrate expression of HBD1, 2 and 
3, and SLPI and elafin in the amnion. IL-1β and IL-17 dramatically upregulate 
production of HBD2 in the amnion in a dose and time-dependant manner. HBD2 is a 
potent natural antibiotic, which also interacts with the adaptive immune system. 
Further study may allow development of new strategies and treatments to help 













It was shown in Chapter 4 that when amnion epithelial cells are stimulated by IL-1β, 
HBD2 mRNA is expressed in a biphasic pattern. The periodicity of this response 
varies somewhat between samples, but two peaks in production are consistently seen; 
one occurring at 6 or 12 hours, and a second at 16 or 24 hours. This suggested that 
one or more secondary gene products may influence HBD2 expression. An unknown 
protein, also stimulated by IL-1β, may inhibit HBD2 production causing the decrease 
in expression. Alternatively it could stimulate a second transient rise in its 
expression. In order to identify factors which could potentially mediate this response, 
a cDNA microarray was used. As cDNA microarrays provide a means of 
characterizing gene expression on a genomic scale, they can be more efficient than 
performing multiple experiments searching for individual factors. Important 
microarray findings were verified by Taqman qPCR, and mechanisms involved in 
the response were investigated with pathway inhibitors. Although many results were 
inconclusive, they will provide direction for further study. 
 
As anticipated the microarray also provided new insights into the inflammatory 
response of the amnion, which is central to parturition but remains poorly 
understood. The results are discussed in the context of other recent microarray 





All materials, reagents and cell lines are detailed in Appendix 1. 
 
5.2.1. Specimen Collection 
 
Samples of amnion were collected as described in Section 2.1.2, from fourteen 
women undergoing prelabour elective Caesarean section at 39 weeks gestation. 
 
5.2.2. Primary amnion epithelial cell culture and treatments 
 
Primary amnion epithelial cells were cultures as detailed in Section 2.2.1.1.  
 
5.2.2.1. cDNA microarray and confirmatory PCR 
Cells were treated with recombinant human IL-1β 10ng/ml or equivalent volumes of 
serum free media for 1, 2, 3, 6 or 8 hours. All treatments were performed in 
duplicate. RNA was extracted as described in Section 2.3.1 and RNA quality was 
checked by Agilent Bioanalysis (Section 2.3.2.1).  
 
The RNA replicate with the highest RIN number from one sample was used for 
microarray analysis. Confirmatory PCR was performed on four separate patient 
samples as described in Section 2.4. Primer and probe sets are detailed in Section 
2.4.3. 
 
5.2.2.2. IL-8, BMP2, endothelin-1 and indomethacin 
Cells were treated with recombinant human IL-8 10ng/ml; BMP2 10ng/ml; 
endothelin-1 1nM; or indomethacin 5µM and/or IL-1β 10ng/ml; or equivalent 
volumes of serum free medium for 0, 6 or 24 hours. The doses chosen were indicated 
by other published reports: IL-8 (Khabar, Al-Zoghaibi et al. 1997); BMP2 (Kim, 
Romero et al. 2005) Endothelin-1 (Mitchell, Romero et al. 1990); indomethacin 
(Sato, Keelan et al. 2002). Treatments were performed in duplicate. RNA was 
extracted and PCR performed as described in Section 2.3-4.  
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5.2.2.3. Pathway inhibitor experiments 
Pathway inhibitors, or equivalent volumes of vehicle, were added as detailed in 
Table 5.1, with or without IL-1β 10ng/ml for 3, 6, 12, 16, 24 or 48 hours. The doses 
chosen were shown to be optimal in other published reports (Lappas, Permezel et al. 
2002) or in experiments in other cell lines performed by other groups in our 
laboratory. Treatments were performed in duplicate. RNA was extracted and PCR 
performed as described in Section 2.3-4.  
 
Pathway Inhibitor Dose Vehicle 
NFκB Sulfasalazine 5µM Serum free media 
ERK PD96059 50µM DMSO 
JNK JNKII inhibitor 5µM DMSO 
p38 SB203560 5µM DMSO 
EGF receptor AG1478 200nM DMSO 
 
Table 5.1 
Pathway inhibitors used in the experiments in this chapter 
 
5.2.3. Oligonucleotide microarray 
 
The Agilent Whole Genome Oligo Microarray platform was used. This contains 
44,000 oligonucleotide probes representing 41,000 unique genes and transcripts. 
These have been verified and optimized by alignment to the human genome 
assembly and Agilents empirical validation process. It is a two colour system that 
allows measurement of the relative expression ratio of a given sample compared to a 
common reference sample. In this experiment, the reference sample for each array 
consisted of the pooled control samples, and was labelled with Cy 5 (red). The 
sample of interest on each microarray was an individual IL-1β treated timepoint and 
was labelled with Cy 3 (green). In total 5 microarrays were performed. 
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5.2.3.1. Amplification 
Amplification of RNA was carried out with Agilent Low RNA Input Fluorescent 
Amplification kit, to generate fluorescent (Cy3/5) linearly amplified complementary 
RNA (cRNA). Firstly cDNA was synthesized by incubating 4.25µl of cDNA 
mastermix (2µl 5x First strand buffer; 1µl 0.1M dithiothreitol [DTT]; 0.5µl 10mM 
deoxyribonucleoside triphosphates [dNTP] mix; 0.5µl MMLV-reverse transcriptase 
[MMLV-RT]; 0.25µl RNase out) with 5.75µl nuclease free water containing 50ng 
total RNA and 0.6µl T7 promoter primer, at 40°C for 2 hours. The MMLV-RT was 
then heat inactivated by incubation at 65°C for 15 minutes. 
 
cRNA was prepared by adding 1.2µl of Cy 5-CTP to the reference sample (pooled 
control samples), and 1.2µl of Cy 3-CTP to each of the IL-1β treated samples. These 
were then incubated with 28.8µl of transcription mastermix (7.65µl Nuclease free 
water; 10µl transcription buffer; 3µl DTT; 4µl ribonucleoside triphosphate [NTP] 
mix; 3.2µl 50% polyethylene glycol [PEG]; 0.3µl inorganic pyrophosphatase; and 
0.4µl T7 RNA polymerase) at 40°C for 2 hours.  
 
The resulting cRNA was purified using Qiagen RNeasy minispin columns. cRNA 
was brought up to a volume of 100µl with nuclease free water. 350µl of RLT buffer 
was added, and mixed with 250µl of ethanol. The resulting mixture was applied to 
RNeasy mini spin columns and centrifuged for 30 seconds at 8000g, whereupon the 
lysate was discarded. The columns were transferred to new collection tubes, 500µl of 
RPE buffer added, and centrifuged for a futher 30 seconds. The lysate was discarded 
and this step was repeated. cRNA was eluted into a new collection tube, by two 
centrifugations each with 30µl of nuclease free water. cRNA was stored at -80°C 
until use for hybridization. 
 
5.2.3.2. Hybridization 
Hybridization was performed using the Agilent In-situ Hybridization Kit Plus. 
0.75µg of Cy-3 and Cy-5 linearly amplified cRNA was added to 50µl of 10x control 
targets and nuclease free water to give a total volume of 240µl. This was added to 
10µl 25x fragmentation buffer, and incubated at 60°C for 30 minutes in the dark. 
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250µl of 2x hybridization buffer was then added, and the mixture was immediately 
loaded on the microarray. Microarrays were hybridized for 16 hours at 60°C. 
 
Following hybridization, microarrays were washed for 1 minute each in wash 
solutions 1 (700 ml nuclease free water; 300ml 20x Saline-sodium-phosphate-EDTA 
buffer (SSPE); and 0.25ml N-Lauroylsarcosine) and 2 (997ml nuclease free water; 3 
ml SSPE; and 0.5ml 20% N-Lauroylsarcosine). They were then immersed for 30 
seconds in Stabilization and Drying Solution (from the hybridization kit) which 
protects against ozone-induced degradation of cyanine dyes on the microarray slides. 
Slides were stored under nitrogen until scanning. 
 
5.2.3.3. Scanning, data extraction and quality control 
Microarrays were scanned on an Agilent DNA microarray scanner. Images were 
analyzed and data extraction performed using Agilent Feature Extraction 8 software.  
 
The relative expression of probes was expressed as the log2 ratio of fluorescence. It 
is microarray convention to have the green channel as the denominator, meaning it 
was calculated by log2 (Red/Green); thus in this experiment log2 (Pooled 
control/IL-β treated sample). This means if expression in the treated sample is 
higher than that of the control, it was represented by a negative log2 ratio. A 
log2ratio of 0 means there was no difference in expression between the treated 
sample and the pooled control; a value of -1 means that expression in the treated 
sample was twice that of the pooled control; and a value of -2 means the expression 
in the treated sample was 4 times (2-2) higher than in the pooled control sample and 
so on. 
 
Plotting colour-coded background intensity values by their location on the array 
showed largely uniform background noise. Gradient patterns were only visible at low 
levels (Appendix 4, Figure A4.1). Expression log2 ratios exhibited no evidence of 
irregularities on the array (Appendix 4, Figure A4.2). 
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Boxplots showing the distribution of expression values per dye channel showed 
generally lower background noise for the green dye-label channel, and good 
similarity of data distributions for signal intensities (Figure 5.1). The only exception 
was the sample for the 6 hour time point, which had fewer probes at the high end of 
expression in both the reference and time point samples.  
 
MA plots (Figure 5.2) show dependencies of expression log ratios on the signal level. 
The X-axis represents the average expression level for both samples on the array. 
The Y-axis is the corresponding log2 ratio of expression. Most of the arrays showed 
a classic hockey stick pattern, with globally very different expression ratios at low 
signal levels. The six hour timepoint again showed some irregularities in the shape of 




Boxplots of expression values (pre-normalisation) per dye-label channel. T1= 1 hour 
timepoint; T2= 2 hour timepooint; T3=3 hour timepoint; T6= 6 hour timepoint and 






MA Plots of pre-normalised data. The X-axis represents the average expression level 
for both samples on the array. The Y-axis is the corresponding log2 ratio of 
expression. The blue line represents no fold difference in expression between the two 
samples. The two red lines represent two-fold up or down regulation. The separate 
data cloud represents the control probes.  T1= 1 hour timepoint; T2= 2 hour 
timepoint; T3=3 hour timepoint; T6= 6 hour timepoint and T8=8 hour timepoint. 
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5.2.3.4. Normalisation of data 
Edwards correction algorithm was used for background correction, to remove noise 
from the measured signal values without introducing negative expression values.  
 
LOESS normalisation is a standard technique in dual-dye arrays (Forster, Roy et al. 
2003) and was performed on each slide. It is based on the assumption that greater 
than 90% of probes on the array should show no difference between the reference 
and time-point sample, thus centres log2 ratios around 0 for all levels of expression. 
Positive control probes were excluded in the fitting of this model, in order to prevent 
skewing. 
 
Between-slide normalisation was also performed to allow comparison of relative 
expression from array to array. This is based on the assumption that the majority of 
arrays should have a similar range of log2 expression values. 
 
Repeat MA plots were created of the normalized data for quality control (Figure 5.3), 
which as expected show that the log2 expression ratios are now centred around the 
no-differentiation line (y=0) for the entire range of expression levels. Separate MA 
plots of positive, negative and bright corner spots were performed, to determine these 
behaved as expected (Figure 5.4). 
 
Boxplots for log2 ratio distributions were matched between arrays (Figure 5.5). Only 
the 6 hour timepoint differed, with fewer upregulated probes in the timepoint 
samples (negative values). RNA from this timepoint was re-labelled and hybridised, 





MA Plots of normalised data (without control probes). The X-axis represents the 
average expression level for both samples on the array. The Y-axis is the 
corresponding log2 ratio of expression. The blue line represents no fold difference in 
expression between the two samples. The two red lines represent two-fold up or 
down regulation. T1= 1 hour timepoint; T2= 2 hour timepoint; T3=3 hour timepoint; 




MA Plots of controls. The X-axis represents the average expression level for both 
samples on the array. The Y-axis is the corresponding log2 ratio of expression. The 
blue line represents no fold difference in expression between the two samples. The 
two red lines represent two-fold up or down regulation. T1= 1 hour timepoint; T2= 2 





Boxplots of expression values of normalised data. T1= 1 hour timepoint; T2= 2 hour 
timepoint; T3=3 hour timepoint; T6= 6 hour timepoint and T8=8 hour timepoint. 
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5.2.4. Confirmatory Taqman qPCR 
 
Reverse transcription and Taqman qPCR were carried out as described in Section 
2.3.-4 
 
5.2.5. Data mining and gene ontology analysis 
 
Interrogation of microarray results was performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID; http://www.david.niaid.nih.gov). 
This is a web-based application that allows users to access a relational database of 
functional annotation.  Functional annotations are derived primarily from LocusLink 
at the National Center for Biotechnology Information (NCBI).  DAVID uses 
LocusLink accession numbers to link gene accessioning systems to biological 
annotations including gene names and aliases, functional summaries, Gene 
Ontologies, protein domains, and biochemical and signal transduction pathways.  
Annotation pedigrees are provided via direct links to the primary sources of 
annotation, which also provide additional gene specific information (Dennis, 
Sherman et al. 2003). 
  
In order to obtain insight into the functional and clinical significance of genes, gene-
ontology analysis was performed. This indicates components involved in particular 
biological processes which were over-represented compared to chance. These results 
are not conclusive as the hierarchical structure of gene ontology annotation causes 
problems with statistical analysis which are as yet unresolved. They do however, 
provide direction for further investigation. 
 
5.2.6. Amnion Tissue 
6 samples of amnion obtained at prelabour Caesarean section, and 5 samples 
obtained after spontaneous vertex delivery were collected as described in Section 
2.1.2. RNA was extracted as detailed in section 2.3, and analysed for CD69 
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expression by Taqman quantitative PCR, using the method and primer and probe set 
detailed in Section 2.4. 
 
5.2.7. Statistical Analysis 
 
Statistical analysis on raw microarray data is described above, whilst any further 
manipulations of the normalized data are described in the appropriate results section. 
One-way repeated measure ANOVA, with Tukeys post test to assign individual 






Global results (no filtering) are represented in a scatterplot (Figure 5.6). This plots 
the control sample of each array versus the corresponding time point. Global results 




Data was filtered by removing all control probes, and any probes that did not have a 
log2 expression of greater than 1 in at least 1 microarray. This left a total of 1022 
probes of interest. These are listed in Appendix 6 on the attached CD. 
 
The majority of genes were upregulated in response to IL-1β, with only 106 
repressed genes identified (Appendix 6; CD). Many of these have as yet unassigned 
functions, and there were no obvious candidates for involvement in the HBD2 
response. 
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5.3.3. K-means clustering 
 
Logarithmically transformed data of the filtered genes was sorted using the K-means 
algorithm, to generate 16 clusters. This method identified subsets of genes with 
similar patterns of expression (Figure 5.7). The gene for HBD2 (DEFB4) was located 
in cluster 4. 
 
Of particular interest were K-means clusters 7 and 15, representing genes that are 
upregulated at 1, 2 and 3 hours, but decrease again at 6 and 8 hours (Table 5.2). The 
kinetics of these clusters made it feasible that products of these genes may negatively 
influence production of HBD2. Several genes were examined by multiple probe sets, 





Scatterplots of expression profiles representing 1022 genes that have different 
expression profiles in pooled control sample versus the IL-1β treated sample of 
primary amnion epithelial cells at each time point. Black dots represent genes of 
interest, red dots represent positive control probes, blue dots represent negative 
control probes, and grey dots represent bright corners (landing spots). T1= 1 hour 
timepoint; T2= 2 hour timepoint; T3=3 hour timepoint; T6= 6 hour timepoint and 
T8=8 hour timepoint. 





K-means clustering of patterns of gene expression. The x axis shows timepoint. The 
y axis shows l of the reference compared to sample. T1= 1 hour timepoint; T2= 2 
hour timepoint; T3=3 hour timepoint; T6= 6 hour timepoint and T8=8 hour 
timepoint. 
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GeneName SystematicName Description 
IL8 NM_000584  interleukin 8 (IL8) 
CCL20 NM_004591  chemokine (C-C motif) ligand 20 (CCL20) 
CXCL1 NM_001511  chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activity, alpha) (CXCL1) 
CXCL2 NM_002089  chemokine (C-X-C motif) ligand 2 (CXCL2) 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
EFNA1 NM_004428  ephrin-A1 (EFNA1), transcript variant 1 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
KLF6 NM_001300  Kruppel-like factor 6 (KLF6), transcript variant 2 
IL1A NM_000575  interleukin 1, alpha (IL1A) 
KLF6 NM_001300  Kruppel-like factor 6 (KLF6), transcript variant 2 
NFκBIZ NM_031419  nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, zeta (NFκBIZ), transcript variant 1 
PLAU NM_002658  plasminogen activator, urokinase (PLAU) 
EREG NM_001432  epiregulin (EREG) 
ATF3 NM_004024  activating transcription factor 3 (ATF3) 
ZFP36 NM_003407  zinc finger protein 36, C3H type, homolog (mouse) (ZFP36) 
BMP2 NM_001200  bone morphogenetic protein 2 (BMP2) 
MAP3K8 NM_005204  mitogen-activated protein kinase kinase kinase 8 (MAP3K8) 
PTGS2 NM_000963  prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase 
and cyclooxygenase) (PTGS2) 
OVOL1 NM_004561  ovo-like 1(Drosophila) (OVOL1) 
CYR61 NM_001554  cysteine-rich, angiogenic inducer, 61 (CYR61) 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
DUSP1 NM_004417  dual specificity phosphatase 1 (DUSP1) 
TNFAIP3 NM_006290  tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) 
TA-NFκBH NM_032721  T-cell activation NFκB-like protein (TA-NFκBH) 
EGR1 NM_001964  early growth response 1 (EGR1) 
BC015987 BC015987  clone IMAGE:4096273 
PHLDA1 NM_007350  pleckstrin homology-like domain, family A, member 1 (PHLDA1) 
EFNA1 NM_004428  ephrin-A1 (EFNA1), transcript variant 1 
PTGER4 NM_000958  prostaglandin E receptor 4 (subtype EP4) (PTGER4) 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
CYR61 NM_001554  cysteine-rich, angiogenic inducer, 61 (CYR61) 
TNFAIP3 NM_006290  tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) 
CEBPD NM_005195  CCAAT/enhancer binding protein (C/EBP), delta (CEBPD) 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
NFκBIA NM_020529  nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha (NFκBIA) 
TNF NM_000594  tumor necrosis factor (TNF superfamily, member 2) (TNF) 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
CXCL2 NM_002089  chemokine (C-X-C motif) ligand 2 (CXCL2) 
IER2 NM_004907  immediate early response 2 (IER2) 
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EDN1 NM_001955  endothelin 1 (EDN1) 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
P2RY4 NM_002565  pyrimidinergic receptor P2Y, G-protein coupled, 4 (P2RY4) 
PTGS2 NM_000963  prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase 
and cyclooxygenase) (PTGS2) 
CD69 NM_001781  CD69 antigen (p60, early T-cell activation antigen) (CD69) 
TRIB1 NM_025195  tribbles homolog 1 (Drosophila) (TRIB1) 
CXCL3 NM_002090  chemokine (C-X-C motif) ligand 3 (CXCL3) 
NR4A1 NM_002135  nuclear receptor subfamily 4, group A, member 1 (NR4A1), transcript 
variant 1 
AK092260 AK092260  cDNA FLJ34941 fis, clone NT2RP7007480 
HSPC159 NM_014181  HSPC159 protein (HSPC159) 
 
Table 5.2 
Probes forming k-means clusters 7 and 15. 
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5.3.4. Gene ontology analysis 
 
In order to obtain insight into the functional and clinical significance of the genes in 
clusters 7 and 15, gene-ontology analysis was performed. This identified 13 
bioprocesses, 7 molecular functions and 1 cellular components which were 
over-represented compared to chance (Table 5.3 and Table5.4).  
 
GO Classification GO ID GO Name P value 
GO Biological Process GO:0006954 inflammatory response 2.44E-06 
GO Biological Process GO:0045087 innate immune response 4.37E-06 
GO Biological Process GO:0006935 chemotaxis 4.70E-06 
GO Biological Process GO:0042330 taxis 4.70E-06 
GO Biological Process GO:0009607 response to biotic stimulus 8.67E-06 
GO Biological Process GO:0009605 response to external stimulus 3.79E-05 
GO Biological Process GO:0009611 response to wounding 4.95E-05 
GO Biological Process GO:0009613 response to pest/pathogen/parasite 2.07E-04 
GO Biological Process GO:0006952 defense response 3.16E-04 
GO Biological Process GO:0042221 response to chemical substance 4.53E-04 
GO Biological Process GO:0006955 immune response 9.55E-04 
GO Biological Process GO:0006950 response to stress 3.01E-03 
GO Biological Process GO:0007154 cell communication 1.97E-02 
GO Molecular Function GO:0005125 cytokine activity 5.91E-06 
GO Molecular Function GO:0005102 receptor binding 8.02E-05 
GO Molecular Function GO:0004871 signal transducer activity 7.42E-04 
GO Molecular Function GO:0042379 chemokine receptor binding 1.20E-03 
GO Molecular Function GO:0008009 chemokine activity 1.20E-03 
GO Molecular Function GO:0042056 chemoattractant activity 1.42E-03 
GO Molecular Function GO:0001664 G-protein-coupled receptor binding 1.42E-03 
GO Cellular Component GO:0005615 extracellular space 1.13E-04 
 
Table 5.3 
Gene ontology classifications that were statistically over-represented in clusters 7 












































































































































































































































IL8                                           
CCL20                                           
CXCL1                                           
CXCL2                                           
CXCL3                                           
IL1A                                           
TNF                                           
PTGS2                                           
NFκBIZ                                           
CD69                                           
NFκBIA                                           
EGR1                                           
DUSP1                                           
KLF6                                           
PLAU                                           
CYR61                                           
BMP2                                           
EFNA1                                           
EREG                                           
EDN1                                           
P2RY4                                           
TRIB1                                           
NR4A1                                           
HSPC15
9                                           
 
Table 5.4 
Signature genes of clusters 7 and 15 which belonged to over-represented gene-
ontology classifications. 
169 
5.3.5. Confirmatory Taqman PCR 
In order to validate the microarray findings, Taqman qPCR of DEFB4 (the gene 
expressing HBD2) along with six of the signature genes from clusters 7 and 15 (IL-8, 
IL-1α, TNFα, BMP2, CD69 and PTGS2) was performed, in four patient samples. 
These genes were chosen to represent either crucial inflammatory mediators known 
to be expressed in pregnancy and labour (IL-8, IL-1α, TNFα, and PTGS2), or novel 
factors, not well described in the amnion (BMP2 and CD69). Four timepoints (1, 2, 3 
and 6 hours) were examined; unfortunately RNA from the 8 hour timepoint of two 
samples was degraded, so this timepoint was not included in validation experiments. 
 
To enable comparison of the patterns of gene expression in the microarray and 
Taqman qPCR data, two adjustments were made. Firstly, the microarray log2 ratios 
were transformed to express the relationship of the sample to the reference, rather 
than vice versa.  This was done using the formula (1/2^ (log2 ref/sample))-1 where 2^ 
(log2 ref/sample) was greater or equal to 1 and -2^ (log2 ref/sample) where 2^ (log2 ref/sample) was 
less than 1. Secondly, in the Taqman qPCR data, mRNA levels in IL-1β treated 
samples were expressed relative to the median of all the untreated controls 
(analogous to the pooled controls, used as the reference in the microarray). 
 
Microarray and Taqman qPCR determined kinetics of gene expression were similar 
in DEFB4, IL-8, IL-1α, TNFα, BMP2 and CD69 (Figures 5.8-5.10). Expression of 
these genes, as determined by Taqman PCR, was also significantly greater in treated 
samples than controls in at least two timepoints (p<0.05). The Taqman qPCR 
determined pattern of expression of PTGS2 was slightly different from that seen in 
the microarray, and was not significant at any timepoint.  
 
5.3.6 CD69 mRNA expression was increased in amnion tissue that had been 
exposed to labour 
 
CD69 mRNA expression was significantly higher after normal labour (spontaneous 
vertex delivery) than after prelabour elective Caesarean section (Figure 5.11; 
P<0.05).  
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DEFB4 (HBD2) (A and B); IL-8 (C and D) and IL-1α (E and F) expression. Graphs 
A, C and E represent relative expression of treated sample to pooled control as 
determined by Agilent cDNA microarray (n=1). Graphs B,D and F represent  mean 
+/- SEM expression of mRNA relative to the median of the timepoint controls, 
determined by Taqman PCR (n=4). **P<0.01 and ***P<0.001 (One-way repeated 
measures ANOVA with Tukeys post-test). 
171 

























































































































































TNFα (A and B); BMP2 (C and D) and CD69 (E and F) expression. Graphs A, C and 
E represent relative expression of treated sample to pooled control as determined by 
Agilent cDNA microarray (n=1). Graphs B,D and F represent  mean +/- SEM 
expression of mRNA relative to the median of the timepoint controls, determined by 
Taqman PCR (n=4). *P<0.05, **P<0.01 and ***P<0.001 (One-way repeated 
measures ANOVA with Tukeys post-test). 
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PTGS2 (COX2) expression. Graph A represents relative expression of treated sample 
to pooled control as determined by Agilent cDNA microarray (n=1). Graph B 
represents  mean +/- SEM expression of mRNA relative to the median of the 











































Figure 5.11  
Mean +/- SEM CD69 mRNA expression in amnion tissue obtained at prelabour 
Caesarean section (n=6) or following normal labour (n=5), relative to positive 
control (primary amnion mRNA) as determined by Taqman qPCR. * P<0.05 
(Unpaired t-test El LSCS vs SVD). 
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5.3.7. IL-8, BMP2, and Indomethacin do not influence HBD2 expression 
 
The effects of IL-8 10ng/ml, BMP2 10ng/ml and endothelin-1 1nM on HBD2 
expression were examined. They had no significant effect on HBD2 mRNA at 6 or 
24 hours (data not shown). In addition the PTGS inhibitor indomethacin 5µM had no 
effect on HBD2 production, either in isolation or in conjunction with IL-1β 10ng/ml 
at 6 or 24 hours (data not shown). 
 
5.3.8. EGFR  inhibition has no effect on IL-1β invoked expression of HBD2 
 
The EGF receptor inhibitor (AG1478 200nM) had no effect on IL-1β induced HBD2 
expression (data not shown). 
 
5.3.9. MAPK p38 inhibition diminishes the effect of IL-1β on HBD2 
 
The p38 MAPK inhibitor SB203580 5µM decreased expression of HBD2 in response 
to IL-1β at mRNA (Figure 5.12A) at all time points. It also decreased protein 
expression (Figure 5.12B). In contrast, it had no demonstrable effect on IL-8 mRNA 
expression invoked by IL-1β (data not shown). 
 
 The ERK inhibitor (PD96059 50µM) and JNK inhibitor (JNKII inhibitor 5µM) had 
no effect on expression of IL-1ß induced HBD2 mRNA expression in preliminary 

















































































































A. Mean +/- SEM expression of HBD2 mRNA in primary cultured amnion epithelial 
cells obtained at prelabour Caesarean section at term (n=3), relative to amount in 
time matched unstimulated control, as determined by Taqman qPCR, after treatment 
with SB203580 5 µM and/or IL-1β 10ng/ml for 3, 6, 12, 16  or 24 hours. *P=<0.05 
IL-1β vs IL-1β + SB203580 (Two-way ANOVA) 
B. Mean amount of HBD2 (pg) per ng of total cellular protein secreted by primary 
cultured amnion epithelial cells obtained at prelabour Caesarean section at term 
(n=1), after stimulation with IL-1β 10ng/ml. Amounts were undetectable from 




5.3.10. NFκB inhibition by sulfasalazine 
 
5.3.10.1. Sulfasalazine diminishes the effect of IL-1β and IL-17 on HBD2 
The NFκB inhibitor sulfasalazine 5µM appeared to abrogate the effect of IL-1β on 
HBD2 mRNA expression in primary amnion epithelial cells, although this trend was 
not significant as only two samples were examined (Figure 5.13A). Sulfasalazine 
also diminished the effect of IL-17 on HBD2 production (Figure 5.13B). 
 
5.3.10.2. NFκB inhibition increases the effect of IL-1β on IL-8 
In contrast, sulfasalazine increased expression of IL-8 mRNA when compared to 
timematched unstimulated control (Figure 15.14). When IL-1β was applied with 
sulfasalazine, there appeared to be further upregulation (Figure 15.14). The addition 
of IL-17 to sulfasalazine did not have any effect on IL-8 expression (data not shown). 
 
5.3.11. IL-1β and IL-17 upregulate NFκBIζ, but have differing effects on 
NFκBIα 
 
5.3.11.1. IL-1β and IL-17 increase expression of  NFκBIζ 
NFκBIζ (IκB-ζ) mRNA was increased by IL-1β 10ng/ml approximately 28 fold at 2 
hours and 13 fold at 3 hours, with a return towards unstimulated levels at 6 hours 
(Figure 5.15A). There was no further elevation over 48 hours (data not shown). IL-
17 also increased NFκBIζ mRNA expression, with an approximately 7 fold rise at 2 
and 3 hours (Figure 5.15B). 
 
5.3.11.2. IL-1β , but not IL-17,  increases expression of  NFκBIα 
NFκBIα was upregulated approximately 4 fold by IL-1β at 1, 2 and 3 hours, with 
return towards baseline values at 6 hours (Figure 5.15C). There was no further 
elevation over 48 hours (data not shown). In contrast, IL-17 had no effect on NFκBIα 














































































































Mean +/- SEM expression of HBD2 mRNA in primary cultured amnion epithelial 
cells obtained at prelabour Caesarean section at term (n=2), relative to amount in 
time matched unstimulated control, as determined by Taqman qPCR, after treatment 
with sulfasalazine 5µM and/or IL-1β 10ng/ml (A) or IL-17 10ng/ml (B) for 3, 6, 12, 























































Mean +/- SEM expression of IL-8 mRNA in primary cultured amnion epithelial cells 
obtained at prelabour Caesarean section at term (n=2), relative to amount in time 
matched unstimulated control, as determined by Taqman qPCR, after treatment with 
sulfasalazine 5µM and/or IL-1β 10ng/ml for 3, 6, 12, 16 or 24 hours. IL-8 expression 
was significantly greater than in timematched unstimulated control after treatment 
with sulfasalazine at 12 hours, 16 hours and 24 hours; IL-1β at 3, 6, 12, 16 and 24 
hours; and IL-1β with sulfasalazine at 6, 12, 16 and 24 hours. IL-8 expression was 
significantly greater after treatment with IL-1β with sulfasalazine, than after 
































































































































A and B. Mean +/- SEM expression of NFκBIζ mRNA in primary cultured amnion 
epithelial cells obtained at prelabour Caesarean section at term and treated with IL-
1β 10ng/ml (A; n=5) or IL-17 10ng/ml (B; n=2) for 1, 2, 3 or 6 hours, relative to 
amount in time matched unstimulated control, as determined by Taqman qPCR.  
C and D.  Mean +/- SEM expression of NFκBIα mRNA in primary cultured amnion 
epithelial cells obtained at prelabour Caesarean section at term (n=2) and treated with 
IL-1β 10ng/ml (A; n=5) or IL-17 10ng/ml (B; n=2) for 1, 2, 3 or 6 hours, relative to 
amount in time matched unstimulated control, as determined by Taqman qPCR 






The results of this chapter provide information regarding the nature of the response 
invoked by IL-1β in the amnion. IL-1β results in a time dependent upregulation of 
genes, many of which are involved in the inflammatory or immune responses. This 
provides pointers to molecules that may be involved in controlling the biphasic 
expression of HBD2. It also has more general relevance in the study of the 
inflammatory nature of labour, as IL-1β can stimulate labour in animal models 
(Romero, Mazor et al. 1991; Sadowsky, Adams et al. 2006) and is elevated in 
normal, and particularly infection associated preterm labour (Romero, Mazor et al. 
1992; Hillier, Witkin et al. 1993; Dudley, Collmer et al. 1996; Gunn, Hardiman et al. 
1996; Figueroa, Garry et al. 2005).  
 
Experimental Design 
Microarray technology was chosen as an efficient means of screening the entire 
genome for changes induced in amnion epithelial cells by IL-1β. Limitations of the 
technique must be recognised, however. The generation of false negative and false 
positive results can occur, especially if poor experimental design, technique or 
analyses are employed. Rigorous planning, standardized culture and treatment 
conditions, and high quality RNA were therefore enforced to maximize the 
significance of the results. In addition microarray standard operating procedures were 
employed to ensure the data was reliable and reproducible (Forster, Roy et al. 2003).  
All data was Minimum Information About a Microarray Experiment (MIAME) 
compliant (Brazma, Hingamp et al. 2001), meaning that standardised information 
about all stages of the experiment can be provided, allowing amalgamation of data 
from different groups and enabling advanced data mining. 
 
Two caveats should be borne in mind when evaluating the results. Firstly, this 
microarray data pertains to only one biological sample. The experiment was designed 
to examine one patient specimen over five timepoints, rather than multiple patient 
samples at one time point. This approach gives maximal information from the fewest 
number of microarray chips. Genotypic variation in the sample responses is 
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excluded, and timepoints, which were relatively close together, could act as 
replicates corroborating genuine changes in gene expression pattern. Secondly, the 
six hour timepoint microarray results showed fewer upregulated probes than the 
other timepoints, which is a minor cause for concern, and additional caution is 
needed in data interpretation of these time points. These factors reinforce the need 
for validatory experiments. 
 
The necessary substantiation of the microarray findings was provided by 
confirmatory Taqman qPCR experiments, performed on four biological replicates. 
Despite its limitations, Taqman qPCR is referred to as the gold-standard for gene 
expression measurements (Shi, Tong et al. 2005). Seven genes were examined in this 
way, which exhibited reassuringly similar expression patterns to those seen in the 
microarray probe sets. As expected, relative expression was higher when analyzed by 
Taqman qPCR than microarray. This is a recognised phenomenon, and may be 
secondary to the optimization of conditions for individual gene detection in Taqman 
qPCR, as opposed to the generalized conditions in microarrays. Additional signature 
genes were not examined by Taqman qPCR, as the experiments would have been 
costly and time-consuming, without providing much additional information for the 
purposes of this thesis. Added credence was given to unconfirmed findings by 
supporting evidence from related published studies, and physiological plausibility of 
the response.  
 
The microarray timepoints were quite close to each other to ensure sequential 
changes in gene expression were not missed, and enable the maximum amount of 
valid data to be extrapolated from one biological replicate. They were chosen to 
provide information on factors that could, allowing for protein translation, be 
temporally associated with the decline in HBD2 production which occurs after an 
initial peak at 6 or 12 hours. This means they are limited to revealing early and 
intermediate changes in gene expression, but give no data on very early or late 
patterns, which also might be important in the HBD2 response. 
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The Inflammatory Response to IL-1β 
The cDNA microarray suggested that the amnion has an inflammatory footprint, 
producing multiple inflammatory mediators in response to IL-1β. Infusion of IL-1β 
has been shown to cause a sterile chorioamnionitis in non-human primates 
(Sadowsky, Adams et al. 2006). It seems likely that this effect would be dependent 
on the ability of IL-1β to elicit inflammatory cell infiltration in the fetal membranes 
a theory supported by the microarray findings. IL-8, CXCL1 (GROα), CXCL2 
(GROβ), CXCL3 (GROγ) are potent neutrophil chemokines, whilst CCL20 (MIP-3α) 
is involved in monocyte differentiation and chemotaxis. Plasminogen activator 
urokinase (PLAU) and cysteine rich angiogenic-inducer 61 (CYR61) are also 
implicated in cellular migration, and IL-1α and TNFα are pro-inflammatory 
cytokines with multiple effects including cellular proliferation and differentiation. 
 
Several of these factors have previously been identified as components of the 
amniotic fluid. The onset of labour at term coincides with rises in TNFα (Romero, 
Mazor et al. 1992) and IL-8 (Romero, Ceska et al. 1991; Laham, Rice et al. 1993; 
Saito, Kasahara et al. 1993). Furthermore, elevations in TNFα (Romero, Manogue et 
al. 1989; Laham, Brennecke et al. 1994; Stallmach, Hebisch et al. 1995; Arntzen, 
Kjollesdal et al. 1998; Weiyuan and Li 1998; Shobokshi and Shaarawy 2002), IL-1α 
(Romero, Mazor et al. 1992; Hillier, Witkin et al. 1993; Figueroa, Garry et al. 2005) 
IL-8 (Cherouny, Pankuch et al. 1993; Saito, Kasahara et al. 1993; Stallmach, Hebisch 
et al. 1995; Hsu, Meaddough et al. 1998; Shobokshi and Shaarawy 2002)and CXCL1 
(Cohen, Ghezzi et al. 1996; Hsu, Meaddough et al. 1998) are evident in the amniotic 
fluid in spontaneous and infection-associated preterm labour. Invading leukocytes 
have been cited as a major source of these inflammatory mediators (Bowen, Chamley 
et al. 2002). The findings of this study suggest that the amnion could also be a 
contributor, its large surface area meaning production could be substantial. Other 
papers have shown increased expression of TNFα. (Dudley, Collmer et al. 1996), IL-
1α (Laham, Brennecke et al. 1996) and IL-8 (Keelan, Marvin et al. 1999) in amnion 




Although there are no studies individually examining the amniotic production of 
CXCL1 (GROα), CXCL2 (GROβ), CXCL3 (GROγ) or CCL20 (MIP-3α), they have 
recently been recognised in a whole genome microarray study of chorioamniotic 
membranes (Haddad, Tromp et al. 2006). In fact, these genes, along with IL-8 and 
BMP2, were found to be amongst the most discriminatory genes between samples of 
chorioamniotic membranes obtained from women in labour and women not in labour 
at term. Other discriminatory genes found, coinciding with those seen in the 
microarray performed in this chapter, include IL-1α, NFκBIα, TNFAIP3 and 
epiregulin. Similar patterns of gene expression were again identified in a medium 
density array of inflammatory probes which compared amnion tissue from women in 
spontaneous labour at term, spontaneous preterm labour, or infection associated 
preterm labour, with amnion from women at term and not in labour (Marvin, Keelan 
et al. 2002).  CXCL2 (GROβ), CXCL3 (GROγ) and IL-8 were more highly 
expressed in amnion exposed to labour; whereas CXCL1 (GROα), CXCL2 (GROβ), 
IL-8 and CCL20 (MIP-3α) were upregulated in preterm labour, particularly when 
associated with infection. Expression of these mediators was attributed to infiltrating 
leukocytes (Marvin, Keelan et al. 2002). However, the exclusion of this cell type in 
the primary amnion culture system suggests that a direct effect of IL-1β on amnion 
epithelial cells may be responsible. 
 
The microarray in this thesis did not show effects on some notable discriminatory 
probes found in the other microarray studies, including Pre-B-cell colony enhancing 
factor (PBEF), IL-6 and TLR2 (Haddad, Tromp et al. 2006) or PBEF, IL-1β and 
MMP14 (Marvin, Keelan et al. 2002). This suggests expression of these genes in a 
different cellular population to amnion epithelial cells, or that their expression is 
outwith the control of IL-1β. It was striking that in all three microarray studies, 
relatively few genes were downregulated. 
 
PTGS2 (COX2) expression was seen to be elevated in primary amnion epithelial 
cells by IL-1β in the cDNA microarray. This is a well recognized response (Mitchell, 
Edwin et al. 1993; Trautman, Edwin et al. 1996; Allport, Pieber et al. 2001), and it is 
likely that the resultant production of prostaglandins is the mechanism by which IL-
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1β can stimulate labour (Sadowsky, Adams et al. 2006). However, in the 
confirmatory PCR experiments, although there was a trend for increased expression, 
it was not significant. This is probably due to a disparity in the timing of the 
response, as a transient rise in PTGS2 was evident in every sample, but the timing of 
this peak varied. In addition there was quite marked variation in PTGS2 mRNA 
expression. This may be secondary to the subjects proximity to labour. PTGS2 in 
the amnion rises at the end of pregnancy and onset of labour (Slater, Dennes et al. 
1999). Whilst women were included only if there were no signs of impending 
delivery, it is obviously impossible to know exactly how close they were to the 
spontaneous establishment of labour.  
 
Other molecules 
BMP2 and endothelin-1 are two other genes which were upregulated in response to 
IL-1β. Although these are not recognised as being part of the classical inflammatory 
response, they have potential of providing stimulant effects on the amnion or 
adjacent tissues. BMP2 has recently been discovered in the chorioamniotic 
membranes, where expression is increased in normal labour, and preterm labour 
associated with chorioamnionitis (Kim, Romero et al. 2005). This study also found 
BMP2 could be upregulated by IL-1β in primary amnion cells, and when it was, it 
co-localized with PGE2.  In addition, recombinant BMP2 was shown to stimulate 
PGE2 synthesis, suggesting its involvement in parturition. Endothelin-1 has also been 
shown to increase prostaglandin synthesis (Benigni, Gaspari et al. 1991), and it is 
also a myometrial activator (Word, Kamm et al. 1990). Expression in the amnion has 
also been previously described (Sunnergren, Word et al. 1990), as has the ability of 
IL-1β to stimulate its production (Casey, Word et al. 1991; Mitchell 1991; Fried, 
Sand et al. 2003). It is a potent vasoconstrictor, but its role in the avascular amnion is 
not clearly defined. It may diffuse and have a regulatory function on the adjacent 
chorion, placenta or myometrium. Further clarification of the roles of these factors in 
vivo is required. 
 
The expression of the CD69 gene in amnion cells was a new finding. It codes for a 
type II C-type lectin ascribed to the family of NK receptors, with an as yet, 
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undetermined ligand. It is expressed following activation on all bone-marrow derived 
cells (Testi, D'Ambrosio et al. 1994), but has never been reported in cells of 
epithelial origin before. Knock-out mice models have shown that CD69 deficiency 
leads to diminished TGF-β production in T cells, NK cells and macrophages. TGF-β 
is an anti-inflammatory cytokine, so this supports an enhanced immune response. 
The knock-out phenotype thus exhibits increased inflammation in a collagen induced 
arthritis model (Sancho, Gomez et al. 2003); and enhanced tumour depletion in an 
NK-sensitive tumour model (Esplugues, Sancho et al. 2003).  However, in vitro 
experiments have shown conflicting pro-inflammatory functions of CD69, including 
production of TNF-α, IL-1β and RANTES, suggesting it may have a dual-role, 
depending on the cellular context (Sancho, Gomez et al. 2005).  
 
In this study CD69 was repeatedly identified in primary cultured amnion epithelial 
cells by Taqman PCR, and expression was upregulated by IL-1β. The stromal layer 
of the amnion does contain a few tissue macrophages, which are mainly of fetal 
origin (Bulmer and Johnson 1984), however it seems unlikely that these cells would 
persist in cell culture at consistently high enough numbers to account for the levels of 
CD69 mRNA expression observed. In addition, CD69 was expressed in amnion 
tissue, with apparent increases seen in tissue exposed to normal labour, although this 
may be secondary to infiltrating leukocytes. Confirmation of expression of CD69 at 
protein level is an area of future investigation. Establishment of its ligand will be 
crucial in elucidation of a possible role in the amnion. 
 
Factors involved in HBD2 production 
It was hypothesized that a secondary gene product could be responsible for the later 
peak in HBD2 mRNA expression, and members of K-means clusters 7 and 15 were 
considered as potential candidates. Unfortunately subsequent investigations provided 
no evidence that these molecules were involved in the regulation of HBD2.  
 
TNFα does increase HBD2 expression, as shown in Chapter 4 (Figure 4.8), but the 
magnitude of this change (5-7 fold) is much less than the peaks invoked by IL-β. As 
IL-1α has identical effects to IL-1β, and IL-1β was added in excess, it seems unlikely 
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that this mediator could further increase production of HBD2. Treatment with IL-8, 
BMP2 and endothelin-1 had no obvious effect on HBD2 expression. Furthermore, 
the PTGS inhibitor indomethacin had no effect, either on its own, or when added 
with IL-1β; indicating that prostaglandins, the PTGS2 products, are not an 
influencing factor. The EGF receptor antagonist AG1478 also did not alter the effect 
of IL-1β on HBD2 expression, implying EGF receptor agonists, such as epiregulin, 
were not responsible for the later peak in HBD2 production. 
 
Further study focused on potential regulatory mechanisms in signalling pathways. 
The results of these were inconclusive on their own, but should provide directions for 
future investigations.   
 
NFκB and AP-1 transcription factors have been previously implicated in IL-1β 
signalling in the amnion (Elliott, Allport et al. 2001; Lindstrom and Bennett 2005; 
Mohan, Sooranna et al. 2007) and WISH cells (Allport, Pieber et al. 2001). It was 
therefore reassuring that components of these pathways were represented in the 
microarray. NFκB and AP-1 are key regulators of the inflammatory and immune 
response, and activation of at least one MAPK is required, in addition to NFκB, to 
promote strong transcription (Kracht and Saklatvala 2002).  
 
SB203580 is a pyridinyl imidazole that is an ATP-competitive inhibitor of p38. It 
was found to decrease the expression of HBD2 provoked by IL-1β. In contrast, 
specific inhibitors of JNK and ERK had no effect on IL-1β induced HBD2 
expression. Together these results suggest that p38 MAPK, but not JNK or ERK may 
be involved in IL-1β induced expression of HBD2. The p38 pathway is also essential 
for mRNA stabilization of many inflammatory genes (Kracht and Saklatvala 2002), 
and this may be an additional or alternative means by which HBD2 production is 
regulated. 
  
The involvement of the NFκB signalling pathway in HBD2 production was also 
examined using pathway inhibitors. The effect of sulfasalazine was examined, after 
trials with two other NFκB inhibitors (BAY 11-7082 and NFκB inhibitor, both from 
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Calbiochem) gave inconsistent results. This may have been due to a cytotoxic effect 
on the cultures, as a decrease in viable cells was seen using trypan blue exclusion. A 
reduction of viable cells and a decrease in mRNA quality and yield was also found 
with sulfasalazine treatment  but this only occurred after 48 hours of treatment. This 
timepoint was therefore excluded from analysis. 
 
Sulfasalazine is a combination of the antibiotic sulfapyridine, and the anti-
inflammatory 5-amino-salicycylic acid. It has been shown to be an inhibitor of NFκB 
activation both in vitro (Wahl, Liptay et al. 1998) and in vivo (Gan, Chen et al. 
2005), and suppresses LPS-induced NFκB DNA binding activity in human 
gestational tissues (Lappas, Permezel et al. 2002). It is thought to inactivate IKKα 
(Weber, Liptay et al. 2000), thereby preventing phosphorylation of IκBα and 
translocation of NFκB subunits to the nucleus, although the exact mechanism of 
action is unconfirmed.  It is recognised however, that its effects are not confined to 
this enzyme, and it may have other anti-inflammatory effects. 
 
Sulfasalazine seemed to decrease expression of HBD2 in response to both IL-1β and 
IL-17 over 24 hours; although this was examined at mRNA level in only 2 patient 
samples, therefore these results must be viewed as being preliminary. Nevertheless, it 
is consistent with the involvement of the NFκB pathway in the production of HBD2. 
Further experiments should be performed to confirm this. 
 
In contrast, sulfasalazine upregulated IL-8 mRNA expression when compared to 
unstimulated controls. This effect was surprising, especially as a previous study has 
shown that sulfasalazine downregulates the effect of IL-1β on IL-8 protein 
production in amnion tissue (Lappas, Permezel et al. 2002). In addition, when 
primary amnion cells were incubated with IL-1β with sulfasalazine, an even more 
dramatic elevation in IL-8 mRNA was seen. The reasons for this are unclear. The 
increase in expression is comparatively late, and no increase is seen at 3 or 6 hours, 
suggesting that sulfasalazine may interfere with the negative feedback of NFκB. One 
hypothesis is that it occurs via secondary inhibition of IκBα production, which itself 
is under the control of NFκB. An alternative theory is that sulfasalazine in some way 
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promotes the nuclear retention and DNA binding of NFκB. This can occur through 
the expression of chaperoning cofactors, such as hypophosphorylated IκBβ 
(Thompson, Phillips et al. 1995; Lindstrom and Bennett 2005).  
 
The identification of NFκBIζ in primary cultured amnion epithelial cells by the 
microarray was a novel observation. NFκBIζ is a recently discovered cofactor of 
NFκB, induced by IL-1β but not TNFα (Haruta, Kato et al. 2001; Eto, Muta et al. 
2003). Initial experiments found it was localized in the nucleus, and acted as a 
negative regulator of NFκB via prevention of DNA binding of the transcription 
factor (Yamazaki, Muta et al. 2001; Totzke, Essmann et al. 2006). Subsequent 
studies have found it is essential for expression of a subset of inflammatory genes 
induced by Toll-like receptor agonists and IL-1β, but not TNFα (Yamamoto, 
Yamazaki et al. 2004) and that it itself has transcriptional activity upon interaction 
with the p50 NFκB subunit, with both stimulatory and inhibitory functions 
(Motoyama, Yamazaki et al. 2005).  
 
A recent study in an airway epithelial cell line has shown that expression of the 
natural antimicrobial neutrophil gelatinase-associated lipocalin (NGAL) is dependent 
on NFκBIζ, and that  HBD2 may be similarly regulated (Cowland, Muta et al. 2006). 
This led to the hypothesis that NFκBIζ may be crucial in the regulation of HBD2 in 
the amnion. Attempts were made to prove this with RNA interference studies. 
Unfortunately, neither transfection agents nor electroporation of cells enabled 
significant knockdown of NFκBIζ with small interfering RNA (siRNA). RNA 
interference in primary cultured cells is recognized to be problematic, and further 
work is required to optimize a technique for use in amnion cells which may clarify 
the role of NFκBIζ. The role of other inhibitory molecules upregulated in the 
microarray, such as TNFAIP3 which is involved in terminating the NFκB response, 
should also be examined. 
 
Indirect support for the involvement of NFκBIζ in HBD2 production was provided 
by the observation that IL-17 upregulated both NFκBIζ and HBD2 mRNA in a 
similar pattern to IL-1β. Interestingly, IL-17 is capable of stabilizing NFκBIζ mRNA 
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in a mouse fibroblast cell line, but this occurs without degradation of NFκBIα or 
activation of NFκB (Yamazaki, Muta et al. 2005). In the amnion, IL-17 did not 
induce NFκBIα mRNA- the inhibitor of NFκB, which is itself induced by NFκB 
forming a negative feedback loop. IL-1β on the other hand, did increase NFκBIα 
expression. It would thus seem that, although IL-1β and IL-17 may both activate 
IKK (as indicated by the abrogation of HBD2 production by sulfasalazine) and 
NFκBIζ, they employ different regulatory mechanisms downstream to this. This is 
further evidenced by the disparate response of IL-8 produced by IL-1β and IL-17 
treatment (Chapter 4; Figure 4.9 D). Exactly how these processes differ is an 
interesting area for future study. It is well recognized that multiple levels of 
regulation in inflammatory signalling occur. The cellular response varies on which 
components are expressed, in what proportions, as well as the stimulus; and mRNA 
stabilization and post-transcriptional modifications are also important. 
 
Summary 
cDNA microarray is a relatively new technique which was used to investigate the 
response of the amnion to IL-1β. The identification of the NFκB cofactor NFκBIζ 
was a novel finding, and it is speculated that this may be crucial in the production of 
HBD2.  
 
Important information about the inflammatory response of the amnion was gleaned. 
Many studies have attributed the production of inflammatory cytokines and 
chemokines seen in labour to invading leukocytes. These results show that the 
amnion may be a direct contributor, responding to IL-1β with production of a host of 
inflammatory mediators. In addition, the identification of CD69 is a novel finding 
which may add to our understanding of the immune response of this tissue.  
 
Microarrays generate an enormous amount of information, which would be 
unfeasible to validate and analyze comprehensively in the context of this thesis. 
However, rigorous methodology and adherence to MIAME conventions ensure the 








6. General Discussion 
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6.1. SUMMARY OF FINDINGS 
 
The study of natural antimicrobials is particularly relevant in reproductive biology, 
where infection can have devastating consequences to fertility and pregnancy. This 
thesis investigated natural antimicrobial production in pregnancy. Two areas were 
looked at: the lower genital tract, where infections can arise which can threaten the 
pregnancy; and the innermost fetal membrane, the amnion. The main results of this 
study are summarized below 
 
• The antileukoproteinases elafin and SLPI are constituents of cervicovaginal 
secretions, and levels of these factors are decreased in association with the 
common vaginal infection bacterial vaginosis (Chapter 3). 
 
• Cells derived from the vagina express higher amounts of elafin than cells 
derived from the ectocervix or endocervix (Chapter 3). 
 
• Cells derived from the endocervix, which is normally sterile, respond to LPS 
challenge by increasing production of elafin and SLPI. This response is not 
seen in cells derived from the vagina or ectocervix; areas which host a diverse 
microflora (Chapter 3). 
 
• The amnion expresses mRNA for potent natural antimicrobials HBD1, 
HBD2, HBD3, SLPI and elafin (Chapter 4). 
 
• HBD2 expression is upregulated in amnion that is exposed to normal labour 
(Chapter 4). 
 
• IL-1β increases HBD2 expression in amnion tissue and primary cultured 
amnion epithelial cells, at both mRNA and protein level (Chapter 4). 
 
• IL-1β and IL-17 upregulate HBD2 expression in primary cultured amnion 
epithelial cells in a characteristic biphasic pattern (Chapter 4). 
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• IL-1β treatment of the amnion results in the upregulation of many 
inflammatory mediators, and some novel factors including the recently 
discovered NFκB cofactor NFκBIζ, and the T cell marker CD69 (Chapter 5). 
 
6.2. CLINICAL APPLICATIONS AND FUTURE DIRECTIONS 
 
In the lower genital tract in pregnancy it seems that the antileukoproteinases elafin 
and SLPI are the predominant natural antimicrobials, but HBD2 is also present at 
low levels. As discussed in Chapter 3, these are multifunctional peptides, which may 
have a variety of protective roles in pregnancy. In addition to being antimicrobial, 
they could help prevent protease mediated degradation of the fetal membranes. 
Furthermore, they have anti-inflammatory activities and are a point of interface with 
the adaptive immune system. They thus may regulate the inflammatory response in 
the cervix, which, if unchecked, could initiate the parturition cascade.  
The clinical relevance of these factors is suggested by the fact that levels of SLPI and 
elafin are decreased in the cervicovaginal secretions of women with bacterial 
vaginosis. Bacterial vaginosis is associated with an increased risk of preterm labour, 
preterm rupture of membranes and miscarriage, yet results of standard antibiotic 
treatments have been disappointing in improving pregnancy outcome. The 
pleiotropic nature of elafin and SLPI mean they may be more useful therapeutic 
agents in the condition whilst the anatomy of the lower genital tract means that local 
administration of synthetic antimicrobials could be a feasible method of delivery, 
minimizing systemic effects. 
In the lung synthetic antileukoproteinases have been effectively delivered by aerosol. 
They exhibit sustained half-lives in lung fluid, and have shown promising results in 
terms of decreasing inflammation and neutrophil elastase activity in cystic fibrosis 
patients (Vogelmeier, Gillissen et al. 1996). SLPIs association with elastin and 
elafins adhesion domain may help their retention in tissues. Synthetic SLPI is 
retained in vivo like native peptide with less than 0.2% excreted within 5 hours of 
treatment (Vogelmeier, Buhl et al. 1990). Gene therapy is another possible method of 
delivery. Natural antimicrobial augmentation using adenovirus vectors have been 
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used in animal studies, however, development of this technology is at early stages 
(Bals, Weiner et al. 1999; Simpson, Wallace et al. 2001). 
A complementary strategy could be based on modulating the efficiency of 
antimicrobials via acidification of vaginal secretions. SLPI and elafin have been 
purported to work through a defensin-like mechanism, dependent on ionic 
attraction to microbial membranes (Hiemstra, Maassen et al. 1996). Alkali milieux 
have been shown to inhibit the antimicrobial activity of defensins (Singh, Tack et al. 
2000). The high pHs found in bacterial vaginosis may decrease the activity of 
antimicrobials, predisposing to bacterial overgrowth and secondary infection. A few 
small trials have examined use of an intravaginal acid-buffering gel in the treatment 
or prophylaxis of bacterial vaginosis in non-pregnant women with mixed results 
(Milani, Barcellona et al. 2003; Holley, Richter et al. 2004; Fiorilli, Molteni et al. 
2005; Simoes, Bahamondes et al. 2006). It would be interesting to evaluate the effect 
of acidification on the antimicrobial capacity of cervicovaginal secretions. It could 
provide a simple, cheap and low risk adjuvant treatment in the management of 
bacterial vaginosis in pregnancy, but large scale trials would be necessary to evaluate 
efficacy. 
An interesting finding in the in vitro work was the different response to LPS in 
vaginally derived and endocervically derived cells. The endocervix is critically 
situated at the interface of the non-sterile lower and sterile upper genital tract, and 
cervical inflammatory mediators can stimulate parturition. The cervical innate 
immune response is thus likely to have a crucial role in the development of preterm 
labour. Both epithelial and inflammatory cell compartments may be important. A 
recent study examined cervical leukocyte subpopulations in the second trimester, in 
women who had experienced a previous preterm delivery. Fewer cervical 
macrophages were found in women who recurrently delivered prematurely, than in 
those who delivered at term (Whitworth, Pafilis et al. 2007), possibly via an increase 
in penetration of infections. Augmentation of antimicrobial expression may be useful 
in such cases, and investigation of the relationship between cervical leukocytes and 
natural antimicrobial production is an area for further investigation. 
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It has been shown that the combination of a genetic polymorphism for TNFα and 
bacterial vaginosis is a significant risk factor for preterm birth, whereas individually 
neither is a risk factor (Macones, Parry et al. 2004). This confirms the importance of 
gene-environment interactions in the development of preterm labour. Single 
nucleotide polymorphisms may affect expression of natural antimicrobials. In 
addition, substantial individual variation in defensin gene copy number is recognized 
(Hollox, Armour et al. 2003). A genetically determined deficit of defensins could 
cause a general susceptibility to infection, which might explain the recognized 
association between periodontitis and preterm labour. Alternatively, it may 
predispose to a less favourable course of an infection; for example allowing the 
ascension of lower genital tract pathogens to the upper genital tract. Conversely, 
excessive production of defensins could overstimulate the inflammatory response via 
their chemotactic activities, which in itself might contribute to preterm labour. Future 
studies will correlate gene copy number with defensin expression in pregnancy, and 
assess whether variation is associated with preterm delivery. This may allow 
identification of a group of women at higher risk of preterm labour, to allow targeted 
therapy or prophylaxis. 
 
HBD2 is upregulated in the amnion in normal labour, perhaps to increase 
antimicrobial protection at this vulnerable time. This illustrates the fact that natural 
antimicrobials may have key roles even when parturition is not actually instigated by 
an infection. A variety of processes can stimulate sterile inflammation and preterm 
labour, and synthetic antimicrobials may be useful in the management of such cases. 
For example, in cervical dysfunction (incompetence) the cervix cannot support the 
weight of the uterine contents and dilates. The cervical mucus plug, which contains 
exceptionally high levels of SLPI (Helmig, Uldbjerg et al. 1995) is lost. One could 
speculate that the resultant decrease in local elastase inhibition and antimicrobial 
activity may hasten fetal membrane rupture, and that topical recombinant SLPI could 
be beneficial. In addition, in cervical incompetence stretch of the fetal membranes 
can occur where the membranes prolapse through the os. As well as causing physical 
disruption, amniotic stretch triggers upregulation of inflammatory signalling and 
prostaglandin synthesis which may contribute to PPROM (Mohan, Sooranna et al. 
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2007). Microbial invasion of the amniotic cavity is a frequent complication of cases 
of PPROM, and it is likely that loss of the physical and natural antimicrobial barrier 
of the amnion can allow direct passage of lower genital pathogens to the uterus and 
fetus. The use of synthetic natural antimicrobials could be useful in this scenario, to 
help decrease the incidence of secondary infections. However, the pro-inflammatory 
and chemotactic functions of HBD2 may limit this factors use, and further studies of 
its effect on the amnion, and its adjacent tissues, are crucial in its evaluation as a 
potential therapy. 
 
If bacteria do penetrate lower genital tract defence mechanisms and gain access to 
the uterine cavity they can cause an inflammatory response in the decidua and fetal 
membranes. Here bacterial products and inflammatory cytokines stimulate 
production of prostaglandins promoting expulsion of the fetus.  Preterm labour may 
be an evolutionary conserved response to infection, developed to optimise survival of 
the fetus by delivering it from a hostile intrauterine environment, and to protect the 
reproductive fitness of the mother (Romero, Espinoza et al. 2006). This thesis 
supports the idea that the amnion has a central role in this process, mediating 
termination of the pregnancy on exposure to overwhelming infection. The amnion 
directly contributes to the inflammatory response by virtue of synthesis of 
chemokines, cytokines and prostaglandins.  
 
Many of the inflammatory mediators expressed by the amnion are regulated by 
NFκB transcription. The expression of the NFκB cofactor NFκBIζ in the amnion was 
a new finding, and its role in the inflammatory responses in the amnion warrants 
further investigation, as it may have important co-stimulatory and/or inhibitory 
functions. NFκB inhibition is an attractive therapeutic target in preterm labour, and it 
has been suggested that agents such as sulfasalazine may be a useful intervention in 
its management. However, one of the problems with this approach is the complex 
nature, multiple interactions and ubiquity of inflammatory signalling pathways. This 
study has shown that although sulfasalazine can downregulate some components of 
the inflammatory response, such as HBD2, others, such as IL-8 are paradoxically 
upregulated. Differing responses may be due to the myriad of adaptors and cofactors 
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that can modulate the response. Caution should be applied to the advocacy of NFκB 
inhibitors as therapy until there is fuller understanding of the controlling 
mechanisms, and specific inhibitors are available to minimize unwanted or 
deleterious side effects. Nevertheless, rapid advances in the field are being made, and 
future research may allow realization of this strategy. 
 
This thesis has provided some novel findings. Expression of CD69 by the amnion 
was unexpected, as this is a marker of myeloid lineages, and has not been described 
in epithelia before. In addition the function of IL-17 in pregnancy has not been 
investigated, but the responsiveness of the amnion to this mediator suggests it may 
be an important component. Both these factors are traditionally associated with T 
cells and are involved in interactions between the innate and adaptive immune 
responses. A speculative hypothesis is that the amnion epithelium has functions akin 
to immune cells, enabling it to modulate both innate and adaptive immunity at the 
fetal-maternal interface. Subsequent investigations will study this theory and may 




This study has shown that epithelial natural antimicrobials are expressed by the 
vagina, cervix, choriodecidua and amnion. Production of SLPI and elafin in the 
lower genital tract may prevent ascending infections, which could threaten the 
establishment and maintenance of pregnancy. In the amnion HBD2 may protect the 
fetus at vulnerable times such as labour. Its expression is upregulated by IL-1β and 
IL-17 in a characteristic biphasic pattern, and it may be an important part of the 
inflammatory response of this tissue. 
 
Natural antimicrobial expression is genetically determined. Individual variation 
could result in a propensity for infections or infectious complications which may be 
crucial in the development of preterm labour. Further study in this area could lead to 
the development of new antimicrobial therapies for the treatment of infections in 
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pregnancy. In addition, it may allow strategies for the recognition of women at 
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TISSUE COLLECTION SOURCE 
Phosphate Buffered Saline Sigma-Aldrich, Poole, Dorset, UK 
RNAlater Ambion, Austin, Texas, USA 
Neutral Buffered Formalin See Appendix 2 
Tri-reagent Sigma-Aldrich, Poole, Dorset, UK 
Ethanol Hayman Ltd., Essex, UK 
Tampons (Tampax Regular) Proctor and Gamble, Surrey, UK 
Glass microscope slides Fischer Scientific, Loughborough, UK 
Acetic Acid BDH Laboratory Supplies, Poole, UK 
Gram Stain Kit BIOS Europe, Skelmersdale, Lancs,UK 
Pertex mounting medium Cellpath plc, Hemel Hempsted, UK 
Cover slips Fischer Scientific, Loughborough, UK 
 
TISSUE & CELL CULTURE SOURCE 
FL cells LGC Promochem, Teddington, UK 
WISH cells 
LGC Promochem, Teddington, UK 
He-La cells 
LGC Promochem, Teddington, UK 
VK2 E6/E7 
LGC Promochem, Teddington, UK 
ECT E6/E7 
LGC Promochem, Teddington, UK 
END E6/E7 
LGC Promochem, Teddington, UK 
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TISSUE & CELL CULTURE SOURCE 
Phosphate Buffered Saline (PBS) Sigma-Aldrich, Poole, Dorset, UK 
EDTA Sigma-Aldrich, Poole, Dorset, UK 
Dispase Gibco, Paisley, UK 
RPMI 1640 medium Sigma-Aldrich, Poole, Dorset, UK 
Fetal Calf Serum Mycoplex, Teddington, UK 
Penicillin Sigma-Aldrich, Poole, Dorset, UK 
Streptomycin Sigma-Aldrich, Poole, Dorset, UK 
Gentamycin Sigma-Aldrich, Poole, Dorset, UK 
L-Glutamine Sigma-Aldrich, Poole, Dorset, UK 
Trypan Blue Sigma-Aldrich, Poole, Dorset, UK 
Culture plates (6 well and 12 well) Corning Costar, High Wycombe, UK 
Keratinocyte Serum Free Medium Invitrogen, Paisley, Scotland, UK 
Bovine Pituitary Extract Invitrogen, Paisley, Scotland, UK 
Epidermal Growth Factor  Invitrogen, Paisley, Scotland, UK 
RNAlater Ambion, Austin, Texas, USA 
Protein Lysis Buffer See Appendix 2 
Minitab protease inhibitor tablets Roche Biochemicals, Burgess Hill, UK 




TISSUE & CELL CULTURE SOURCE 
Interleukin-17 (IL-17) Peprotech EC, London, UK 
Calcium Chloride Sigma-Aldrich, Poole, Dorset, UK 
Tumour Necrosis Factor α (TNFα) Peprotech EC, London, UK 
Interleukin-8 (CXCL8) Peprotech EC, London, UK 
Bone Morphogenic Protein 2 (BMP2) Peprotech EC, London, UK 
HBD2 Peprotech EC, London, UK 
SLPI HycultBiotechnology, Uden, Netherlands 
Lipopolysaccharide (LPS)  E. coli Sigma-Aldrich, Poole, Dorset, UK 
Lipoteichoic acid (LTA) Sigma-Aldrich, Poole, Dorset, UK 
Progesterone Sigma-Aldrich, Poole, Dorset, UK 
Indomethacin Sigma-Aldrich, Poole, Dorset, UK 
Dexamethasone Sigma-Aldrich, Poole, Dorset, UK 
Sulfasalazine Sigma-Aldrich, Poole, Dorset, UK 
NFKB Activation Inhibitor Calbiochem, Darmstadt, Germany 
BAY 11-7082 Calbiochem, Darmstadt, Germany 
SB2030580 Calbiochem, Darmstadt, Germany 
PD8059 Calbiochem, Darmstadt, Germany 




RNA EXTRACTION AND PCR SOURCE 
RNeasy mini RNA extraction kit Qiagen, Crawley, West Sussex, UK 
TRI reagent Ambion, Austin, Texas, USA 
Chloroform BDH Laboratory Supplies, Poole, UK 
DNase I Qiagen, Crawley, West Sussex, UK 
Ethanol Hayman Ltd., Essex, UK 
RNA6000nano chips and reagents Agilent Biotechnologies, Stockport, 
Cheshire,UK 
Mineral Oil Sigma-Aldrich, Poole, Dorset, UK 
Stratgene PCR Mastermix Applied Biosystems, Warrington, 
Cheshire, UK 
18s Control Primer and Probe Applied Biosystems, Warrington, 
Cheshire, UK 
CD69, BMP2, NFKBIZ and latterly used 
HBD2 and HBD3 Primers and Probes 
MWG-Biotech, Ebersberg, Germany 
All other Primers and Probes Biosource, Nivelles, Belgium 
 
ELISA SOURCE 
96 well assay plates Nunc Maxi-Sorp, Gibco, Paisley, UK 
HBD2 Assay Development kit Peprotech EC, London, UK 
HBD3 Assay Development kit Peprotech EC, London, UK 
IL-8 Capture Antibody R&D Systems, Oxford, UK 
IL-8 Standard Toray Industries, Tokyo, Japan 
IL-8 Detection antibody R&D Systems, Oxford, UK 
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ELISA SOURCE 
IL-1β Capture Antibody R&D Systems, Oxford, UK 
IL-1β  Standard R&D Systems, Oxford, UK 
IL-1β Detection Antibody R&D Systems, Oxford, UK 
IL-1RA Capture Antibody R&D Systems, Oxford, UK 
IL-1RA Standard R&D Systems, Oxford, UK 
IL-1RA Detection Antibody R&D Systems, Oxford, UK 
TNFα Capture Antibody R&D Systems, Oxford, UK 
TNFα Standard R&D Systems, Oxford, UK 
TNFα Detection Antibody R&D Systems, Oxford, UK 
SLPI ELISA HycultBiotechnology, Uden, Netherlands 
Elafin ELISA HycultBiotechnology, Uden, Netherlands 
Phosphate Buffered Saline tablets Sigma-Aldrich, Poole, Dorset, UK 
Tween Sigma-Aldrich, Poole, Dorset, UK 
ELISA Buffer See Appendix 2 
Dry coat See Appendix 2 
Wash Buffer See Appendix 2 
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Substrate See Appendix 2 
2N sulphuric acid BDH Laboratory Supplies, Poole, UK 
Bovine Serum Albumin Sigma-Aldrich, Poole, Dorset, UK 
Reagent A and S Bio-Rad Laboratories, Hemel 
Hempstead, UK 




Xylene BDH Laboratory Supplies, Poole, UK 
Ethanol Hayman Ltd., Essex, UK 
Harriss Haematoxylin Pioneer Research Chemicals Ltd, 
Colchester, UK 
Acid Alcohol BDH Laboratory Supplies, Poole, UK 
Scotts tap water See Appendix 2 
Eosin Pioneer Research Chemicals Ltd, 
Colchester, UK 
Pertex Cellpath plc, Hemel Hempsted, UK  




Triton  Sigma-Aldrich, Poole, Dorset, UK 
Phosphate Buffered Saline  See Appendix 2 
Phosphate Buffered Saline + Tween  See Appendix 2 
0.01M sodium citrate See Appendix 2 
Hydrogen Peroxide BDH Laboratory Supplies, Poole, UK 
Methanol BDH Laboratory Supplies, Poole, UK 
Blocking serum  See Appendix 2 
Anti-Cytokeratin Dako Ltd., Cambridge, UK 
Rabbit anti-mouse Antibody Dako Ltd., Cambridge, UK 
Avidin-Biotin complex (ABC) Dako Ltd., Cambridge, UK. 
Diaminobenzidine  Dako Ltd., Cambridge, UK 
 
MICROARRAY SOURCE 
Low RNA Input Fluorescent 
Amplification kit 
Agilent Biotechnologies, Stockport, 
Cheshire,UK 




Cyanine 3-CTP (10.0mM) PerkinElmer/NEN Life Sciences 
Cyanine 5-CTP(10.0mM) PerkinElmer/NEN Life Sciences 
Ethanol BDH Laboratory Supplies, Poole, UK 
Qiagen Rneasy mini kit Qiagen, Crawley, West Sussex, UK 
20x Saline-Sodium-Phosphate-EDTA 
Buffer 
Amresco, Solon, Ohio, USA 
20% N-lauroylsarcosine Sigma-Aldrich, Poole, Dorset, UK 
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All dilutions are in deionized water, unless otherwise stated. 
 
Neutral buffered formalin (NBF) 
In 1 litre:  
6.5g Na2HPO4 (BDH Laboratory Supplies, Poole, UK) 
4.5g NaH2PO4.2H20 (BDH Laboratory Supplies, Poole, UK) 
100ml 40% formaldehyde (BDH Laboratory Supplies, Poole, UK) 
900ml distilled water 
 
Protein Lysis Buffer 
150 mmol/l NaCl  
50 mmol/l Tris pH 7.4 
10 mmol/l EDTA  
10 mmol/l EGTA  
0.6% Nonidet P40 (Roche Biochemicals, Burgess Hill, UK) 
10% Glycerol (Sigma-Aldrich, Poole, Dorset, UK)  
10µg Peptain (Sigma-Aldrich, Poole, Dorset, UK) 
1mM PMSF (Sigma-Aldrich, Poole, Dorset, UK) 




In 1 litre: 
12.1g Tris (Sigma-Aldrich, Poole, Dorset, UK) 
2g BSA (Sigma-Aldrich, Poole, Dorset, UK) 
9g NaCl (Sigma-Aldrich, Poole, Dorset, UK) 
0.7g EDTA (Sigma-Aldrich, Poole, Dorset, UK) 
300µl phenol red (Flow Laboratories, UK) 
1ml preservatives (Boehringer, Mannheim, Germany) 
pH 7.2 
Dry Coat 
In 1 litre: 
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20g polyvinylpyrollidone 2% (Sigma-Aldrich, Poole, Dorset, UK) 
5g BSA (Sigma-Aldrich, Poole, Dorset, UK) 
1ml preservatives (Boehringer, Mannheim, Germany) 
1.9g EDTA (Sigma-Aldrich, Poole, Dorset, UK) 
6.1g Tris (Sigma-Aldrich, Poole, Dorset, UK) 
 
ELISA wash buffer 
In 1 litre: 
5ml Tween 20 (Sigma-Aldrich, Poole, Dorset, UK) 
90g NaCl (Sigma-Aldrich, Poole, Dorset, UK) 
12.1g Tris (Sigma-Aldrich, Poole, Dorset, UK) 
pH 7-7.5 
Dilute 1:20 to use 
 
ELISA substrate 
1ml tetramethyl benzidine:  1ml urea hydrogen peroxide : 10ml sodium acetate 
100mM sodium acetate  
In 1 litre:  
13.6g sodium trihydrate (Sigma-Aldrich, Poole, Dorset, UK) 
1ml preservatives (Boehringer, Manheim, Germany) 
pH 6 
Tetramethyl Benzidine 
3mg/ml in dimethylformamide (Sigma-Aldrich, Poole, Dorset, UK) 
Urea Hydrogen Peroxide 
0.5% in 50mM sodium acetate (Sigma-Aldrich, Poole, Dorset, UK) 
pH6 
 
Phosphate buffered saline 
In 1 litre:  




Phosphate buffered saline + Tween  
In 1 litre: 
5 PBS tablets (Sigma-Aldrich, Poole, Dorset, UK) 
100µl Tween-20 (Sigma-Aldrich, Poole, Dorset, UK) 
pH 7.4-7.6 
 
Scotts Tap Water 
In 1litre: 
3.2g Sodium Bicarbonate (Sigma-Aldrich, Poole, Dorset, UK) 
36.1g Magnesium Sulphate (Sigma-Aldrich, Poole, Dorset, UK) 
 
0.1M sodium citrate buffer 
In 1litre: 
29.4g Tri-sodium citrate (BDH Laboratory Supplies, Poole, UK) 
0.1g sodium azide (Sigma-Aldrich, Poole, Dorset, UK) 
pH 6 
Dilute 1:10 to use 
Blocking Serum 
20ml Normal Rabbit Serum (Vector Laboratories, Peterborough, UK) 
80 ml Phosphate Buffered Saline (Sigma-Aldrich, Poole, Dorset, UK) 

























You are being invited to take part in a research study. Before you decide it is important that you 
understand why the research is being done and what it will involve. Please read this information 















Natural Antimicrobial Proteins in Pregnancy
 Patient Information Leaflet 
Study 1: Natural Antimicrobial 
Proteins in Labour 
30/06/04 
Do I have to take part? 
It is up to you to decide whether or not 
to take part. If you do decide to take part 
you will be given this information sheet 
to keep and be asked to sign a consent 
form. If you do decide to take part, you 
are still free to withdraw at any time and 
without giving a reason. A decision to 
withdraw at any time, or a decision not 
to take part, will not affect the standard 
of care you receive in this pregnancy, or 
any future pregnancies. 
What is the purpose of the study? 
At the Simpson Centre for Reproductive 
Health we are researching premature 
birth. Studies have shown that the cause 
for this is sometimes infection. We think 
that both the mother and the baby 
produce substances that act as natural 
antibiotics to help protect the pregnancy, 
and when these defences are overcome, 
infection can take hold and may cause 
labour to start. Exactly how these natural 
antibiotics work is unknown, but we 
think they may have an important role in 
mainta ining pregnancy. We are currently 
performing studies investigating this.  
Why is it important? 
Premature birth occurs in about 10% of 
pregnancies. Despite advances in the 
care of very small or premature babies, it 
still is the leading cause of babies dying 
in this country. Although we know some 
of the risk factors for developing preterm 
labour, exactly why it happens is still a 
mystery, and it remains difficult to 
predict and to treat. 
How are we doing the research? 
Many different tissues produce these 
natural antibiotics, called natural 
antimicrobial proteins. We would like to 
collect some samples from you to look at 
them. We will then study these to see if 
natural antimicrobia l prote ins are present
and how they work.  
We are collecting samples from women 
who are delivered by caesarean section. 
We would like to collect a small amount 
of the waters or amniotic fluid that 
surrounds your baby. This is done by 
sucking up a little of the fluid with a 
syringe, just before your baby is 
delivered. After delivery we are taking 
samples of the after-birth (the placenta) 
and membranes that surrounded your 
baby. We also want to take a small 
sample of the umbilical cord that 
attached your baby to the placenta. None 
of this involves any additional 
procedures or alters delivery or care of 
your baby in any way.  





























If you consent to take part in the 
research, we will send a letter to your 
GP to let him/her know of your 
involvement. Your medical records may 
be inspected by the researchers, where it 
is relevant to analyzing the results. All 
information that is collected about you 
during the course of the research will be 
kept strictly confidential. Any 
information about you, which leaves the 
hospital, will have your name and 
address removed so that you cannot be 
recognized from it. 
This research study is taking place over 
a three-year period. Any results will be 
published in peer reviewed medical and 
scientific journals. Updates to the 
progress of this, and other studies from 
this department can be found on our 
website at www.piggybankkids.org 
Will my taking part in this study be kept confidential?
What will happen to the results of this research study? Who is organizing and funding the research? 
This research study is funded by The 
Jennifer Brown Research Trust, which is 
supported by the PiggyBankKids appeal 
(registered charity number 1092312). The 
aim of the charity is to find solutions to 
pregnancy difficulties and save newborn 
lives. The Local Ethics Committee has 
approved this study.  
Who can I contact for further information? 
If you would like to ask any questions 
about the study please contact either Dr 
Sarah Stock on 0131 242 6425 or Dr 
Anne Armstrong on 0131 242 6424 or via 
hospital switchboard. If you would like to 
speak to someone not in any way involved 
in the study please contact Dr Christine 
West on telephone 0131 242 2525. 
 
The Jennifer Brown 
Research Trust
The Chancellors Building 
The New Royal Infirmary of 
Edinburgh 
51 Little France Crescent 
Edinburgh EH16 4SA 
 
Phone: 




Were on the Web! 
See us at: 
www.piggybankkids.org 
After the study is complete any 
remaining fresh or frozen samples will 
be destroyed. However some small 
tissue samples will have been made in to 
slides and some samples will have 
protein extracts taken from them. We ask 
if we can keep these samples to use in 
future similar research studies. The exact 
nature of these studies will depend upon 
future scientific advances, and some may 
be carried out by other researchers. 




Study Title: Natural Antimicrobial Proteins in Pregnancy 
Name of Researcher: Dr Sarah Stock 
 
1. I confirm I have read and understand the information sheet dated 30/06/04 
(Natural Antimicrobial Proteins In Labour) for the above study and have had 
the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected. 
 
3. I understand that my medical notes may be looked at by the researchers 
involved in the study or by the regulatory authorities where it is relevant to my 
taking part in the research. I give permission for these individuals to have 
access to my records. 
 
4. I agree to a letter being sent to my General Practitioner to notify them about 
my participation in this study. 
 
5. I understand that fresh and frozen tissue samples will be destroyed at the end 
of the study. However I agree that slides and certain protein extracts, made 
from the tissue that I have given, may be kept by Professor Andrew Calder at 
the Centre for Reproductive Biology, University of Edinburgh, for possible 
use in future similar projects. I understand that some of these projects may be 
carried out by researchers other than Professor Calders laboratory who ran the 
first project. 
 
6. I understand that this is non-therapeutic research from which I cannot expect 
to derive any benefit. 
 





_______________________  _____________ _____________________ 





_______________________  _____________ _____________________ 





____________________________  ________________ _________________________ 
Researcher    Date   Signature 
Samples: Amniotic Fluid Fixed specimen placenta/membranes
     







You are being invited to take part in a research study. Before you decide it is important that you 
understand why the research is being done and what it will involve. Please read this information 















Natural Antimicrobial Proteins in Pregnancy
 Patient Information Leaflet 
Study 2: Natural Antimicrobial 
Proteins in Vaginal Secretions 
10th January 2006 
What is the purpose of the study? 
At the Simpson Centre for Reproductive 
Health we are researching premature 
birth. Studies have shown that the cause 
for this is sometimes infection. We think 
that both the mother and the baby 
produce substances that act as natural 
antibiotics to help protect the pregnancy, 
and when these defences are overcome, 
infection can take hold and may cause 
labour to start. Exactly how these natural 
antibiotics work is unknown, but we 
think they may have an important role in 
maintaining pregnancy. We are currently 
performing studies investigating this.  
Why is it important? 
Premature birth occurs in about 10% of 
pregnancies. Despite advances in the 
care of very small or premature babies, it 
still is the leading cause of babies dying 
in this country. Although we know some 
of the risk factors for developing preterm 
labour, exactly why it happens is still a 
mystery, and it remains difficult to 
predict and to treat. 
How are we doing the research? 
Many different tissues produce these 
natural antibiotics, called natural 
antimicrobial proteins. We think that 
they are present in the vagina, and may 
help stop infections from the vagina, 
traveling up to affect your baby. We 
would like to collect some samples of 
vaginal fluid from you. We will then 
study the amounts of natural 
antimicrobial proteins that are present, 
how they work, and what may control 
their production. We will also 
investigate whether these proteins can be 
used as a marker to predict premature 
labour.  
We are asking women who are booked 
for delivery in Edinburgh to take part. 
Firstly, we would like a sample of 
vaginal fluid. This is collected yourself, 
by simply inserting a tampon that we 
provide into the vagina. You can remove
it about fifteen minutes later, into a 
specimen pot provided. This will not 
harm the pregnancy in any way, and 


































If you consent to take part in the 
research, we will send a letter to your 
GP to let him/her know of your 
involvement. Your medical records may 
be inspected by the researchers, where it 
is relevant to analyzing the results. All 
information that is collected about you 
during the course of the research will be 
kept strictly confidential. Any 
information about you, which leaves the 
hospital, will have your name and 
address removed so that you cannot be 
recognized from it. 
This research study is taking place over 
a three-year period. Any results will be 
published in peer reviewed medical and 
scientific journals. Updates to the 
progress of this, and other studies from 
this department can be found on our 
website at www.piggybankkids.org 
Do I have to take part? 
It is up to you to decide whether or not 
to take part. If you do decide to take part 
you will be given this information sheet 
to keep and be asked to sign a consent 
form. If you do decide to take part, you 
are still free to withdraw at any time and 
without giving a reason. A decision to 
withdraw at any time, or a decision not 
to take part, will not affect the standard 
of care you receive in this pregnancy, or 
any future pregnancies. 
Will my taking part in this study be kept confidential?
What will happen to the results of this research study?
Who is organizing and funding the research?
This research study is funded by The 
Jennifer Brown Research Trust, which is 
supported by the PiggyBankKids appeal 
(registered charity number 1092312). The 
aim of the charity is to find solutions to 
pregnancy difficulties and save newborn 
lives. The Local Ethics Committee has 
approved this study. 
Who can I contact for further information?
If you would like to ask any questions 
about the study please contact either Dr 
Sarah Stock on 0131 242 6425 or Dr 
Anne Armstrong on 0131 242 6424 or via 
hospital switchboard. If you would like to 
speak to someone not in any way involved 
in the study please contact Dr Christine 
West on telephone 0131 242 2525. 
 
The Jennifer Brown 
Research Trust
Queens Medical Research 
Institute,






Were on the Web!
See us at: 
www.piggybankkids.org 
After the study is we ask if we can keep 
any remaining vaginal fluid samples to 
use in future similar research studies. 
The exact nature of these studies will 
depend upon future scientific advances, 
and some may be carried out by other 
researchers. 





Study Title: Natural Antimicrobial Proteins in Pregnancy 
Name of Researcher: Dr Sarah Stock 
 
1. I confirm I have read and understand the information sheet dated 09/09/04 
(Natural Antimicrobial Proteins Throughout Pregnancy) for the above study 
and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected. 
 
3. I understand that my medical notes may be looked at by the researchers 
involved in the study or by the regulatory authorities where it is relevant to my 
taking part in the research. I give permission for these individuals to have 
access to my records. 
 
4. I agree to a letter being sent to my General Practitioner to notify them about 
my participation in this study. 
 
5. I understand that fresh and frozen tissue samples will be destroyed at the end 
of the study. However I agree that slides and certain protein extracts, made 
from the tissue that I have given,  may be kept by Professor Andrew Calder at 
the Centre for Reproductive Biology, University of Edinburgh, for possible 
use in future similar projects. I understand that some of these projects may be 
carried out by researchers other than Professor Calders laboratory who ran the 
first project. 
 
6. I understand that this is non-therapeutic research from which I cannot expect 
to derive any benefit. 
 





_______________________  _____________ _____________________





_______________________  _____________ _____________________





____________________________  ________________ _________________________





















Plots of background signal intensities by position on microarray. T1= 1 hour 
timepoint; T2= 2 hour timepoint; T3=3 hour timepoint; T6= 6 hour timepoint and 





Plots of expression log2 ratios (pre-normalisation) by position on microarray. T1= 1 
hour timepoint; T2= 2 hour timepoint; T3=3 hour timepoint; T6= 6 hour timepoint 












































Appendix 6: Microarray Data (CD) 
